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Introduction  
A woman visited me as her general practitioner (GP) in mid-December with pain and reddish 
discoloration of her toes1. The pain caused problems for her daily work on her farm. Her 
symptoms had recurred every winter, but resolved completely in the summer. In previous 
years, she had experienced similar symptoms on her fingers. Her mother told her to visit me 
because she recognized the illness as the same she had suffered from previously. I diagnosed 
chronic chilblains and advised an injection containing vitamin D3, a therapy my supervisor 
advised me to prescribe during my GP-training in the early 1990s. 
 
Definition of the illness 
Chilblains is a well-described disease entity consisting of painful or itching, red-blue lesions 
on the fingers, feet, ears, or thighs with or without ulceration (Figures 1, 2 and 3). Symptoms 
usually start in early winter and vanish in spring1-4. Sometimes symptoms persist owing to 
continued exposure to cold, which is commonly associated with work conditions (cold 
storage work, for instance). The condition occurs throughout the world, more commonly in 
women than men1. Prevalence reported by the Netherlands Institute for Health Services 
Research (NIVEL) varies between 0.9 per 1000 and 1.7 per 1000 depending on year-to-year 
variation and coding issues, and the condition is more common among women than men 
(prevalence 0.9 - 2.1 per 1000 respectively 0.6 - 1.2 per 1000) (written information NIVEL). 
Biopsies of affected skin areas show characteristic histopathological changes that in most 
cases consist of oedema of the papillary dermis, a perivascular mononuclear infiltrate and 
oedema of the blood vessel walls5. Chilblains is considered to be a common disease that 
causes discomfort but is harmless.  
 
 
Figure 1: Chilblained hand 
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Figure 2: Chilblained foot 
 
 
 
Figure 3: Winter kibes 
 
 
Three forms of chilblains probably exist: acute chilblains, chronic chilblains and chronic-
chilblains-like symptoms associated with inflammatory diseases. Acute chilblains emerge 
after a single exposition to low ambient temperatures and last two weeks at most3,4. Chronic 
chilblains, also referred to as chronic idiopathic chilblains, emerge after repeated or 
prolonged exposure to low ambient temperatures and last for longer periods1-4. In clinical 
settings, chronic chilblains-like symptoms also referred to as secondary chronic chilblains, 
are associated with other diseases, particularly systemic lupus erythematosus6-8. The 
evidence for this association is not substantial. Although up to one third of cases of chronic 
chilblains are reported to be diagnosed as chilblain lupus erythematosus, the proportion of 
patients with chilblains in a group with systemic lupus erythematosus did not differ from 
patients in the control group9. Persistent symptoms during the summer, a rash associated 
with discoid lupus erythematosus, photosensitivity, arthralgia, arthritis, oral ulcers, seizures, 
or psychosis suggest chilblain lupus erythematosus3. Case reports have linked the disorder to 
rare forms of vessel disease and rare conditions such as Sjögren syndrome and chronic 
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myelomonocytic leukaemia. The presence of cryoproteins, cold agglutinins, and hereditary 
protein C and S deficiencies are not associated with chronic chilblains3.  
Chronic chilblains are commonly confused with Raynaud’s syndrome. If the patient reports a 
history of the characteristic paroxysmal and biphasic white, and later blue discoloration, 
after each exposure to cold, this will help to differentiate this syndrome from chronic 
chilblains. 
Diagnosis is manly based on anamnesis and physical examination. Ask about the typical 
symptoms of chronic chilblains, particularly the specific pattern of the course: did the 
symptoms start when average temperatures drop below 10-15 degrees Celsius? Do the 
symptoms decline in spring? And does relapse occur in consecutive winters1? Inspect the 
affected skin for red-blue lesions that are typical of the disorder. Such lesions are usually 
swollen and may be ulcerated. Pulsation of the peripheral arteries should be normal; 
otherwise peripheral vessel disease is a possibility. For diabetic patients the possibility of a 
diabetic foot should be considered, particularly if peripheral vessel disease or other 
ischaemic problems are present1. Additional tests are useful in some cases: If chilblain lupus 
erythematosus is suspected, a negative antinuclear antibody test makes systemic lupus 
erythematosus unlikely. Other laboratory investigations are not usually helpful1. Skin biopsy 
does not usually help differentiate between chronic idiopathic chilblains and its mimics2. 
 
Problem definition 
The case and the considerations presented here outline three problems we have when 
advising our patients with chronic chilblains and trying to understand their disease. For 
centuries, doctors have recognised patients with complaints of a cold-induced condition 
known as perniones or chilblains10. It has also been a topic worth discussing in the Dutch 
medical community since the early days of the Nederlands Tijdschrift voor Geneeskunde 
[Dutch Journal for Medicine] onwards but the backgrounds of the condition remain largely 
unknown11-13.  
In the first place most GPs consider chronic chilblains to be a minor illness even though we 
have minimal knowledge about patient experiences of the disease. 
Secondly the pathophysiological mechanism of chronic chilblains is undisclosed14. It is 
generally accepted that chronic chilblains is caused by low ambient temperatures in patients 
who are in some way susceptible to the threat4. The relation of chilblains with low ambient 
temperatures is more or less clear2-5,15. The nature of the proposed susceptibility to the 
disease is not. As mentioned before, in clinical settings chronic chilblains are associated with 
connective tissue disease, particularly systemic lupus erythematosus, but the evidence for 
this association is not substantial6-8. Case reports have linked the disorder to rare forms of 
vessel disease and rare conditions such as Sjögren syndrome and chronic myelomonocytic 
leukaemia. The presence of cryoproteins, cold agglutinins, and hereditary protein C and S 
deficiencies are not associated with chronic chilblains3. Our observations on chronic 
chilblains indicate that multiple diseased members may be diagnosed in a family. A case-
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control study from Pakistan also suggests this phenomenon called familial clustering16. 
Familial clustering may suggest phenotypic familial aggregation (an on average greater 
frequency of disease in close relatives)17. Phenotypic familial aggregation suggests 
involvement of genetic determinants in a disease17. 
Lastly doctors issue different advice for the treatment of chronic chilblains18. In 2002, we 
asked all 59 GPs working at that time in the region Waterland (in the north-west of the 
Netherlands) how they preferred to treat their patients suffering from chronic chilblains. A 
total of 52 returned the questionnaire (response 88%). Besides simple advice for self-
management, 41% advised an intramuscular injection containing vitamin D, 35% prescribed 
nifedipine and 14% preferred other therapies like topical steroids, indifferent cream or 
homeopathic treatments18. These differences are probably caused by a lack of theoretical 
background regarding the disease mechanism. Vitamin D supplementation may be pure 
empiric and is supported by a case series12. Prescribing nifedipine is probably based on cold 
induced vasoconstriction as a proposed disease mechanism and is supported by a small 
number of randomized clinical trial and case series19,20. Finally, prescribing a topical steroid is 
probably based on the histopathological findings in skin biopsies and is also supported by a 
case series21,22.  
 
Aim of the research 
This thesis is about several aspects of chronic idiopathic chilblains based on the observations 
mentioned (Figure 4):  
1. How are patients affected by the disease and what do they expect from their doctors? 
2. Is the observed familial clustering caused by familial aggregation indicating a familial 
susceptibility to the disease? 
3. What would be the best advice for treatment of chronic chilblains? 
 
Research questions 
Based on the aims the following research questions were studied: 
1. On patient experiences: 
1.1. How do patients experience chronic chilblains, how do they cope with the disease 
and what are their needs? 
2. On familial susceptibility: 
2.1. Is phenotypic familial aggregation demonstrable in chronic chilblains? 
3. On treatment: 
3.1. What is known about the treatment of chilblains and how effective are these 
treatments? 
3.2. Is oral administration of 2000 IU vitamin D3 per day an effective treatment for 
chronic chilblains? 
3.3. Is oral administration of 60 mg nifedipine per day an effective treatment for chronic 
chilblains? 
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3.4. Is topical administration of betamethasone valerate 0.1% cream twice a day an 
effective treatment of chronic chilblains? 
 
 
Figure 4: Aim of the research 
 
 
Methods 
The use of the concepts common disease and minor ailment (further common disease) 
varies between authors23. In 1983, Mulder proposed eleven criteria for defining a disorder as 
a common disease and eight of these had to be fulfilled24: not serious, not progressive, not 
health threatening, often resolving spontaneously, often short lasting, therapeutic options 
unknown or simple, easy diagnosis, short or no disability to work, referral to secondary care 
seldom necessary, often no consensus on pathophysiology, and does not always lead to a 
consultation with the doctor. 
Chronic chilblains fulfils these criteria and is also generally considered to be a common 
disease. Like many other common diseases the disorder is not extensively investigated: How 
patients with chronic chilblains experience the disease is simply not known, consensus on 
the pathophysiological mechanism of the disease is lacking, and consensus on therapeutic 
options and their mode of action is also lacking. Furthermore, the prevalence of chronic 
chilblains is relatively low and the disease is only symptomatic in the winter months. These 
disease characteristics influenced the choice of methods used in our studies. Patient 
experiences, coping and needs were studied using a qualitative design with semi-structured 
interviews25,26. To approach the proposed phenotypic familial aggregation we used a case 
control family design27,28. Therapeutic options were inventoried using the principles of 
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systematic review29,30. The effectivity of vitamin D3 was studied using a design analysing 
time series31. The effectivity of nifedipine and betamethasone was assessed using a 
crossover randomised clinical trial according to the two-stage model originally proposed by 
Grizzle32,33. 
 
Thesis outline 
This thesis reflects on six separate studies concerning the three main aims of the research: 
patient experience, phenotypic familial clustering and therapy options. The different studies 
address the research questions and are reported in a series of six articles. A general 
introduction and a general discussion on the topic are provided in Chapters 1 and 8 
respectively. 
Chapter 1 provides a general introduction to the thesis. 
Chapter 2 describes a qualitative study performed using semi-structured interviews about 
patients’ needs and experiences.  
Chapter 3 describes a study using a case-control family design on phenotypic familial 
aggregation in chronic chilblains. 
Chapter 4 describes a literature study on present treatment options for chronic chilblains, 
updated until September 2016. 
Chapter 5 describes a study on de effect of Vitamin D3 using a time series analysis design. 
Chapter 6 describes a crossover, randomised clinical trial on the effectivity of nifedipine in 
chronic chilblains using Grizzles two-stage model. 
Chapter 7 describes a crossover, randomised clinical trial on the effectivity of topical 
betamethasone in chronic chilblains also using Grizzles two-stage model.  
Chapter 8 presents a general discussion on the topic of chronic chilblains. 
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Chilblains from the patient’s perspective.  
Eur J Gen Pract 2007;13(3):159–60.  
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Introduction 
Chronic chilblains is generally considered by doctors to be a slightly inconvenient and 
harmless condition. We observed that a large number of our patients showed unexpectedly 
severe complaints, with a distinct impact on daily life. Adequate information about the 
clinical picture is available1-6, but we did not find any publications about how patients feel 
about their symptoms, nor about the measures they take to cope with them.  
Therefore, the aim of our study was to gain better insight by interviewing patients on two 
issues: 1) how do patients experience chronic chilblains, and what are their views on the 
condition?  2) How do patients cope with the disease, and what are their needs? 
 
Methods 
We opted for a qualitative design, obtaining information by a semi-structured interview. The 
setting of the study was general practice.  
The study population consisted of all the participants in a study on the effect of vitamin D38. 
The participants had a confirmed diagnosis, with complaints lasting at least 3 weeks. Patients 
were, for reasons concerning the original study, excluded in case of a history of 
inflammatory diseases, urolithiasis, hypercalcaemia, hyperparathyroidism, pregnancy, 
breast-feeding, or when using a calcium entry blocker.  
In the winter of 2004-2005, these participants were asked to participate in an interview. The 
interview was structured by using a guidebook, and included the nature of the complaints 
and discomfort; causes of chilblains and contributing factors as experienced and recognized 
by the patient; and measures for relief and help-seeking behaviour. All interviews were 
performed by one well-trained MD (L.R.), using standard techniques such as asking, 
summarizing, and pursuing the questions.  
The complete interviews were recorded and transcribed afterwards by the interviewer. Two 
researchers (L.R., I.S.) analysed the transcriptions. We used an open approach regarding the 
basic rules of qualitative research, coding key words and key phrases to work towards our 
conclusions9. 
 
Results 
We asked all 33 patients of the original study to participate. Seven refrained. The age and 
gender distribution of the remaining 26 patients met the distributions reported by others for 
the disease1,2,4,7.  
The ages at the onset of chronic chilblains varied between 8 and 60 years. The mean age of 
onset was 29 years (SD 16.5).  
Most of the patients were troubled by red to purple discolouration, pain, and oedema. 
Increased sensitivity, itching, stiffness, numbness, fissures and wounds, a burning and 
glowing sensation, and tingling were mentioned as well (Table I).  
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Table I: Experienced complaints (n=26). 
 
Complaints  Number of 
patients 
Discolouration, red to purple  26 
Pain  24 
Swelling  16 
Increased sensitivity  12 
Itching 9 
Stiffness  6 
Diminished sensitivity  6 
Formation of fissures and 
wounds  
5 
Burning and glowing sensation  4 
Tingling  3 
 
Chronic chilblains were experienced by patients as an annoying and disturbing condition that 
led to restrictions in everyday life. The seriousness of these restrictions and handicaps varied 
considerably, ranging from a necessity to use peeled and cut-up vegetables and fruits or not 
being able to write down the answers during an exam, to feeling ashamed and not being 
able to wear normal shoes. It is mainly this impact on everyday life that determines quality 
of life10,11.  
The majority of patients visited a general practitioner. Patients complained of a shortage of 
information.  
We found a large number of measures that had been tried, unfortunately without positive 
effect. The patients were willing to try almost anything to get rid of their complaints, but 
they found the availability of effective measures to be lacking. Patients look upon chilblains 
as a disorder that is still commonly unknown and offers few therapeutic possibilities. Most 
patients stated that they could cope with this, but they hoped that a cure would soon be 
found.  
Patients were not able to give a clear reason for the development of their complaints. 
However, all patients reported that chronic chilblains occurred at temperatures below 10-
15oC. The presence of chilblains in the first-degree relatives of 10 patients suggested a 
hereditary component in the aetiology of chronic chilblains. 
 
Discussion 
We performed a qualitative study, with a large variety of ages. The number of participants 
was sufficient when considering saturation12. Our study has, however, some restrictions. The 
study population was selected from participants of a trial to assess the effect of vitamin D on 
chronic chilblains. This may have influenced the severity of their conditions and thus the 
results of our study. Furthermore, all participants live in the same region in the northwest of 
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the Netherlands. Local conditions may influence our findings, but we think that this kind of 
bias does not significantly affect our results.  
Taken together, our findings support the observation that chilblains prove to be an annoying 
and disturbing disorder, causing major restrictions in daily life. Patients lack proper 
information about the disease and the availability of an effective therapy, and the 
hypothesis that cold in combination with a hereditary factor plays a role in chronic chilblains 
needs further research. Patients usually see their general practitioner for advice. We 
therefore strongly urge further research into the disease and its therapy. 
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Abstract 
Background. Our clinical observations and two earlier studies indicate familial clustering to 
be involved in chronic chilblains. Demonstrating phenotypic familial aggregation is a next 
step to investigate the origin of familial clustering. 
 
Objective. This study was initiated to assess evidence for phenotypic familial aggregation in 
chronic chilblains. 
 
Methods. Using a case–control family design in a primary care setting, we computed the 
familial relative risk of at least one episode of chronic chilblains during life with 95% 
confidence intervals (CIs). The study population consisted of 192 relatives of 31 case 
probands (at least one confirmed episode of chronic chilblains). The control population 
consisted of 178 relatives of 31 sex- and agematched index controls (no history of chronic 
chilblains). 
 
Results. The familial relative risk of chronic chilblains was 3.6 (95% CI 1.9–7.3). Additional 
sensitivity analysis shows similar figures. 
 
Conclusion. We demonstrate robust phenotypic familial aggregation in chronic chilblains. 
 
Key words: Case–control study, cold temperature, chilblains, disease susceptibility, general 
practice, genetics. 
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Introduction 
Chronic chilblains are cold-induced, painful or itching, red-blue lesions on the fingers, feet, 
ears or thighs1. Affected patients consider chronic chilblains to be an annoying and 
disturbing disorder causing major restrictions in daily life. The majority of patients visit a GP 
but complain of a shortage of information and therapeutic options2. 2010 data from the 
Netherlands Information Network of Primary Care (LINH) show a prevalence of chronic 
chilblains of between 0.9 and 1.7 cases per 1000 enlisted patients. Prevalence among 
women (0.9–2.1 cases per 1000 patients) is higher than among men (0.6–1.2 cases per 1000 
enlisted patients).Histopathological examinations of skin biopsies show typical findings: 
oedema of the dermis, a perivascular inflammation and vascular damage3. 
It is generally believed that chronic chilblains can occur after repeated exposure to 
temperatures <10–15°C among patients susceptible to the disease2,4,5. The nature of the 
susceptibility is unknown. In secondary care, the condition is often associated with serious 
underlying problems such as systemic lupus erythematosus but GPs consider the disease to 
be common and idiopathic6–9. 
Our observations in chilblained families and the outcomes of an earlier study indicate that 
familial clustering (the clinical sense of multiple diseased members in a family) is involved in 
chronic chilblains2. A case–control study from Pakistan also suggests familial clustering10. 
Familial clustering may suggest phenotypic familial aggregation (an on average greater 
frequency of disease in close relatives of chilblained individuals compared to relatives of 
healthy individuals)11. Phenotypic familial aggregation suggests involvement of genetic 
determinants in a disease11. The aim of our study is to assess the proposed phenotypic 
familial aggregation in chronic chilblains. 
 
Patients and methods 
Study design 
We used a case–control family design with population-based controls to compute the 
familial relative risk (RR; the risk ratio comparing the risk among relatives of chilblained 
patients and the risk among relatives of healthy individuals) of at least one episode of 
chronic perniones. A case–control family design can be seen as a retrospective cohort study 
of relatives12. In a case–control family design with population-based controls, the case 
cohort is recruited among relatives of patients and the control cohort is recruited among 
relatives of individuals selected by population-based sampling12. We studied a cohort cases 
(relatives of the case probands: chilblained patients) and a cohort controls (relatives of the 
index controls: healthy individuals enlisted to a general practice) (Table 1). The study design 
is well described and very suitable to address phenotypic familial aggregation in relative rare 
diseases such as chronic chilblains11,12. 
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Table 1; Flow diagram 
 
 
 
 
 
  
Questionnaire returned 
n=128 (45%) 
Available for confirmation 
n=5 (2%) 
Confirmed 
n=5 (2%) 
Questionnaire returned 
n=111 (43%) 
Available for confirmation 
n=0 (0%) 
Confirmed 
n=0 (0%) 
Not 
n=81 
Not 
n=123 
Not 
n=63 
Not 
n=111 
Cases 
n=287 (100%) (9.3 / case proband) 
Controls 
n=260 (100%) (8.3 / index control) 
Study population Control population 
Enrollment 
Case probands 
Available n=31 
Index controls 
Selected n=31 
Included n=31 Included n=31 
Alive 
n=223 (78%) 
Alive 
n=193 (74%) 
Not 
n=64 (22%) 
Not 
n=67 (26%) 
Traced 
n=209 (73%) 
Traced 
n=174 (67%) 
Not 
n=14 (5%) 
Not 
n=19 (7%) 
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Sampling 
The study population (cases) consisted of all identified family members (relatives) of 31 case 
probands with a history of chronic chilblains. Case probands were selected by asking 
informed consent to all traceable participants from our studies on the effect of vitamin D3, 
nifedipine and betamethasone cream (in draft, registration Dutch Trial Register NTR2171) in 
chronic chilblains13,14. We included participants with a minimum age of 18 years, with 
complaints of chronic chilblains lasting at least 3 weeks. The diagnosis was confirmed by one 
of the authors (IS) based on common used diagnostic criteria: complaints emerging in the 
winter months with itching and/or painful purple-blue discoloured lesions on fingers and/or 
toes and/or other localizations on the feet and/or on the lateral side of the thigh, without a 
history of complaints persisting in the summer months1,4. Swollenness and ulceration could 
be present but were not obligatory. Earlier episodes in any winter before could be present 
but were also not obligatory. The control population (controls) consisted of all identified 
relatives of 31 index controls without any history of chronic chilblains. The absence of a 
history of chilblains was assessed by checking the medical record of the participant and by 
verification with the participant during face-to-face contact. We selected the index controls 
sex-matched and age-matched but otherwise at random among patients from the surgery of 
one of the authors (IS). 
Relatives of case probands and index controls were identified in a face-to-face contact with 
each case proband and index control constructing an at least three-generation pedigree 
containing all identified relatives; predecessors and offspring; and deceased or alive. 
 
Data collection 
Data collection took place between January and May 2012. During a face-to-face contact 
with all individual case probands and all individual index controls, the pedigree was 
constructed. Hear-say information about deceased relatives was provided by the case 
proband or index control (hear-say episodes). After permission from the case proband or 
index control, all identified approachable living relatives received information on the study, 
an informed consent form, a disease description including pictures to inform them about the 
symptoms of chronic chilblains, a questionnaire and a stamped reply envelope. The disease 
information was extensive but the questionnaire was kept basic in an effort to ensure a high 
response rate (online Supplementary Data Table S1). The participant was asked to report any 
episode of chronic chilblains current or in the past (self-reported episodes) if a current 
episode was reported permission was asked for confirmation by one of the authors (IS) 
(confirmed episodes). Information about smoking habits and connective tissue disease was 
obtained. 
 
Statistical analysis 
We used a two-sample, unpaired t-test (means) and Yates corrected chi-square test 
(proportions) to demonstrate possible differences between case and control groups. 
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Basic analysis included all relatives using hear-say information in case of a deceased relative 
and self-reported or confirmed information in case of living relatives. The familial relative 
risk with 95% confidence intervals (CIs) between cases and controls of at least one episode 
of chronic chilblains during life was calculated. Calculations were made for three levels of 
evidence: total (hear-say episodes, selfreported episodes and confirmed episodes together), 
self-reported (self-reported episodes and confirmed episodes together) and confirmed 
(confirmed episodes only). Correction for sex and age differences between cases and 
controls was not necessary. The sensitivity analysis was based on all identified relatives 
(relatives from whom no information could be obtained were considered to be healthy). 
Familial RR was calculated using 2 × 2 tables15. CIs were computed using a method based on 
constant chi-square boundaries16. 
 
Results 
Recruitment 
We were able to trace 31 case probands and included all. About 287 cases were identified 
(9.3 per case proband) of which 223 were alive and 64 deceased. We approached 209 cases 
of which 128 responded. We were able to confirm a total of five episodes of chronic 
chilblains. We selected 31 sex-matched and age-matched index controls and included all. 
About 260 controls were identified (8.4 per index control), 193 alive and 67 deceased. About 
174 controls could be approached of which 111 responded. No episodes of chronic chilblains 
were confirmed (Table 1).  
 
Characteristics of probands, cases, index controls and controls 
Table 2 shows the characteristics of all identified relatives and those relatives included in the 
basic analysis. No statistically significant differences between cases and controls could be 
demonstrated for sex distribution, number of deceased relatives, number of relatives who 
lost contact with the case proband or index control or mean year of birth. Questionnaire 
response was 61% among cases and 64% among controls. For unknown reasons, 
questionnaire response on connective tissue disease and smoking habit items was poor 
among participants not reporting any episodes of chronic chilblains. Only 3 out of 29 cases 
reporting chilblains and none of the 11 controls reporting chilblains smoked. Connective 
tissue disease was not reported by either chilblained cases or chilblained controls. Because 
of this and because information about smoking habits and connective tissue disease was not 
available in case of hear-say information, we did not analyse this data. 
 
Familial RR 
Table 3 shows the number of cases and controls, the number of relatives with at least one 
episode of chronic chilblains, the familial risk among cases (Rcase), the familial risk among 
controls (Rcontrol) and the familial RR with 95% CI for the basic analysis and the sensitivity 
analysis. For basic analysis, data of 192 cases were available. Hearsay information was 
positive on chilblains in 14 deceased cases, 24 cases reported chilblains. A current episode 
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was confirmed in five cases. Data of 178 controls were available. Hear-say information was 
positive on chilblains in one deceased control. Ten controls reported chilblains. No current 
episode was confirmed. Analyses of hear-say, self-reported and confirmed episodes together 
(total) give a RR of 3.6 (95% CI 1.9–7.3). Analysis of only self-reported and confirmed 
episodes (self-reported) give a RR of 2.7 (95% CI 1.3–5.8). The differences are statistically 
significant. We confirmed five episodes among cases and none among controls. This 
difference is not statistically significant. Sensitivity analysis shows similar figures [total: RR 
2.2 (95% CI 1.1–4.4 and self-reported: RR 2.6 (95% CI 1.3–5.7)]. 
 
Table 2: Characteristics of the cases and controls 
 Basic analysisa  Sensitivity analysis
b 
 Cases 
(n=192) 
Controls 
(n=178) 
P  Cases 
(n=287) 
Controls 
(n=260) 
P 
 n% n%   n% n%  
Women 101 (53) 80 (45) 0.171  149 (52) 116 (45) 0.105 
Deceased 64 (33) 67 (38) 0.449  64 (23) 67 (26) 0.521 
Lost contact - - -  14 (5) 19 (7) 0.359 
        
 Mean SD Mean SD   Mean SD Mean SD  
Year of birth 1956 (32.97) 1953 (31.63) 0.357  1961 (31.17) 1955 (29.99) 0.061 
a 
Including deceased relatives and relatives responding to questionnaire. 
b 
Including all identified relatives. 
 
 
Table 3: The number of cases and controls (N), the number of chilblained relatives, the 
familial risk among cases, the familial risk among controls and the familial relative risk with 
95% confidence interval 
 Cases 
(n) 
Controls 
(n) 
Familial risk 
case 
Familial risk 
control 
Familial 
relative 
risk 
95% 
confidence 
interval 
Basic analysis       
    N 192 178     
    Totala 43 11 0.22 0.06 3.642 1.884–7.290 
    Self-reportedb 29 10 0.15 0.05 2.689 1.303–5.781 
    Confirmedc 5 0 0.03 0.00 ∞ 0.808–∞ 
Sensitivity 
analysis 
      
    N 287 260     
    Totala 43 11 0.16 0.04 2.179 1.127–4.398 
    Self-reportedb 29 10 0.10 0.04 2.627 1.258–5.685 
    Confirmedc 5 0 0.02 0.00 ∞ 0.787–∞ 
a 
Hear-say and self-reported episode of chilblains (including confirmed episodes). 
b 
Self-reported episode of chilblains (including confirmed episodes). 
c
 Confirmed episode of chilblains only. 
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Discussion 
In this case–control family study, we found a familial RR ~3.0. This figure implicates 
phenotypic familial aggregation in chronic chilblains. It was found using hear-say information 
about deceased relatives and self-reporting and confirmed cases from living relatives (RR 
3.6) as well as self-reporting and confirmed cases from living relatives only (RR 2.7). The 
difference is statistically and clinically significant and was confirmed in the additional 
sensitivity analysis. The results of this study concur with the familial clustering found in our 
2004–05 qualitative study2. About one-third of participants in that study reported 
chilblained first-degree relatives. The findings also concur with the observation of familial 
clustering by Raza et al. in their 2006–07 case–control study: 26% of the chilblained cases 
and 3% of the healthy controls reported a positive family history of chilblains (RR 8.7, 95% CI 
2.7–35.5)10. 
 
Strengths and limitations 
The strength of our study is the design and composition of the case and control population. 
Case probands were well diagnosed. 
Comparable case and control populations and high response rates are vital for interpreting 
familial RR11. To avoid ascertainment bias we matched the index controls on sex and age and 
recruited them in the same geographical region as the study population. We used a basic 
questionnaire to prevent a low response rate. Due to the design, differences between case 
and control population arise by chance. In addition, we demonstrated no statistical 
significant differences in characteristics between the groups. Additional sensitivity analysis 
based on all identified relatives, considering relatives from whom no information could be 
obtained to be healthy, did not change the outcomes. 
One limitation of this study is that we mainly used hear-say and self-reported information on 
episodes of chronic chilblains. Due to the information on chronic chilblains (online 
Supplementary Data Table S1) provided to all participants, we expect probable confounding 
effects in regard to self-reported information to be randomly distributed in the case and 
control population, but this does not apply to the probable confounding effect of hear-say 
information. Chronic chilblains are likely to be more of an issue and episodes among 
deceased family members may be remembered better in chilblained families. We think this 
limitation is inescapable due to the nature of the disease and the study design. However, it 
may have influenced the results in favour of the proposed phenotypic familial aggregation. 
Another limitation is the recruitment of index controls in one general practise, which may 
cause bias. Our main consideration to do this was our need to recruit healthy index controls 
in the same geographical region as the case probands under efficient conditions and with 
easy access to their medical records. Because the practice serves inhabitants of a 70 km2 
area in the ~300 km2 region where the case probands were recruited, and the relatives of 
the index controls are not restricted to the practice, we think our choice is acceptable. Low 
ambient temperatures are generally accepted to influence the disease, but the role of other 
confounding factors in chronic chilblains is not well understood1. Due to our design, ambient 
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temperatures could not be documented and information about smoking habits and 
connective tissue disease was not available in case of hearsay information. For unknown 
reasons, questionnaire response on connective tissue disease and smoking habit items was 
poor among participants not reporting any episodes of chronic chilblains. We demonstrated 
no statistical significant differences in characteristics between the groups on sex distribution, 
number of deceased relatives, number of relatives who lost contact with the case proband 
or index control, mean year of birth and questionnaire response. 
Therefore and also because, due to the design, differences between case and control 
population arise by chance, we analysed our results with a univariate technique. 
 
Implications 
The phenotypic familial aggregation found is robust but is probably based on a complex of 
genetic and non-genetic factors11. The underlying mechanism of chronic chilblains remains 
uncertain. Involvement of the cold-induced vasodilatation (CIVD or hunting response) has 
been proposed17. CIVD can be seen as a protective mechanism to prevent skin damage 
during exposure to cold and is part of and influenced by other cold-induced vascular 
mechanisms18,19. Sex and ethnic differences in CIVD have been demonstrated17,20. As stated 
in the introduction, Dutch prevalence of chronic chilblains in primary care is between 0.9 and 
1.7 cases per 1000 enlisted patients. It is unlikely that exposure to low temperatures alone 
causes chronic chilblains. We therefore suggest that the familial aggregation involved in 
chronic chilblains, among possible other factors, may represent a genetic predisposition that 
influences the quality of CIVD leading to skin damage after exposure to cold that results in 
chronic chilblains. 
Further evaluation of the origin of the familial aggregation, the possible genetic disposition 
and the possible relationship with CIVD will probably help to provide more evidence-based 
advice and treatment in the future. 
 
Conclusion 
In this case–control family study, we found a familial RR between 3.6 (hear-say and self-
reported episodes) and 2.7 (self-reported episodes only). This figure implicates robust 
phenotypic familial aggregation in chronic chilblains. 
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Supplementary Data 
Table S1: Information on chronic chilblains and questionnaire as sent to the relatives of 
probands and index controls. 
 
Information on chronic chilblains 
 
Chronic chilblains are cold-induced, painful or itching, red-blue swollen lesions on fingers, 
toes, ears or thighs (see figure). Ulceration may be present. Complaints occur in the winter 
months (from October onwards) and resolve in spring (April or May). 
In some cases the complaints recur every winter. Other cases report only one episode of 
chronic chilblains after which the complaints do not recur for a long period or never occur 
again. 
The figure shows pictures of chilblained hand, feet and thigh (figure S1) 
 
Questionnaire 
 
Have you had complaints ever in your life compatible with chronic chilblains? 
o No, never 
o Yes, but I don’t have complaints now. 
Please answer the following questions: 
o I was diagnosed by a physician 
o I concluded based on the information given in this booklet 
o Otherwise (please specify):  
o Yes, I have complaints at this very moment. 
We would like to contact you in order to confirm the diagnosis. 
Do you agree? 
o No 
o Yes, use this telephone number: 
Do you suffer or have you ever suffered from any connective tissue disease? 
o No, never 
o Yes (please specify): 
Do you smoke or have you ever smoked? 
o No, never 
o Yes, but not anymore 
o Yes, I smoke 
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Figure S1: pictures of chilblained hand, feet and thigh. 
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Present treatment options for chronic chilblains 
A systematic review 
 
Souwer IH, Lagro-Janssen ALM. The treatment of chilblains: a literature study 
Huisarts Wet 2004;47(12):561-2 (translated to English, edited and updated August 2016)  
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Abstract 
 
Backgrounds 
Chronic chilblains are cold-induced, painful or itching lesions on the fingers, feet, ears or 
thighs. We performed a systematic literature review on treatment options. 
 
Methods 
We searched in Medline, Embase, The Cochrane Database of Systematic Reviews and The 
Cochrane Central Register of Controlled Trials until August 2016. The methodological quality 
of the studies was assessed with an evaluation list. Publications that were not based on 
original research into the treatment of chilblains and studies not meeting minimal quality 
requirements were excluded. 
 
Results 
One case series and three placebo-controlled randomised clinical trials met our quality 
criteria. 
 
Conclusion 
We conclude that vitamin D3 administered orally is not effective but cannot draw any 
further conclusions concerning effective treatment options for chronic chilblains. Nifedipine, 
fluocinolone cream and pentoxyfyline might appear to be effective but due to the moderate 
quality of the research no unequivocal statement can be made about this.  
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Background 
Chilblains are cold-induced, painful or itching lesions on the fingers, feet, ears or thighs1. The 
condition occurs throughout the world during the winter months when daily mean 
temperatures drop below 12-150C2. Probably three forms of chilblains exist: acute chilblains, 
chronic (idiopathic) chilblains and chilblain like symptoms (secondary chilblains)1-8. Acute 
chilblains emerge after a single exposition to low ambient temperatures and last two weeks 
at most. Chronic chilblains emerge after repeated or prolonged exposition to low ambient 
temperatures and last for longer periods. Chilblain-like symptoms are associated with other 
diseases, particularly systemic lupus erythematosus.  
Although diagnosis of chronic chilblains on the basis of the clinical picture is not difficult, 
there is little certainty about the choice of treatment for this condition. Until recently Dutch 
general practitioners treated chronic chilblains with vitamin D3 injections, oral nifedipine, 
topical corticosteroids and a variety of other therapies4. But the effectiveness of the various 
treatments for chronic chilblains can be doubted. We therefore performed a systematic 
literature review to determine what is known about the treatment of chilblains and how 
effective these treatments are. 
 
Method 
Inclusion of studies 
The original search strategy aimed at finding as many publications as possible that contained 
original research applicable to Dutch primary care. The search was made in Medline, 
Embase, The Cochrane Database of Systematic Reviews, The Cochrane Central Register of 
Controlled Trials (Central), Cinahl and the index of two Dutch journals (“Nederlands 
tijdschrift Geneeskunde” and “Huisarts en Wetenschap”). Additional material was searched 
for on the Internet using the search engines Google and Alta Vista. The search covered the 
period from the start of the registration of the database concerned until March 2004. In July 
2016 we updated the search using Medline, Embase, the Cochrane Database of Systematic 
Reviews and the Cochrane Central Register of Controlled Trials (Central).  
The following search terms were used (as MESH term and/or as text word): chilblain OR 
chilblains OR pernio OR perniones, NOT (lupus OR lupus erythematosus OR sle OR 
sarcoidosis OR tuberculosis) AND (therapy OR therapeutics OR treatment OR injection OR 
injections OR vitamin D OR cholecalciferol OR calcium channel blockers OR adrenal cortex 
hormones OR corticosteroid OR ultraviolet) AND (randomised clinical trial OR clinical trial OR 
cohort study OR case control study OR single case study OR study OR double blinded OR 
single blinded). For the Dutch databases the search was conducted with equivalent terms in 
Dutch: pernio, perniones, winterhanden, wintervoeten and wintertenen. The references of 
the literature found and two key publications were subsequently followed up to detect 
missed articles1,3.  
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Table 1: The quality assessment list. 
  Article details:  
Assessor: 
 
It concerns a parallel RCT/crossover RCT/case series.    
 
A. Randomisation: 
How has the randomisation been applied? 
 
B. Comparability of the groups: 
At inclusion, were groups similar with respect to the prognostic indicators age, gender 
exposure to cold and medication use? 
 
C. Inclusion criteria:  
Are the inclusion and exclusion criteria described (for all groups)? 
 
D. Blinding of the outcome measure: 
Is the person assessing the outcome blinded? 
 
E. Blinding of the patient: 
Is the patient blinded? 
 
F. Description of the outcome measures: 
Are the most important outcome measures described clearly enough? 
 
G. Intention to treat analysis: 
Does the analysis include an intention-to-treat analysis? 
 
H. Compliance: 
Is the number of people who have completed the allocated treatment described for both 
the study and the control groups? 
 
I. Exposure to cold in the study period: 
Was the exposure to cold during the study period documented? 
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Exclusion of studies 
We excluded publications that were not based on original research into the treatment of 
chilblains and articles referring to the original study (exclusion due to irrelevance). 
Furthermore we excluded studies not meeting minimum quality requirements as defined 
below (exclusion due to low quality). 
 
Quality assessment 
The methodological quality of the studies not excluded due to irrelevance was assessed with 
the help of a simple evaluation list (Table 1). We made a limited choice of the criteria 
included in the Delphi list9. For the case series our assessment was for obvious reasons 
limited to the description of the outcome measurement, the compliance and the exposure 
to cold. Each item was equally weighted. Therefore the maximum quality score for case 
series was 3 and for randomised clinical trials (RCT) 9. Each article was assessed by two 
researchers (IHS and ALJ) independently from each other. The final score was determined by 
reaching consensus. To address bias due to differences in outcome measurement and cold 
exposure we defined minimum quality requirements: 
 a well-described outcome measurement (all studies); 
 in addition a description of cold exposure during the research period (case series 
only); 
 in addition a well-described blinding of the patient and outcome measurement 
(randomised clinical trials only).  
 
Meta-analysis 
We did not make an attempt to perform a meta-analysis. 
 
Results  
Fifty-four articles were selected of which 36 were excluded due to irrelevance (Figure 1)10-45. 
Twenty-five of these concerned a wide variety of not chilblain related diseases 13,14,17,21-29,31-
33,35-38,40-45. Ten articles concerned chilblains and related skin conditions but did not describe 
original research on therapy 10-12,15,18-20,30,34,39. We were not able to obtain a full text copy 
nor an abstract of one article12.  
The methodological quality of the remaining 18 articles describing original research into the 
treatment of chilblains was assessed46-63. One of the articles describes three distinct studies 
with nifedipine that were assessed independently of each other53. One study was written in 
Hebrew and another in Italian49,54. Both of these studies were translated into Dutch by a 
sworn translator before assessment. We were not able to obtain a full text copy of two 
studies and decided to assess the abstracts in English53,56. This resulted in 20 studies that 
were available for quality assessment. Nine case series, six placebo-controlled RCTs and five 
active-control RCTs. Various aspects from the studies are summarised in Tables 2, 3 and 4. 
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Figure 1: Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Search 
Publications identified (n = 54) 
Excluded due to irrelevance (n = 36) 
 Not chilblain related (n = 25) 
 Not original research (n = 10) 
 Unavailable (n = 1) 
Selection 
Publications available for quality assessment (n = 18) 
One publication described 3 studies 
Studies available for quality assessment (n = 20) 
Excluded due to low quality (n = 16) 
Included studies (n = 4) 
 Cases series (n = 1) 
 Placebo-controlled RCTs ( n = 3) 
 Active control RCTs (n = 0) 
Quality assessment 
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Table 2: Case series with assessment. 
 
+ = Yes, described well. 
-  = No, uncertain, not described (well). 
  
Description of the study Quality assessment Outcome 
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Renes 1943 46 18 - - + + - 2 Positive effect urtinatrin 
Broers 1944 47 66 - - - + - 1 Positive effect vitamin D 
Ganor 1973 49 20 - - + + + 3 
Positive effect fluocinolone 
cream 
Rustin et al. pilot 
study 1989 52 
10 - - - + - 1 Positive effect nifedipine 
Rustin et al. open 
study 1989 52 
34 - - - + - 1 Positive effect nifedipine 
Cappugi et al. 1995 53 10 - - - - - 0 Positive effect capsaicin 
Bilancini et al. 1998 54 16 - - + + - 2 
Positive effect 
iontophoresis 
Yang et al. 2010 59 5 - - - + - 1 
Positive effect 
hydroxychloroquine 
Verma 2015 62 22 
10-
30 
days 
+ - + - 1 
Positive effect topical 
nitroglycerine 
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Table 3: Placebo-controlled RCTs identified with assessment. 
 
CRCT = Randomised Controlled Trial crossover type. 
PRCT = Randomised Controlled Trial parallel type. 
TRCT = Randomised Controlled Trial time series analysis 
+ = Yes, described well. 
-  = No, uncertain, not described (well). 
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SE-Scotland 
Faculty 
College of 
General 
Practitioners 
1957 48 
PRCT 128 - - + - - + + + - + - 5 positive effect 
phenoxy- 
benzamine 
Jaffe et al. 
1980 50 
CRTC 33 - - - - - - + + - + - 3 no effect 
thymoxamine 
Langtry et al. 
1989 51 
PRCT 9 - - + + - - + + - + - 5 no prophylactic 
effect 
ultraviolet 
phototherapy 
Rustin et al. 
1989 52 
CRCT 10 - - - - - + + + - + - 4 positive effect 
nifedipine 
Souwer et 
al. 
2008 58 
TRCT 33 + - + + + + + + - + + 8 Vitamin D3 not 
superior to 
placebo 
Al-Sudany 
2016 63 
PRCT 118 - + - - - - - + - + - 2 positive effect 
pentoxifylline 
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Table 4: Active-control RCTs with assessment. 
 
CRCT = Randomised Controlled Trial crossover type. 
PRCT = Randomised Controlled Trial parallel type. 
+ = Yes, described well. 
-  = No, uncertain, not described (well).  
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Patra et al. 
2003 55 
PRCT 36 - - - - - - - - - + - 1 Nifedipine 
superior to 
diltiazem 
Noaimi et 
al. 2008 57 
PRCT 40 - + - - + - - - - + - 2 Pentoxyfyline 
superior to oral 
plus topical 
glucocorticoids 
Kubais et 
al. 2010 60 
PRCT 62 3-35 
days 
- - - + - - + - + - 3 Nifedipine 
superior to 
topical minoxidil 
Xiang et al. 
2005 56 
PRCT 264 - - - - - - - - - - - 0 Acupuncture plus 
massage superior 
to dong chuang 
plaster 
Khalid et al. 
2014 61 
PRCT 65 - + + + + - - + - + - 4 Topical nitro-
glycerine not 
superior to 
nifedipine 
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One case series, three placebo-controlled randomised clinical trials and none of the active-
control clinical trials met the minimal requirements of methodological quality48,49,52,58. The 
included studies are described below in order of publication date. The studies excluded after 
quality assessment are described in the appendix. 
 
Phenoxybenzamine  
The South-East Scotland Faculty of the College of General Practitioners (1954) published a 
double-blinded, placebo-controlled, parallel type RCT with 128 participants in a primary care 
setting48. The alpha-receptor blocker phenoxybenzamine 10mg three times daily was 
compared to placebo. Duration of symptoms at inclusion was not reported. Outcome after 4 
weeks was the assessment of the effect as reported by the doctor on a 3-point scale. Results 
of 103 participants were available for analysis but only 62 completed the 4-week study 
period. Good/not good ratio was 24/4 participants in the phenoxybenzamine group 
compared to 17/17 in the placebo group. The difference was statistically significant. Adverse 
effects were seen in 22 out of 59 patients receiving phenoxybenzamine urging 9 participants 
to discontinue treatment.  
 
Fluocinolone acetonide cream  
Ganor (1973) described the results of the treatment of 20 patients with the topical 
corticosteroid fluocinolone acetonide 0.025% cream under occlusion49. The research took 
place in his dermatology practice. Duration of symptoms at inclusion was not described. 
Seventeen patients came back for a check-up and in 14 of them an improvement had 
occurred in terms of pain as well as for objective characteristics such as eczema, swelling and 
discolouration.  
 
Nifedipine 
Rustin et al. (1989) published about the effectiveness of the calcium channel blocker 
nifedipine52. It was a publication with three associated studies including a randomised, 
double-blind, placebo-controlled, crossover type RCT of 10 patients in a secondary care 
setting. Participants had severe acral chilblains for 5 months per annum during the last 3 
years before inclusion and were enrolled as soon as lesions occurred. In this crossover study 
with a research period of 12 weeks, patients received nifedipine for 6 weeks and placebo for 
6 weeks. There was no washout period. It is not clear how the randomisation took place and 
the comparability of the groups is not clear. Doctors assessed the effect of the intervention 
based on the lesions and the diary the patients kept. Seven out of 10 patients receiving 
nifedipine became clear of lesions within 10 days. Of the 5 patients initially treated with 
nifedipine, 3 relapsed severely after crossover to placebo and restarted with nifedipine. All 
of the 5 patients initially treated with placebo and 2 patients who continued to receive 
placebo after crossover continued to develop new lesions. The authors concluded that 
nifedipine is an effective treatment of chilblains.  
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Vitamin D3 
Souwer et al. (2009) published an RCT using time-series analysis with 33 participants in a 
primary care setting58. The study is described fully in Chapter 5 of this thesis. Oral 
administration of 2000 IU vitamin D3 per day was compared to placebo. Duration of 
symptoms at intake was 3 weeks or more. Outcomes were decrease of complaints and 
decrease of disability after 3 weeks use of placebo, 4 weeks use of vitamin D3 and 7 weeks 
use of vitamin D3. Confounding effects of temperature changes and baseline instability were 
taken into account. Decrease in complaints after 3 weeks of placebo was reported by 6 
participants (38%), after 4 weeks vitamin D3 by 11 participants (48%) and after 7 weeks 
vitamin D3 by 8 participants (47%) After correction for both temperature and baseline 
change, 3 participants (19%) remained in all three groups. For decrease in disability similar 
results were reported. The authors concluded that vitamin D3 is not effective in the 
treatment of chronic chilblains.  
 
Discussion 
Internal validity  
We assessed the methodological quality of the studies by the South-East Scotland Faculty of 
the College of General Practitioners as 5, by Ganor as 3, by Rustin et al. as 4 and by Souwer 
et al. as 8. 
Although in the included case series by Ganor the primary outcome was described properly 
and the exposure to cold and, in particular, the variability in this due to changes in the 
weather conditions throughout the research period was documented, objections can be 
made against the conclusions of the study49. Inherent to the case-series design the results 
may at least partly be determined by the placebo effect and the natural course of the 
condition. The duration of symptoms at inclusion is unclear. The treatment may therefore 
have been applied to patients with acute chilblains. This form of chilblains it is known to 
usually resolve spontaneously within several weeks. Due to the case series design a 
Hawthorne effect, caused by patients’ own efforts to alleviate their symptoms by changing 
habits during the study, could also have biased the outcomes64. 
The placebo-controlled RCTs by the South-East Scotland Faculty of the College of General 
Practitioners and Rustin et al. did not describe inclusion and exclusion criteria well48,52. 
However the description of participants by Rustin et al suggests that only patients with 
chronic chilblains were included. Randomisation was not described in the study reported by 
Rustin et al. Comparability of the groups was not described in the studies reported by the 
South-East Scotland Faculty of the College of General Practitioners and Rustin et al. 
Compliance was described well in all studies but an intention-to-treat analysis was 
performed in none of them. Only the study reported by Souwer et al described cold 
exposure properly58.  
In our opinion the two studies by the South-East Scotland Faculty and Rustin et al. are likely 
to be biased, for instance by differences in cold exposure between the groups receiving 
active medication and placebo respectively. A different mix of acute and chronic chilblains 
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between the study arms may also have biased the results in the South-East Scotland faculty 
study. 
 
External validity 
The generalisability to current patients suffering of chronic chilblains in primary care of the 
studies found can be questioned.  
In two of the four included studies, reported by the South-East Scotland Faculty of the 
College of General Practitioners and Ganor, it remains unclear if the studied participants 
suffered from acute or chronic chilblains. The treatment may therefore easily have been 
applied to patients with acute chilblains and the outcomes seem at least in part to be 
determined by the natural course of acute chilblains. Therefore the results of all studies may 
not be applicable to patients suffering from chronic chilblains. Acute chilblains is known to 
resolve spontaneously within several weeks while chronic chilblains is a long-lasting 
condition.  
Only the South-East Scotland Faculty of the College of General Practitioners and Souwer et 
al. studied patients with chilblains in a primary care setting. The other two studies were 
carried out in a secondary care setting. The applicability of the latter studies for patients 
with chronic chilblains in primary care is not obvious.  
Phenoxybenzamine is not currently available in Europe. The results of the study by the 
South-East Scotland Faculty of the College of General Practitioners cannot therefore be 
applied to the current treatment of chronic chilblains in primary care. 
 
Comparison with conventional treatments 
Chronic chilblains have been treated with vitamin D3 injections, oral nifedipine, topical 
corticosteroids and a variety of other therapies4. Vitamin D3 administered intramuscularly 
finds support in only one case series (Broers 1944), which did not meet our minimal quality 
criteria47. Our RCT (Souwer et al 2009) showed vitamin D3 administered orally was not an 
effective treatment for chronic chilblains. Nifedipine administered orally is supported by one 
small RCT of moderate quality (Rustin et al 1989) and topical application of corticosteroids is 
supported by one case series of moderate quality (Ganor 1973). 
 
Conclusion 
In view of these considerations of the internal and external validity of the identified studies 
we conclude that vitamin D3 administered orally is not effective in chronic chilblains. We 
cannot draw any further conclusions concerning effective treatment options in chronic 
chilblains. Nifedipine administered orally, fluocinolone cream applied locally and 
pentoxyfyline administered orally might appear to be effective but due to the moderate 
quality of the research no unequivocal statement can be made about this. 
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Appendix: excluded studies 
 
Alpha receptor blockers 
Thymoxamine  
Jaffe et al. (1980) published a double-blind, placebo-controlled, crossover type RCT with 
thymoxamine50. A total of 33 patients in a primary care setting were investigated. Duration 
of symptoms at inclusion is not described. Thymoxamine was administered for 2 weeks and 
placebo for 2 weeks over a period of 4 weeks. There was no washout period. How the 
randomisation took place is not clear. The effect of the treatment was evaluated on the basis 
of clinical assessment and the evaluation of symptom diaries. In this study a positive effect 
of thymoxamine could not be demonstrated. Thymoxamine is not currently available in 
Europe. 
 
Calcium channel blockers 
Diltiazem 
Patra et al. (2003) published an active control parallel type RCT with 36 participants from a 
military dermatologic clinic55. Diltiazem 60 mg three times daily was compared to nifedipine 
20 mg twice daily. Duration of symptoms at inclusion is not reported. Participants in the 
diltiazem group not responding in the first 7-10 days of treatment were switched to 
nifedipine (and apparently taken out of the trial) Outcome was relief of complaints after 3 
weeks graded on a 5-point scale (range: very good-nil response). In the diltiazem group, 5 
out of 12 participants (47%) showed a good response compared to 24 out of 24 participants 
(100%) in the nifedipine group. The authors concluded that diltiazem is less effective than 
nifedipine. 
Nifedipine 
Rustin et al. (1989) published about the effectiveness of nifedipine52. It was a publication 
with three associated studies including a pilot study of 10 patients and a description of a 
non-placebo-controlled treatment of 34 patients. These two studies took place among 
patients from a dermatological outpatients clinic. Duration of symptoms at intake is not 
clear. Clinical course of existing lesions and the development of new lesions were examined. 
The authors concluded that nifedipine was an effective treatment for chilblains and provided 
the theoretical argument that after the administration of nifedipine the cutaneous blood 
flow rate increased. 
Patra et al. (2003) published an active control, parallel type RCT with 36 participants from a 
military dermatologic clinic mentioned before55. Diltiazem was compared to nifedipine 20 
mg twice daily. Duration of symptoms at inclusion is not reported. Outcome was relief of 
complaints after 3 weeks graded on a 5-point scale. In the diltiazem group, 5 out of 12 
participants (47%) showed a good response compared to 24 out of 24 participants (100%) in 
the nifedipine group. The authors concluded that Diltiazem is less effective than nifedipine. 
The effect of nifedipine was reported to be comparable to other studies. 
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Kubais et al (2010) published an active control parallel type RCT with 62 patients in a 
secondary care setting60. Nifedipine (20 mg daily in the first week and 40 mg daily in the 
second week) was compared to topical application of 5% minoxidil solution twice daily. 
Mean duration of symptoms at inclusion was 17 days (range 3-35 days). Pregnant patients 
and patients with known connective tissue disease, cardiovascular disease or systemic 
medication use were excluded. Outcome was the response after 2 weeks graded on a 5-
point scale (range: very good-no response). The authors report statistically significant 
differences between the nifedipine and minoxidil groups on very good and good response in 
favour of nifedipine and on satisfactory response in favour of minoxidil. However, the data 
showed that very good, good and satisfactory response together was reported in 22 out of 
25 participants in the nifedipine group (96%) compared to 4 out of 4 (100% in the minoxidil 
group. This difference was not statistically significant. 
 
Corticosteroids 
Oral and topical glucocorticosteroids combined 
Naomi et al (2008) described an active control, parallel type RCT with 40 participants in a 
secondary care setting57. Duration of symptoms at inclusion is not clear. Oral prednisolone 
0.5 mg/kg in two doses combined with topical clobenasol ointment (dose and frequency of 
application unclear) was compared to oral pentoxyfyline 400 mg three times daily. Study 
period was 2 weeks. Outcome measurement was disappearance of symptoms and lesions 
(“good improvement”). Blinding of patient and blinding of assessor were not described. 
Participants were asked to avoid further exposure to cold. Ambient temperatures were not 
monitored. 11 (out of 20) participants in the corticosteroid arm and 9 (out of 20) participants 
in the pentoxyfyline arm completed the two-week study period. 3 out of 11 participants in 
the corticosteroid arm (27%) showed “good improvement” compared to 5 out of 9 (56%) 
participants in the pentoxyfyline group. The difference was statistically significant (p <0.05). 
The authors concluded that pentoxyfyline is superior to oral plus topical corticosteroids.  
 
Topical vasodilators 
Minoxidil 
Kubais et al (2010) published an active control, parallel type RCT with 62 patients in a 
secondary care setting mentioned before60. Nifedipine was compared to topical application 
of 5% minoxidil solution twice day. Mean duration of symptoms at inclusion was 17 days 
(range 3-35 days). Pregnant patients and patients with known connective tissue disease, 
cardiovascular disease or systemic medication use were excluded. Outcome was the 
response after 2 weeks graded on a 5-point scale (range: very good-no response). The 
authors reported statistically significant differences on very good, good and satisfactory 
response between nifedipine group and minoxidil group merely in favour of nifedipine.  
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Nitro-glycerine 
Khalid et al (2014) published an active control, parallel type RCT with 65 participants in a 
secondary care setting60. Topical application of nitro-glycerine 0.4% gel twice daily was 
compared to oral nifedipine 10-40 mg per day. Duration of symptoms at inclusion is unclear. 
Outcome was complete clearance of lesions after 6 weeks of treatment. 23 out of 26 
patients (88%) in the nitro-glycerine group showed complete regression compared to 21 out 
of 27 patients (77%) in the nifedipine group (p = 0.52). The authors concluded that nitro-
glycerine 0.4% cream is an effective and safe alternative to oral nifedipine in the treatment 
of idiopathic chilblains. 
Verma (2015) published a case series with 22 patients in a secondary care setting62. Patients 
were treated with topical nitro-glycerine 0.2% ointment twice daily combined with oral 
cetirizine dihydrochloride 10 mg once daily. Duration of symptoms at inclusion was 10-30 
days. Outcome was complete regression of the lesions after 2-3 weeks based on digital 
pictures of the lesions and a patient kept diary of any change in the clinical condition, degree 
of irritation, pain and soreness of the lesions assessed on a 3-point scale (better-same-
worse). Warm water soaks and cold protection measurements were prescribed to all 
patients. 20 out of 22 patients showed complete regression. Two patients were lost to 
follow-up. The authors concluded that topical nitroglycerine is an innocuous and effective 
treatment for perniosis and requires further exploration through randomised double-blind 
studies. 
 
Others 
Acupuncture 
Xiang et al (2005) published an active control, parallel type RCT with 264 patients56. As we 
were unable to obtain the original article in Chinese for translation we used the abstract in 
English only. The setting and the duration of symptoms at inclusion are unclear. Acupuncture 
combined with massage was compared to dong chuang plaster. Duration of symptoms at 
inclusion is unclear. Outcomes was ‘cured’ or ‘effective’ after a unknown follow-up period. In 
the acupuncture plus massage group 136 out of 136 patients were ‘cured’ or ‘effective’ 
(100%) compared to 98 out of 111 patients (77%) in the dong chuang plaster group. The 
difference was statistically significant. The authors concluded acupuncture combined with 
massage was superior to dong chuang plaster. 
 
Capsaicin 
Cappugi et al (1995) published a case series with 10 patients53. As we were unable to obtain 
the original article we used the abstract only. The setting and the duration of symptoms at 
inclusion are unclear. Patients were treated with topical capsaicin. Outcome was “clinical 
resolution” which was observed in all participants within 10 days of treatment.  
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Dong chuang plaster 
Xiang et al (2005) concluded based on the active control, parallel type RCT described above 
that dong chuang plaster was inferior to acupuncture combined with massage57. Don chuang 
plaster is not currently available in Europe. 
 
Hydroxychloroquine 
Yang et al. (2010) published a retrospective case series with 5 patients in a secondary care 
setting59. Patients were treated with hydroxychloroquine in various doses. The duration of 
symptoms at inclusion is unclear. Two patients suffered from secondary chilblains (chilblains 
lupus erythematosus), one suffered from probable Sjogren’s disease (but lip biopsy was 
inconclusive) and one had a family history of autoimmune disease. Outcome was (partial) 
resolution. Follow-up varied between approximately 1 to 3 months. 4 out of 5 patients 
showed partial or complete resolution. The authors concluded that hydroxychloroquine is an 
effective, well-tolerated and relatively safe treatment for perniosis, especially when 
associated with systemic lupus erythematosus. 
 
Iontophoresis 
Bilancini et al (1998) described the treatment of acute chilblains with iontophoresis54. The 
study included 16 patients with acute chilblains but the setting and duration of symptoms at 
inclusion is not clear. The treatment consisted of the application of an electric current to the 
affected body part. The effect of this was evaluated by assessing the severity of the 
condition with the help of a severity scale. Eleven patients were cured and in four others an 
improvement occurred. 
 
Pentoxyfyline 
Noami et al (2008) described an active control, parallel type RCT with 40 participants in a 
secondary care setting57. The duration of symptoms at inclusion is not described. Oral 
pentoxyfyline 400 mg three times daily was compared to oral prednisolone 0.5 mg/kg in two 
doses combined with topical clobenasol ointment (dose and frequency of application 
unclear). The study period was 2 weeks. Outcome measurement was disappearance of 
symptoms and lesions (“good improvement”). Blinding of patients and, blinding of assessor 
were not described. Participants were asked to avoid further exposition to cold. Ambient 
temperatures were not monitored. 11 (out of 20) participants in the corticosteroid arm and 
9 (out of 20) participants in the pentoxyfyline arm completed the two-week study period. 3 
out of 11 participants in the corticosteroid arm (27%) showed “good improvement” 
compared to 5 out of 9 (56%) participants in the pentoxyfyline group. The difference was 
statistically significant (p <0.05). The authors concluded that pentoxyfyline is an effective 
and safe drug for treatment of perniosis and superior to oral plus topical corticosteroids.  
Al-Sudani (2016) reported a double-blind, placebo-controlled, parallel type RCT with 118 
enrolled patients in a secondary care setting63. Average duration of complaints was 5 days at 
inclusion. Participants were studied for 3 weeks comparing pentoxyfyline 400 mg three 
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times daily to placebo. Endpoint was the therapeutic response (a combined endpoint based 
on improvement of symptoms as reported by the participants and reduction of the size of 
the lesions as measured by the researcher) graded on a 4-point scale. Al-Sudani reported a 
statistically significant difference in best therapeutic response (improvement or 
disappearance of symptoms with >80% reduction of the size of the lesions) in favour of 
pentoxyfyline after 1, 2 and 3 weeks. After 3 weeks the best therapeutic response was 73% 
in the pentoxyfyline group compared to 20% in the placebo group. 
 
Ultraviolet light 
Langtry et al. (1989) published a randomised, double-blind, placebo-controlled parallel type 
RCT with 9 patients from a dermatology outpatients clinic51. Duration of symptoms at 
inclusion is not described. Dependent on the randomisation, the left or the right hand was 
illuminated with ultraviolet light. The effect was assessed by evaluating the lesions with the 
help of a clinical score and an assessment of symptoms by the patient. The conclusion was 
that ultraviolet phototherapy had no prophylactic effect. The existence of a curative effect 
was not investigated. 
 
Urtinatrin II injections 
Renes (1943) described the outcomes of the treatment of 18 patients from his general 
practice with Urtinatrin II injections46. Duration of symptoms at inclusion is not described. 
Twelve patients were cured and the others improved. He assessed the effect of the 
injections on itching, pain and redness of the affected parts. The injections consisted of a 
combination of caffeine, procaine and formic acid and have not been available for a long 
time (Scientific Institute Dutch Pharmacists (WINAp): Written information 2004). 
 
Vitamin D3 injections 
Broers (1944) reported about the treatment of chilblains with vitamin D3 injections47. The 
study included 66 patients from his dermatology practice. Duration of symptoms at start of 
treatment is not described. The article is of historical importance because the treatment of 
chilblains through intramuscular injection with vitamin D3 in the Netherlands almost 
certainly finds its basis in this publication. The outcome measure used was based on the 
patients' symptoms and is not further explained. A total of 42 patients were cured. Broers 
wrote that under the remaining patients there was ‘a number’ who ‘experienced far fewer 
symptoms’. 
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Summary 
Background: Chronic chilblains is a common disease causing major restrictions in daily life, 
nevertheless little is known about effective treatment. In a literature search, we found thin 
evidence of three interventions: fluocinolone cream, nifedipine and vitamin D3. Objective: 
We have conducted a study to assess the effect of oral administration of 2000 IU vitamin D3 
per day on patients suffering from chronic chilblains. Methods: The study was based on a 
self-controlled design. The study population consisted of patients with a confirmed 
diagnosis. Outcome measurement was the change in severity of the complaints and 
disability. We checked for interference by temperature and other confounders. Limitations: 
The size of the cohort (n = 33) was a limitation. Results: After correction for confounding 
factors, 19% of the subjects reported fewer complaints and 6% fewer disability, in both the 
placebo and vitamin D3 treatment groups. Conclusion: Oral administration of 2000 IU 
vitamin D3 per day is not better than placebo in the treatment of patients with chronic 
chilblains. 
 
What’s known 
• Chronic chilblains is a common disease causing major restrictions in daily life. 
• Nevertheless little is known about effective treatment. 
• Thin evidence exists for three interventions: fluocinolone cream, nifedipine and vitamin 
D3. 
 
What’s new 
• Vitamin D3 is not better than placebo in the treatment of patients with chronic chilblains. 
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Introduction 
Chronic chilblains and winter kibes, chronic pernio, are an annoying and disturbing disorder 
causing major restrictions in daily life1–3. The disease is reported to occur all over the world, 
especially in areas with a temperate climate. Typical complaints include painful or itching 
lesions on fingers, feet, ears or thighs, with discolouration and swelling of the skin. The 
complaints commence in winter and vanish in spring. Dutch general practitioners (GPs)see 
about four new patients with chronic chilblains per year [Continue Morbiditeit Registratie 
Nijmegen (The Netherlands), unpublished results]. The clinical and pathological presentation 
of chronic chilblains has been clearly reported2,4–6. Nevertheless, little is known about 
effective treatment. In an extensive literature search, we found thin evidence for three 
interventions: fluocinolone cream, nifedipine and vitamin D37–10. Vitamin D was commonly 
used in the treatment of chilblains7,11. Dutch GPs have treated their patients suffering from 
chronic chilblains for more than 60 years with an intramuscular (i.m.) injection containing 
600,000 IU vitamin D3. Since 2003, the injection is no longer available, leaving the patients 
and their doctors in search of an effective alternative. Therefore, we conducted a study to 
assess the effect of oral administration of 2000 IU vitamin D3 per day for treating the 
patients suffering from chronic chilblains. 
 
Methods 
All patients aged 16 years or older with a confirmed diagnosis of chronic chilblains and 
complaints lasting at least 3 weeks were included in the study. Patients were referred to us 
in the winter of 2003–2004 between November 1 and February 15, by GPs in the northwest 
of the Netherlands. The diagnosis was confirmed after clinical examination by a trained GP 
(IS). We checked the quality of the decisions of this GP by comparing his decisions with the 
decisions of a dermatologist, using slides with intake photographs of the lesions and intake 
data on age, gender and complaints. They expressed the probability of the diagnosis of 
chronic chilblains on a 5-point scale. In 21 patients (64%), there was complete agreement. In 
six patients with diagnosis of chronic chilblains (18%) the dermatologist scored the 
probability one category lower and in another six patients (18%) one category higher than 
the GP did. 
Exclusion criteria were: a history of inflammatory disease, urolithiasis, hypercalcaemia, 
hyperparathy- reoidism, pregnancy, breast feeding, the use of a calcium entry blocker and 
incapability of keeping a diary.  
The patients were studied for 8 weeks in a selfcontrolled design (Figure 1). This design was 
chosen for two reasons. Although exposure to cold is generally accepted to influence the 
complaints of pernio, little is known about other possible confounders, such as the individual 
susceptibility to the disease. The fact that each patient serves as his or her own control 
reduces the susceptibility to the effect of (unknown) patient-related confounders, in view of 
which a randomised controlled design would not do12,13. Furthermore, the mechanism of the 
supposed effect of vitamin D on chronic pernio is unknown, leaving questions about 
washout period and possible bias by patient-related factors using a crossover design. The 
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first week was used to collect baseline data and no medication was administered. The 
administered medication in the following 3 weeks was randomised (vitamin D3 or placebo). 
During the last 4 weeks, each patient used vitamin D3 (Figure 1). During the full 8 weeks’ 
period, the patients kept a diary of their complaints. The diary of the patient was checked on 
completeness, and patient compliance was checked by counting forgotten capsules, during 
face-to-face contact at the end of week 1, week 4 and week 8. The active medication was 
checked on content uniformity by an independent control laboratory. Vitamin D3 content of 
each capsule varied between 91.3% and 107.6% of the content declared, which is acceptable 
according to Dutch regulations. 
Permuted block randomisation with a block size of 10 was used to blind the start of the 
administration of vitamin D314. Randomisation took place at the pharmacy where the 
research medication was produced, concealed from both the patient and the research 
physicians. The capsules containing vitamin D3 were indistinguishable from those containing 
placebo. 
We checked the uniformity of both groups of subjects (those first starting with placebo and 
those starting directly with vitamin D3 therapy) by attempting to demonstrate significant 
differences between the groups. We used a Chi2 test with α 0.05 to assess possible 
differences concerning gender and age distribution, comorbidity and factors concerning 
disposition to cold, smoking habits, nicotine use otherwise and use of medication. A t-test 
(two sample, independent groups t-test) with α 0.05 was used to assess possible significant 
differences with respect to duration of symptoms at inclusion and baseline scores on 
‘Complaint’ and ‘Disability’. 
Outcome measurement was the change in severityof the complaints as expressed by the 
patient, on a 100-mm visual analogue scale (VAS). Three scales were used; one for itch, one 
for pain and one for disability. The daily mean temperature was recorded separately during 
the entire study period of all individuals, using data from the Royal Netherlands 
Meteorological Institute. Most patients describe the complaints as either itch or pain, and 
therefore we defined ‘Complaint’ as either itch or pain, depending on which item showed 
the highest mean score on the VAS at baseline. ‘Disability’ was defined as the restrictions in 
everyday life recorded by the patient, on the VAS. A single-case time-series analysis tool with 
a sample size of eight data points per phase was used to evaluate changes in reported VAS-
scores. The same tool was used to evaluate temperature changes recorded for each patient 
and each time period. The technique is based on the C-statistic15. Significance was defined 
by a p-value of 0.05 (Z-value 1.64 and higher). The C-statistic is powerful enough to detect a 
trend using this sample size and the formulae regarding this technique have been 
published16,17.The intervention was assumed to be effective in the treatment of a patient if a 
downward trend was evident in ‘Complaint’ or ‘Disability’, comparing datasets before and 
after intervention (Figure 1). Temperature was presumed to be responsible for a possible 
effect in the case of an upward trend in the recorded temperature between both datasets. 
Furthermore, vitamin D3 was presumed not to be responsible for a possible effect in the 
case of a downward trend in the ‘Complaint’ or ‘Disability’ baseline datasets. Analysis 
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included a subgroup analysis of 10 (30%) patients with the highest score on complaint at 
baseline and an intention-to-treat analysis.  
The ethics review board CMO Region Arnhem–Nijmegen approved the study under number 
2002 ⁄ 267 (CMO Regio Arnhem–Nijmegen, UMC St Radboud, huispost 722, Box 9101, 6500 
HB Nijmegen, the Netherlands. 
 
 
Figure 1: Intervention depending on randomization and sampling of the data. 
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Group 1: Subjects randomized for placebo administration first. 
Group 2: Subjects randomized for vitamin D3 treatment only. 
 
 
Results 
We included 37 patients in our study. Data of 33 patients were available for analysis (Table 
1).  
 
Table 1: Patients available for analysis 
Patients included  37 
Not available for analysis  4 
  withdrawals (1st week after inclusion) 2  
  hospitalization (not related to perniones) 1  
  excluded after inclusion   1  
  (no complaints reported after inclusion)   
Available for analyses  33 
 
We studied 26 women and seven men, with a mean age of 44 years. Gender and age 
distribution is shown in Figure 2. The mean duration of symptoms at intake was 6 weeks. In 
addition to the daily mean temperature, we collected extensive data on the possible 
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exposure to cold (clothing habits, heating of the different rooms at home, exposure caused 
by profession or hobbies), comorbidity, smoking habits and nicotine use otherwise, use of 
medication and baseline scores on ‘Complaint’ and ‘Disability’ in our subjects. Four subjects 
in our study population had a history of Raynaud’s phenomenon. None of them suffered 
from any connective tissue disorder. One subject was a smoker, none of the subjects used 
nicotine in chewing gum or otherwise. With the exception of four subjects using a beta-
blocker, no usage of medication relevant to the study was reported. With the exception of 
beta-blocker use (all four subjects in the group starting with placebo) and Raynaud’s 
phenomenon (all four subjects in the group starting directly with vitamin D3 therapy), the 
baseline data were comparable. The compliance of the participants was excellent. All 33 
patients fully completed their diary. No face-toface contacts were missed. Medication was 
taken conscientiously: we counted only 27 forgotten capsules (out of 1617 to be taken). 
 
Figure 2: Gender and age distribution. 
  
 
 
Table 2 (‘Complaint’) and Table 3 (‘Disability’) show the outcomes after intervention. 38% of 
our patients reported a decrease in ‘Complaint’ and 19% a decrease in ‘Disability’ after 3 
weeks of placebo. After 4 weeks of vitamin D3, 33% of the subjects reported decrease in 
’Complaint’and 45% decrease in ’Disability’changing to 47% (‘Complaint’) and 35% 
(‘Disability’) respectively after 7 weeks of vitamin D3 treatment. After correction for patients 
with an upward temperature trend during the intervention period, 31% reported fewer 
‘Complaint’ and 13% less ‘Disability’ after 3 weeks of placebo, dropping to 18% (fewer 
‘Complaint’) and 6% (less ‘Disability’) after 7 weeks of vitamin D3. After correction for 
patients with an upward temperature trend during the intervention period or a downward 
‘Complaint’ or ‘Disability’ trend in the baseline dataset, or both; thus after correction for 
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possible recovery for any reason other than vitamin D3 administration, 19% report fewer 
‘Complaint’ and 6% less ‘Disability’ after 3 weeks of placebo, with equal figures after 7 weeks 
of vitamin D3. In order to not miss an effect masked by mild disease severity, we stratified 
the cohort. Analysis of the highest 30% (n = 10) VAS-scoring patients on ‘Complaint’ at 
baseline, showed no decrease of ‘Complaint’ or ‘Disability’, neither after 3 weeks of placebo 
nor after 7 weeks of vitamin D3. Intention-to-treat analysis (17% decrease of ‘Complaint’ and 
6% decrease of ‘Disability’ after 3 weeks of placebo, not rising after 7 weeks of vitamin D3) 
show comparable results. 
 
 
Table 2: Patients reporting decrease in complaints (as defined) after intervention (n=33). 
intervention without correction 
for confounding 
factors 
after correction for 
temperature 
change 
after correction for 
both temperature  
and baseline 
change  
 n % n % n % 
3 wks placebo (n=16) 6 38 5 31 3 19 
4 wks D3 (n=33) 11 33 7 21 3 9 
7 wks D3 (n=17) 8 47 3 18 3 18 
 
 
Table 3: Patients reporting decrease in disability (as defined) after intervention (n=33). 
intervention without correction 
for confounding 
factors 
after correction for 
temperature 
change alone 
after correction for 
both temperature 
and baseline 
change 
 n % n % n % 
3 wks placebo (n=16) 3 19 2 13 1 6 
4 wks D3 (n=33) 15 45 8 24 6 18 
7 wks D3 (n=17) 6 35 1 6 1 6 
 
 
Discussion 
At first sight, it seems that substantially more patients report a decrease in complaints or 
disability after vitamin D3 than after placebo. However, after correction for the influence of 
temperature changes, by ignoring the data of individuals with an up-sloping temperature 
trend during the study period, no effect of treatment is seen. Correction for possible 
interference by other confounders, by additionally ignoring data of individuals with a 
downward trend of ‘Complaint’ or ‘Disability’ or both in the baseline period, does not change 
this outcome.  
The results of the analysis of a subgroup of patients with the highest level of complaints and 
the intention-to-treat analysis are compatible with these findings.  
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We therefore conclude that the effect of oral administration of 2000 IU vitamin D3 per day 
does not exceed the placebo effect in the treatment of patients suffering from chronic 
chilblains.  
In a literature study, we found that in almost all studies with a positive effect on the 
intervention, between 60% and 70% of the patients improved7. In none of these studies a 
thorough correction was made for the influence of exposure to cold and other confounders. 
Our results before correction for the effect of confounders meet the results of these studies. 
In our opinion, the results of our study before correction and possibly also the 
aforementioned studies on fluocinolone cream, nifedipine and vitamin D3 represent the 
natural course of the disease and the influence of exposure to cold8–10. The placebo effect 
can be responsible for up to 30% of treatment effects18. Our findings after treatment with 
placebo are comparable with this figure. The effect of vitamin D3 does not exceed this 
placebo effect. It is likely that natural course, influence of changes in exposure to cold and 
the placebo effect are responsible for the common (but false) opinion among patients and 
physicians that vitamin D3 is effective. 
Our study has several strong points, especially with regard to the aforementioned studies on 
chronic chilblains. We properly confirmed the intake diagnosis, known confounders such as 
comorbidity, exposure to cold, use of medication and patient compliance were checked, and 
the study design is appropriate with regard to the relatively unknown features of the disease 
and confounders.  
However, there are also limitations. The study is not a complete double-blind placebo-
controlled cross-over study. The subjects producing data on placebo and the subjects 
producing data on vitamin D use for 7 weeks are not the same, although 
we found no relevant differences between both groups on the extensive amount of baseline 
data. Because of the design of the study, it is unlikely that the distribution of subjects with 
Raynaud’sphenomenon and beta-blocker use disturbed the outcomes. Also because of the 
design, and the rigorous way we addressed possible interference of confounders, we may 
have missed a very small effect of vitamin D3 administration. We are convinced that such a 
minimal effect would not be clinically relevant. Furthermore, outdoor temperature was 
recorded in order to evaluate the confounding effect of temperature, leaving questions 
about the actual exposure of the subjects to cold. In our opinion, our choice is correct. Seven 
out of 10 patients in the cases of whom temperature change played a role did not heat all 
the rooms at home or worked in an unheated surrounding. Furthermore, vitamin D3 for 
injection is no longer available. Therefore, we were not able to study the effect of i.m. 
injection of vitamin D3, the common treatment for pernio. Instead, we used the advised 
maximum oral dose vitamin D3. Finally, our cohort of 33 patients is relatively small. 
Nevertheless, we conclude on our findings in this study that vitamin D3 should no longer be 
used for the treatment of patients with chronic chilblains in general practice. Based on our 
findings, we also question the positive results of studies on the effect of fluocinolone cream 
and nifedipine8,9. The claimed effect is likely to have been caused by natural course, the 
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influence of cold and other confounders. The study designs used were not suitable enough 
to address this problem. 
Consequently, a proper advice on the treatment of chronic chilblains in general practice 
cannot be given. It would be a good idea to study nifedipine and fluocinolone cream again, 
using a different design addressing the aforementioned confounders. 
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ABSTRACT 
Purpose  
Nifedipine is commonly prescribed for the treatment of chilblains (pernio, perniosis) on the 
basis of observational studies and a single small, older clinical trial. We aimed to confirm the 
proposed superiority of oral nifedipine 60 mg per day over placebo for treatment of chronic 
chilblains in primary care. 
 
Methods  
We performed a randomized, placebo-controlled, double-blind, crossover trial, closely 
following the design of the older trial. A total of 32 patients with chronic chilblains were 
randomly assigned to nifedipine (30 mg controlled release twice a day) or placebo. The 
primary outcome was patient-reported complaints; the secondary outcome was patient-
reported disability. Both were assessed from daily ratings on 100-mm visual analogue scales 
recorded in a diary. We took ambient temperatures into account and checked for a carry-
over effect, and monitored for adverse effects. 
 
Results  
After 6 weeks of treatment, mean scores on the visual analogue scale on complaints showed 
a nonsignificant difference of 1.84 mm (95% CI, –6.67 to 2.99 mm) in favor of nifedipine (P = 
.44). Mean scores on the visual analogue scale on disability showed a nonsignificant 
difference of 0.56 mm (95% CI, –2.97 to 4.09 mm) in favor of placebo (P = .75). There was no 
carry-over effect of prior study treatment. Nifedipine was associated with significantly lower 
systolic blood pressure and a significantly higher incidence of edema. 
 
Conclusions 
In our study, nifedipine was not superior to placebo for treating chronic chilblains. These 
findings contrast with those of the older study and do not support routine use of nifedipine 
for this condition. 
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Introduction 
Chilblains (pernio, perniosis) are cold-induced, painful or itching lesions on the fingers, feet, 
ears, or thighs. The condition occurs throughout the world during the winter months when 
daily mean temperatures drop below the range of 12oC to 15oC.1 The prevalence in the 
Netherlands as reported by the Netherlands Institute for Health Services Research (NIVEL) 
varies between 0.9 per 1,000 and 1.7 per 1,000 depending on year-to-year variation and 
coding issues. The condition is more common among women than men, with respective 
prevalences of 0.9 to 2.1 per 1,000 vs 0.6 to 1.2 per 1,000 (written information provided by 
NIVEL). 
Patients with chilblains report serious restrictions in daily life and feel an urgent need for 
effective treatment.2 A review of the literature through March 15, 2016 revealed evidence 
that vitamin D3, corticosteroidcontaining cream, nifedipine, and pentoxyfylline, among a 
wide range of other therapies, are used to treat symptoms of chronic chilblains.3,4 In an 
earlier study, we found that vitamin D3 was not superior to placebo, however.5 Five studies 
evaluating the effectiveness of nifedipine in patients with chilblains have been published and 
have concluded that the drug is an effective treatment. These studies included only 1 
randomized controlled trial, having 10 patients and conducted in 1989, comparing nifedipine 
with placebo.6 The others—a pilot case study with 10 patients, a case series with 34 patients, 
a randomized trial comparing diltiazem with nifedipine in 34 patients, and a study comparing 
nifedipine with topical minoxidil in 62 patients—were not placebo controlled.6-8  
Physicians and patients are commonly advised to consider the prescription of nifedipine for 
the treatment of chronic chilblains.9-13 This advice finds support in a proposed disease 
mechanism for chilblains (ie, cold-induced vasospasm9,14,15) and in the results of the 5 
studies previously described.6-8 Current discussion in the field regarding the reliability and 
reproducibility of these studies has called into question the soundness of the basis for the 
advice, however.16  
We undertook a trial to confirm the proposed superiority of oral administration of nifedipine 
60 mg per day compared with placebo for the treatment of chronic chilblains in a primary 
care setting. 
 
Methods 
Trial Design 
Following the methodology of the original study by Rustin et al,6 we conducted a 13-week 
randomized, double-blind, placebo-controlled, cross-over trial.6 A washout period was not 
incorporated in the design for 3 reasons. First, the original trial did not include a washout 
period. Second, for obvious reasons, the study had to be completed during the winter 
months; a washout period would have resulted in too long a research period per patient and 
problems with higher ambient temperatures in spring. Third, the exact mechanism of the 
proposed effect of nifedipine is unclear, so the necessary duration of a washout period is 
uncertain. Instead of using a washout period, we sampled the last week of every 6-week 
treatment phase and checked for a possible carry-over effect. 
76 | Chapter 6 
 
Participants 
The study population consisted of consecutively enrolled patients with chronic chilblains 
during the winters of 2010 to 2012. Patients volunteered after being informed of the trial by 
their primary care physician during consultation. 
Patients were eligible for the trial if they were aged 18 years or older and reported 
symptoms of chronic chilblains that had lasted at least 3 weeks. The diagnosis was confirmed 
by an author (I.H.S.) based on commonly used diagnostic criteria: symptoms emerging in the 
winter months with itching and/or painful purpleblue discolored lesions in any of several 
locations (fingers, toes, feet, or lateral thigh) without a history of persistence into the 
summer months.1,9 Swelling and ulceration, and reporting of earlier episodes in previous 
winters could also be present but were not mandatory for diagnosis. The validity of diagnosis 
by this author has previously been demonstrated.5 
We excluded patients who had a known rheumatologic disorder, were already using 
nifedipine or another calcium channel blocker, were pregnant or lactating, or had 
contraindications to use of nifedipine.  
Our sample size calculation was based on the following premises related to the visual 
analogue scale (VAS) used for the trial’s primary outcome. Specifically, in an earlier study,5 
we observed a baseline visual analogue scale on complaints (VOC) score of 27.97 mm (SD 
18.82) in a similar population. We used an estimate of 0.5 for the correlation between 2 
scores from the same patient on 2 occasions.5 We considered the treatment effect to be 
clinically relevant if patients experienced a decrease in the VOC score of at least 10 mm.  
On the basis of use of a t test for the difference between 2 dependent means, 1-tail testing, 
an α of 0.05, and a β of 0.10 (power of 90%), we calculated that we would need a minimum 
of 32 participants for the trial. 
 
Procedures 
The intervention consisted of oral administration of 30 mg nifedipine controlled release once 
a day for 2 weeks followed by 30 mg nifedipine twice a day for another 4 weeks. The 
research medication was produced and certified under project number AKF 1720 by the 
Department of Pharmacy and Clinical Pharmacology, Radboud University Medical Center, 
Nijmegen, The Netherlands. 
The pharmacy that produced the research medication used block randomization with a block 
size of 10 to assign patients to 2 arms that differed with respect to the order of treatments: 
placebo first or nifedipine first. Both research personnel and patients were blinded to arm 
assignment. Blinding was ensured by use of indistinguishable capsules for active medication 
and inactive placebo. Consecutively enrolled patients received medication sets with 
consecutive therapy numbers. The pharmacy released the randomization key only after the 
last patient had left the study. 
In the placebo-first arm, patients received no medication for 1 week to collect baseline data 
(phase 0), followed by use of placebo once a day for 2 weeks, followed by use of placebo 
twice a day for 4 weeks (phase 1), followed by nifedipine 30 mg controlled release once a 
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day for 2 weeks, followed by nifedipine 30 mg controlled release twice a day for 4 weeks 
(phase 2). In the nifedipine-first arm, patients received no medication for 1 week to collect 
baseline data (phase 0), followed by nifedipine 30 mg controlled release once a day for 2 
weeks, followed by nifedipine 30 mg controlled release twice a day for 4 weeks (phase 1), 
followed by use of placebo once a day for 2 weeks, followed by use of placebo twice a day 
for 4 weeks (phase 2).  
Each day, we documented the mean ambient temperature provided by the Royal 
Netherlands Meteorological Institute. Patients used a diary to score the presence and 
severity of itch, pain, and disability using the VAS daily throughout the full research period, 
as described below. Investigators had 6 face-to-face contacts with patients: at intake and at 
the end of weeks 1, 3, 7, 9, and 13. During these contacts, the investigators checked diaries 
for completeness, assessed therapy compliance by counting capsules, and documented 
remaining lesions. 
The Dutch Competent Authority (NL31484.091.10 BI) and the Medical Research Ethics 
Committee CMO Arnhem-Nijmegen (CMO dossier number 2010/240) granted permission for 
this study. 
 
Outcomes 
The trial’s primary and secondary outcomes were patient-reported complaints (symptoms) 
and disability, respectively, assessed with VAS having 100- mm ranges. Patients rated these 
outcomes daily and recorded their ratings in diaries.  
The primary outcome was the difference in score on the VOC between nifedipine and 
placebo after 6 weeks of treatment. Patients rated pain and itch separately; we used the 
higher of these 2 scores at the time of reporting. The VOC score was calculated as the mean 
value for the last 7 days of the 6-week treatment period. Higher scores indicated greater 
pain or itch.  
The secondary outcome was the difference in score on the visual analogue scale on disability 
(VOD) between nifedipine and placebo after 6 weeks of treatment. For this outcome, 
patients rated their ability to function normally in daily life. The VOD score was also 
calculated as the mean value of the last 7 days of the treatment period. Higher scores 
indicated greater disability.  
To follow the design of the original study6 as closely as possible, investigators assessed the 
chilblain lesions during face-to-face contacts and rated redness, purpleness, edema, and 
ulceration on 100-mm VAS. We also monitored for adverse effects—unfavorable changes in 
blood pressure reading and in scores for headache, dizziness, and peripheral edema on 100-
mm VAS—at each of these contacts. 
 
Statistical Analysis 
We used a modified intention-to-treat analysis, including data only of patients who began 
the study. We performed analysis of the primary and secondary patientreported outcomes 
using the 2-stage model originally proposed by Grizzle17 and more recently reviewed,18 
78 | Chapter 6 
 
correcting for temperature changes during the research period for each patient with a mixed 
effects model (Grizzle model using the mixed procedure with random effect, SAS PROC 
MIXED, SAS version 9.2; SAS Institute Inc). Investigator-assessed outcomes and adverse 
effects were analyzed using 2-sample paired t tests.  
 
Results 
Patient Characteristics 
The procedure used to assess and enroll patients is shown in Figure 1. Data for 32 patients 
(18 women and 14 men) were available for analysis, and their baseline characteristics are 
shown in Table 1. The patients had a mean age of 53 years (SD 16.1). The mean duration of 
symptoms at intake was 6.5 weeks (SD 3.6). At baseline, the mean score on the VOC scale 
was 24.92 mm (95% CI, 21.70-28.13) and the mean score on the VOD scale was 16.11 mm 
(95% CI, 13.09-19.13). Eleven patients had possibly relevant comorbidities, 6 smoked, and 9 
used potentially relevant drugs. 
 
Figure 1: Flowchart of patients in the trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
0 patients lost to follow-up 
Enrollment 
42 patients assessed for eligibility 
Randomisation 
5 patients met exclusion 
criteria 
Follow-up 
Analysis 15 patients analyzed 
0 patients lost to follow-up 
17 patients analyzed 
19 patients assigned to 
Nifedipine-first arm 
15 patients received 
assigned intervention 
18 patients assigned to 
placebo-first arm 
17 patients received 
assigned intervention 
37 patients randomized 
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Table 1; Patient Characteristics at Baseline 
Characteristic Placebo-First 
Arm 
(n = 17) 
Nifedipine-First 
Arm 
(n = 15) 
Age, mean, y   50 59 
Sex   
    Women, No. 8 10 
    Men, No.  9 5 
Chilblain symptoms   
    Mean duration at intake, wk 7  6 
    Experiencing first episode, No.  2  2 
    Experienced >1 episode, No. 4  4 
    Experiences episode every year, No. 12  10 
Mean VOC score, mma,b  25  24 
Mean VOD score, mmb  17  15 
Smoking, No.  3  3 
Comorbidity   
    Diabetes, No. 0  1 
    Peripheral arterial disease, No.  1  0 
    Raynaud phenomenon, No.  6  3 
Relevant medication use   
    β-blocker, No. 0 0 
    Nicotine replacement drug, No.  0  0 
    Acetylsalicylic acid, No.  0  1 
    ACE or angiotensin II receptor  blocker, No. 3  2 
ACE = angiotensin-converting enzyme; VOC = visual analogue scale on complaints; VOD = visual analogue scale 
on disability. 
a The higher of either the visual analogue scale itch score or the visual analogue scale pain score. 
b Scores measured on 100-mm scales where higher values indicate more complaints (symptoms) or greater 
disability. 
 
 
Our capsule counts indicated that patients did not take 502 capsules (11%) of the 4,480 they 
had been assigned to take. Diaries were conscientiously completed. No face-to-face contacts 
were missed.  
We did not find any missing data for the patientreported primary and secondary outcomes 
or for adverse effects. One assessment for our investigator-assessed outcomes was missing, 
representing 4 VAS scores out of 384 to be analyzed; we did not replace these missing data. 
 
Primary and Secondary Outcomes 
Figure 2 shows the plots of mean VOC and VOD scores per week, not corrected for 
temperature, in each arm and study phase. 
The mean VOC score at 6 weeks of treatment was 11.44 mm (95% CI, 6.12-16.75 mm) with 
nifedipine treatment and 13.28 mm (95% CI, 7.96-18.59 mm) with placebo treatment (Table 
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2). This resulted in a difference between arms of 1.84 mm (95% CI, –6.67 to 2.99 mm) in 
favor of nifedipine (P = .44). 
The mean VOD score at 6 weeks of treatment was 4.65 mm (95% CI, 1.65-7.65 mm) with 
nifedipine treatment and 4.09 mm (95% CI, 10.9-7.09 mm) with placebo treatment. This 
resulted in a difference between arms of 0.56 mm (95% CI, –2.97 to 4.09 mm) in favor of 
placebo (P = .75). 
 
 
Figure 2; Patient-reported scores for complaints (VOC) and disability VOD (not corrected for 
temperature) for each arm and study phase. 
 
 
 
 
 
 
 
 
 
Week Number 
 
 
Carry-Over Effect 
Results of analyses assessing any carry-over effect on the primary outcome are shown in 
Table 2. The mean VOC score at 6 weeks of treatment was 14.07 mm (95% CI, 7.16-20.98 
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VAS = visual analogue scale; VOC = visual analogue scale on complaints; VOD = visual analogue scale on disability. 
Notes: Scores measured on 100-mm scales where higher values indicate more complaints (symptoms) or greater 
disability. Phase 0: no-treatment baseline; phase 1: first assigned treatment; phase 2: second assigned treatment. 
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mm) in the arm given placebo first and 10.46 mm (95% CI, 4.16-17.14 mm) in the arm given 
nifedipine first. This resulted in a nonsignificant difference between arms of 3.43 mm (95% 
CI, –6.08 to 12.93 mm) in favor of the nifedipine-first arm (P = .47), indicating no carry-over 
effect. 
 
 
Table 2; Primary and Secondary Outcomes Corrected for Differences in Ambient Temperature 
 Score, mma 
 
Test of Fixed Effects 
 
Outcome 
 
Mean (95% CI) 
 
Difference (95% CI) F Value P Value 
(r>F) 
Primary: VOC 
score 
    
Treatment     
   Nifedipine  11.44 (6.12 to 16.75) – – – 
   Placebo  13.28 (7.96 to 18.59) –1.84  (–6.67 to 2.99) 0.61 .44 
Arm     
   Placebo first  14.07 (7.16 to 20.98) – – – 
   Nifedipine first  10.65 (4.16 to 17.14) 3.43 (–6.08 to 12.93) 0.54 .47 
Temperature  – – 3.62 .07 
Secondary: VOD 
score 
    
Treatment     
   Nifedipine  4.65 (1.65 to 7.65) – – – 
   Placebo  4.09 (1.09 to 7.09)  0.56 (–2.97 to 4.09) 0.10 .75 
Arm     
   Placebo first  4.95 (1.40 to 8.50) – – – 
   Nifedipine first  3.79 (0.46 to 7.12)  1.17 (–3.72 to 6.05) 0.24 .63 
Temperature  – – 1.63  .21 
VAS = visual analog scale; VOC = visual analogue scale on complaints; VOD = visual analogue scale on disability. 
a
 On a visual analogue scale in week 6 of treatment. Scores measured on 100-mm scales where higher values 
indicate more complaints (symptoms) or greater disability. 
 
 
 
Results of analyses assessing any carry-over effect on the secondary outcome are shown in 
Table 3. The mean VOD score at 6 weeks of treatment was 4.95 mm (95% CI, 1.40-8.50 mm) 
in the placebo-first arm and 3.97 mm (95% CI, 0.46-7.12 mm) in the nifedipine-first arm. This 
resulted in a nonsignificant difference between arms of 1.17 mm (95% CI, –3.72 to 6.05 mm) 
in favor of the nifedipine-first arm (P = .63), also indicating no carry-over effect.  
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Investigator-Assessed Outcomes 
We found no statistically significant differences between nifedipine and placebo for 
investigator-assessed redness or purpleness, edema, or ulceration after 6 weeks of 
treatment (Table 3). 
 
 
Table 3; Investigator-Assessed Outcomes After 6 Weeks of Treatment 
Outcomea  
 
Placebo Nifedipine Mean Difference 
(95%CI) 
P 
Value 
Redness score, mean, mm  17.0 18.3 1.9 (–3.8 to 7.6) .50 
Purpleness score, mean, mm  6.6 4.9 –1.5 (–5.6 to 2.6) .47 
Edema score, mean, mm  4.9 7.8 3.2 (–0.5 to 6.9) .09 
Ulceration score, mean, mm  0.0 0.2 0.2 (–0.2 to 0.6) .33 
a 
Assessed using 100-mm visual analogue scales where higher values indicate greater severity. 
 
 
Adverse Effects  
Mean systolic blood pressure was 134.5 mm Hg after 6 weeks of nifedipine use and 147.1 
mm Hg after 6 weeks of placebo use (Table 4). The mean difference was –13.1 mm Hg (95% 
CI, –24.1 to –2.0 mm Hg), which was statistically significant (P = .02). The mean assessed 
peripheral edema score on the VAS was 12.1 mm after 6 weeks of nifedipine use and 2.5 mm 
after 6 weeks of placebo use. The mean difference was 9.6 mm (95% CI, 1.1-18.1 mm), which 
was also statistically significant (P = .03). Headache and dizziness did not differ significantly 
between nifedipine and placebo after 6 weeks of treatment (Table 4). 
 
 
Table 4; Adverse Effects After 6 Weeks of Treatment 
Outcomea  
 
Placebo Nifedipine Mean Difference 
(95%CI) 
P 
Value 
Systolic blood pressure, 
   mean, mm Hg 
147.1  134.5 –13.1 (–24.1 to –2.01) .02 
Headache score, mean, mma 2.2  6.9 4.7 (–0.8 to 10.3) .09 
Dizziness score, mean, mma 1.6  4.7 3.1 (–1.0 to 7.2) .13 
Peripheral edema score, 
   mean, mma 
2.5  12. 1 9.6 (1.1 to 18.1) .03 
a 
Assessed using 100-mm visual analogue scales where higher values indicate greater severity. 
 
 
Discussion 
We did not find any clinically or statistically significant differences in favor of nifedipine over 
placebo for the treatment of chronic chilblains. The difference in patient-reported 
complaints (symptoms) tended to favor nifedipine, while the difference in patient-reported 
disability tended to favor placebo. Nifedipine was associated with a lower systolic blood 
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pressure and a higher incidence of edema. We did not find any significant carry-over effect 
of prior treatment on the primary or secondary outcome. Differences between the 
nifedipinefirst and placebo-first arms tended to favor the former.  
 
Strengths and Limitations 
The main strength of this study is our effort to confirm the findings of the original 
randomized controlled trial that led to the current general advice to consider nifedipine for 
the treatment of chronic chilblains. No such confirmation study had previously been 
performed. We followed the design of the original study as closely as possible but tripled the 
number of patients based on our sample size calculation. Improving on the original design, 
we further took into account ambient temperature as a major confounder.3,19,20  
We assessed primary and secondary outcomes with VAS scores for pain, itch, and disability 
using patient diaries. These scales are generally used and validated for this purpose.21-23 
Patient compliance was good. Although 11% of assigned capsules were not taken, known 
adverse effects of nifedipine (lower systolic blood pressure and more edema) were still seen 
during nifedipine treatment. Patients conscientiously completed their diaries and did not 
miss any face-to-face contacts.  
Because of the recruitment method used for our trial, we can generalize our findings to 
patients with idiopathic chronic chilblains in general practice. Almost one-half of our 
participants reported having Raynaud phenomenon as a comorbidity (Table 1). This high 
figure may suggest some sort of relationship between chronic chilblains and Raynaud 
phenomenon. We did not exclude participants who had this condition because it can be 
easily distinguished from chronic chilblains.24-26 It is unlikely that the high prevalence of 
Raynaud phenomenon affected our results as placebo-controlled trials indicate that 
nifedipine and other calcium channel blockers are effective for treating that condition.27 
We found a remarkable reduction of chilblains symptoms during placebo treatment that 
may have several explanations. First, the placebo effect may have been responsible.28 
Second, almost all studies on chilblains report that 60% to 70% of the patients experience an 
improvement.3 None of these studies thoroughly corrected for the influence of exposure to 
cold and other confounders, however. Third, we did not collect information about therapy 
received for previous episodes, but in our opinion, prior therapy is unlikely to have 
influenced our results. Last, we did not ask our patients not to change their habits during the 
study, which raises the possibility of a Hawthorne effect.29 We are unable to exclude such an 
effect caused by patients’ own efforts to alleviate their symptoms by changing habits during 
the study. Nevertheless, we consider it to be unlikely because nearly all patients with 
chilblains have already tried almost everything to relieve their symptoms.2 In our opinion, 
the reduction of symptoms during placebo treatment likely reflects both a placebo effect 
and the natural course of the disease. 
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Comparison With Existing Literature 
Our findings contrast with those of the original randomized controlled trial by Rustin et al.6 
We did not reproduce their clear positive effect of nifedipine compared with placebo either 
in patient diary data or in our investigator assessment of the chilblains. Our findings are also 
at odds with the results of the other, non–placebocontrolled studies on the use of nifedipine 
to treat chronic chilblains.6-8 
 
Implications for Practice 
Our randomized controlled trial failed to confirm effectiveness of nifedipine for the 
treatment of chronic chilblains in general practice and showed evidence that its use in this 
context may cause harm. These findings underscore the importance of rigorous evaluation 
of treatments, with adequate numbers of patients and control for potential confounders, 
before widespread adoption. Current advice to prescribe nifedipine for chilblains should be 
revisited, and clinicians should weigh and discuss with patients evidence on the potential 
benefits and harms of various treatment options before making treatment decisions. 
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Abstract 
Background 
GPs prescribe topical corticosteroids to patients with chronic chilblains despite poor 
evidence for their effectiveness. The authors of the current study therefore decided to 
assess the effectiveness of topical steroids in a primary care setting. 
Aim 
To assess the effectiveness of topical application of betamethasone valerate 0.1% cream in 
patients with chronic chilblains. 
Design and setting 
A placebo-controlled, double-blind, crossover, randomised clinical trial in a Dutch primary 
care setting. 
Method 
The study population consisted of 34 participants suffering from chronic chilblains. 
Intervention was topical application of betamethasone valerate 0.1% cream twice a day for 6 
weeks compared with placebo. Primary outcome was the visual analogue scale on 
complaints (VOC). Secondary outcome was the visual analogue scale on disability (VOD). 
Both were assessed with a diary of daily scores on a 100 mm visual analogue scale. The 
authors took ambient temperatures into account, checked for a carry-over effect, performed 
additional analysis, and monitored adverse effects. 
Results 
On the primary outcome mean VOC, there was a difference of 0.56 mm (95% confidence 
interval [CI] = –2.88 to 3.99 mm) in favour of placebo (P = 0.744). On the secondary outcome 
mean VOD, there was a difference of 0.88 mm (95% CI = –2.22 to 3.98 mm) in favour of 
placebo (P = 0.567). This study found no carry-over effect and no adverse effects. 
Conclusion 
In this study, topical betamethasone was not superior to placebo in the treatment of chronic 
chilblains. Topical betamethasone should not be used for chronic chilblains without new 
evidence. 
Keywords 
betamethasone; chilblains; general practice; randomised clinical trial; therapy. 
 
 
How this fits in 
Chronic chilblains are cold-induced painful or itching lesions on the fingers, feet, ears, or 
thighs. The prescription of topical steroids for patients with chilblains finds support in one 
study. The current randomised, placebo-controlled trial does not confirm the conclusions of 
this study. Topical betamethasone should not be used in the treatment of chronic chilblains 
without new evidence. 
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Introduction 
Chronic chilblains are cold-induced painful or itching lesions on the fingers, feet, ears, or 
thighs. The condition occurs throughout the world during the winter months when daily 
mean temperatures drop below 12–15°C.1 Prevalence reported by the Netherlands Institute 
for Health Services Research (NIVEL) varies between 0.9 per 1000 and 1.7 per 1000 
depending on year-to-year variation and coding issues; the condition is more common 
among females than males (prevalence 0.9–2.1 per 1000 and 0.6–1.2 per 1000, respectively) 
(NIVEL, personal communication, 2016). Patients report serious restrictions in daily life and 
urgently feel the need for an effective treatment.2 A literature study updated to 15 March 
2016 reveals that vitamin D3, corticosteroid-containing cream, nifedipine, and pentoxifylline, 
together with a wide range of other therapies, are used to treat the symptoms of patients 
with chronic chilblains.3,4 Two of the current authors found that vitamin D3 was not superior 
to placebo.5 GPs advise topical corticosteroids for patients suffering from chilblains.6–10 Only 
one previous study evaluating the effectiveness of topical steroids in patients with chilblains 
has been published.11 This case-series with topical fluocinolone provides some evidence for 
the effectiveness of topical steroids for chronic chilblains but the current discussion on the 
reliability and reproducibility of original studies calls into question the soundness of 
recommendations based on it.12 As patients suffering from chilblains usually contact their GP 
for help, the authors decided to assess the effectiveness of topical corticosteroids in a 
primary care setting. Topical betamethasone was chosen because fluocinolone cream is not 
available in the Netherlands. 
The aim of this study was to assess the proposed superiority of the topical application of 
betamethasone valerate 0.1% cream twice a day for 6 weeks compared with placebo cream 
in patients with chronic chilblains in a primary care setting. 
 
Method 
Trial design 
The authors conducted a placebo-controlled, double-blind, crossover, randomised clinical 
trial in a primary care setting (Netherlands National Trial Register: number NTR 2171). A 
washout period was not included in the design because, for obvious reasons, the study was 
dependent on the winter months. A washout period would have caused too long a research 
period per participant and problems with high ambient temperatures in spring. Instead this 
study checked for a possible carry-over effect. 
 
Participants 
The study population consisted of consecutively recruited participants who suffered from 
chronic chilblains during the winters of 2010 to 2012. Participants volunteered after being 
informed about the trial by their GP during a consultation. The authors included participants 
aged ≥18 years with complaints of chronic chilblains lasting ≥3 weeks. The diagnosis 
(International Classification of Primary Care [ICPC] A88.01) was confirmed by one author, 
based on commonly used diagnostic criteria: complaints emerging in the winter months with 
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itching and/or painful purpleblue discoloured lesions on fingers and/ or toes and/or other 
localisations on the feet and/or on the lateral side of the thigh, without a history of 
complaints persisting in the summer months.1,7 The validity of the confirmation of the 
diagnosis had previously been demonstrated.5 The authors excluded people with a known 
rheumatic disorder (for example, rheumatoid arthritis or systemic lupus erythematosus), 
those who were using nifedipine or other calcium antagonist, those who had been using a 
corticosteroidcontaining cream in the previous 4 weeks, and females who were pregnant or 
lactating. 
 
Intervention 
The intervention to be compared with placebo consisted of topical application of 
betamethasone 0.1% cream twice a day. The research medication (betamethasone valerate 
0.1% cream and placebo) was produced and certified by an independent pharmacy: 
Pharmacy Waterland Oost, Volendam, the Netherlands. 
 
Outcomes 
Primary outcome was the difference between the visual analogue score (VAS) on complaints 
(VOC) scale in the betamethasone cream and placebo cream groups, respectively, after 6 
weeks of treatment. VOC was assessed by a diary and defined as the 100 mm VAS score on 
pain or the VAS score on itch, depending on which item had the highest value at the moment 
of sampling. VOC was calculated using the mean value of the last 7 consecutive days of the 
6-week treatment period. Secondary outcome was the difference between the VAS on 
disability (VOD) score in the betamethasone cream and placebo cream groups, respectively, 
after 6 weeks of treatment. VOD was assessed by a diary and defined as the VAS score on 
inability to function normally in daily life. VOD was calculated using the mean value of the 
last 7 consecutive days of the treatment period. Additionally, the chilblain lesions were 
assessed during face-to-face consultations. Redness, purpleness, oedema, and ulceration of 
the lesions were scored by one author on a VAS for each item. The authors monitored for 
any adverse effects from the two therapies (skin irritation and signs of skin atrophy). 
 
Sample size 
Sample size calculation was based on the following premises. In an earlier study on the 
effectiveness of vitamin D3 with 33 participants recruited in a similar way, two of the current 
authors observed a baseline VOC of 27.97 mm (standard deviation [SD] 18.82).5 An estimate 
was used of the correlation between two VAS scores from the same individual on two 
occasions of 0.5. Treatment effect was considered to be clinically relevant in the case of a 10 
mm decrease in the VOC. Based on use of a t-test for the difference between two dependent 
means, one-tail testing, α 0.05, and β 0.10 (power 90%) the authors calculated a minimum 
sample size of 32 participants. 
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Randomisation, blinding, and treatment allocation 
Block randomisation with a block size of 10 was used to assign one of the two arms (placebo 
cream first or betamethasone cream first) to research medication sets with consecutive 
therapy numbers. This procedure was performed by the pharmacy that produced and issued 
the research medication sets blind to both research personnel and participants. Treatment 
allocation was ensured by the similarity of the pharmaceutical products and packaging 
between the betamethasone cream and placebo cream, which were indistinguishable. 
Consecutively recruited participants received research medication sets with consecutive 
therapy numbers. The randomisation key was only released after the last subject had left the 
study. 
 
Study procedures 
The participants were randomised over two arms: 
Arm 1: No creams for 1 week to collect baseline data (phase 0), followed by topical 
application of betamethasone 0.1% cream twice a day for 6 weeks (phase 1), followed by 
topical application of placebo cream twice a day for 6 weeks (phase 2). 
Arm 2: No creams for 1 week to collect baseline data (phase 0), followed by topical 
application of placebo cream twice a day for 6 weeks (phase 1), followed by topical 
application of betamethasone 0.1% cream twice a day for 6 weeks (phase 2). 
The measuring instrument was a diary to be completed by the subject during the full 13-
week research period. Each day the complaints (pain and itch) and disability in normal 
functions of daily life were documented using a 100 mm VAS for each item. Each day the 
mean outside air temperature, provided by the Royal Netherlands Meteorological Institute, 
was documented. 
The authors performed six face-to-face assessments: intake (T1), end of week 1 (T2), end of 
week 4 (T3), end of week 7 (T4), end of week 10 (T5), and end of week 13 (T6). During face-
to-face assessments the diary was checked for completeness, therapy compliance was 
checked by weighing remaining cream, and remaining lesions were documented. 
 
Statistical analysis 
The analysis was intention to treat. The authors performed analysis of the primary and 
secondary outcomes using the twostage model originally proposed by Grizzle and correcting 
for temperature changes in the research period for each participant with a mixed effects 
model (Grizzle’s model using the mixed procedure with random effect, SAS PROC MIXED, 
SAS version 9.2).13,14 Additional analyses were undertaken and adverse effects monitored 
using a two sample paired t-test. 
 
Results 
Characteristics of the populations 
The flowchart (Figure 1) shows the procedure for including participants. Data for 34 
participants were available for analysis. The participants had a mean age of 53 years (SD 
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14.1), 19 were female, and 15 male. Mean duration of complaints at intake was 7 weeks (SD 
4.2). At baseline mean VAS score on complaint was 26.80 mm (95% CI = 24.04 to 29.57) and 
mean VAS score on disability was 17.55 mm (95% CI = 14.90 to 20.20). Eleven participants 
suffered from a comorbidity that might have been relevant. Five participants smoked. 
Four participants used possibly relevant drugs (Table 1). Diaries were conscientiously 
completed. No face-to-face assessments were missed. 
 
 
Figure 1: Flowchart for patient inclusion  
 
 
 
 
 
 
 
 
  
Assessed for eligibility (n=39) 
Excluded (n=5) 
 Meeting exclusion criteria (n=5) 
 
Analysed (n=19) 
Lost to follow-up (n=0) 
 
 
Allocated to Arm 1 (n=19) 
 Received allocated intervention (n=19) 
 
Lost to follow-up (n=0) 
Allocated to Arm 2 (n=15) 
 Received allocated intervention (n=15) 
 
Analysed (n=15) 
 
Allocation 
Analysis 
Follow-Up 
Randomised (n=34) 
Enrollment 
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Table 1: Baseline data 
  Arm 1 Arm 2 
Participants, n 19 15 
 Mean age, years 51 56 
 Women n 11 8 
 Men n 8 7 
Complaints     
 Mean duration at intake, weeks 8 6 
 First episode, n 2 3 
 More than one episode, n 4 2 
 Episode every year, n 13 10 
 Mean VAS score max: pain, itch, mm 29 25 
 Mean VAS score disability, mm 21 13 
Smoking, n 3 2 
Comorbidity     
 Diabetes, n 2 0 
 Peripheral arterial disease, n 1 0 
 Raynaud’s phenomenon, n 5 3 
Relevant medication use     
 Beta blocker, n 0 1 
 Nicotine replacement drug, n 0 0 
 Acetylsalicylic acid, n 1 0 
 ACE or A2 inhibitor, n 2 0 
A2 = angiotensin. ACE = angiotensin-converting enzyme. VAS = visual analogue scale. 
 
 
 
Outcomes 
Figure 2 shows plotted scores of ‘complaint’ and ‘disability’ (mean VAS score per week) not 
corrected for temperature in each arm and phase. 
 
Primary outcome. Mean VOC at 6 weeks of treatment was 9.10 mm (95% CI = 5.31 to 12.88 
mm) in the betamethasone cream group and 8.54 mm (95% CI = 4.75 to 12.33 mm) in the 
placebo cream group (Table 2). This resulted in a difference of 0.56 mm (95% CI = –2.88 to 
3.99 mm) in favour of placebo (P = 0.744). 
 
Secondary outcome. Mean VOD at 6 weeks of treatment was 5.07 mm (95% CI = 2.37 to 7.77 
mm) in the betamethasone cream group and 4.19 mm (95% CI = 1.49 to 6.89 mm) in the 
placebo cream group (Table 2). This resulted in a difference of 0.88 mm (95% CI = –2.22 to 
3.98 mm) in favour of placebo (P = 0.567). 
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Figure 2: Plotted scores on complaints (VOC) and disability (VOD) (not corrected for 
temperature) for each arm and phase. Arm 1 = betametasone + placebo. Arm 2 = placebo + 
betametasone. VAS = visual analogue scale. VOC = visual analogue scale on complaints. VOD 
= visual analogue scale on disability.  
 
 
 
Carry-over effect 
Carry-over effect on the primary outcome. Mean VOC at 6 weeks of treatment was 10.31 
mm (95% CI = 5.82 to 14.79 mm) in Arm 1 (betamethasone cream first) and 7.33 mm (95% CI 
= 2.28 to 12.38 mm) in Arm 2 (placebo cream first). This resulted in a difference of 2.98 mm 
(95% CI = –3.78 to 9.74 mm) in favour of Arm 2 (P = 0.376) (Table 2). 
 
Carry-over effect on the secondary outcome. Mean VOD at 6 weeks of treatment was 5.57 
mm (95% CI = 2.63 to 8.51 mm) in Arm 1 (betamethasone cream first) and 3.69 (95% CI = 
0.38 to 7.00) in Arm 2 (placebo cream first). This resulted in a difference of 1.88 mm (95% CI 
= –2.56 to 6.31 mm) in favour of Arm 2 (P = 0.396) (Table 2). 
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Table 2: Results corrected for temperature differences on primary (VOC) and secondary 
(VOD) outcome 
Primary outcome 
 Mean (mmVas, 6th week of treatment) Test of fixed effects 
 VOC 95%CI Difference 95%CI F value P (r>F) 
Betamethasone 9.10 5.31 – 12.88 
0.56 -2.88 – 3.99 0.11 0.744 
Placebo 8.54 4.75 – 12.33 
Arm 1 10.31 5.82 – 14.79 
2.98 -3.78 – 9.74 0.81 0.376 
Arm 2 7.33 2.28 – 12.38 
Temperature  6.24 0.018 
Secondary outcome 
 Mean (mmVas, 6th week of treatment) Test of fixed effects 
 VOD 95%CI Difference 95% CI F value P (r>F) 
Betamethasone 5.07 2.37 – 7.77 
0.88 -2.22 – 3.98 0.33 0.567 
Placebo 4.19 1.49 – 6.89 
Arm 1 5.57 2.63 – 8.51 
1.88 -2.56 – 6.31 0.74 0.396 
Arm 2 3.69 0.38 – 7.00 
Temperature  0.88 0.357 
Arm 1 = betametasone + placebo. Arm 2 = placebo + betametasone. VAS = visual analogue 
scale. VOC = visual analogue scale on complaints. VOD = visual analogue scale on disability. 
 
 
 
Additional analyses 
The authors found no statistically significant differences between topical betamethasone 
cream and placebo cream for assessed redness, purpleness, oedema, and ulceration after 6 
weeks of treatment (Table 3). 
 
Adverse effects 
No adverse effects (skin irritation or signs of skin atrophy) were found during 
betamethasone cream application or during placebo cream use. 
 
 
Table 3: Outcomes on additional analyses (6 weeks of treatment) 
 Placebo 
(mean) 
Betamethasone 
(mean) 
Mean difference 
(95%CI) 
p 
Assessed redness, mmVAS 18.9 17.9 -0.52 (-5.50 – 4.47) 0.835 
Assessed purpleness, mmVAS 7.1 8.3 1.42 (-2.46 – 5.31) 0.461 
Assessed oedema, mmVAS 5.5 7.5 2.24 (-2.16 – 6.65) 0.307 
Assessed ulceration, mmVAS 0.6 0.2 -0.42 (-1.42 – 0.57) 0.392 
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Discussion 
Summary 
There was no clinically or statistically significant difference between treatment with topical 
betamethasone valerate cream and placebo cream treatment. The authors also found no 
significant carry-over effect on either the primary or the secondary outcome. Adverse effects 
were absent. 
 
Strengths and limitations 
The main strength of this study was to confirm the findings of the original study that 
generated weak evidence for the effectiveness of topical steroids in the treatment of chronic 
chilblains.11 No randomised trial on this topic had previously been performed. Nevertheless, 
topical steroids are widely prescribed by GPs. The authors used a randomised, placebo-
controlled, crossover design and checked for a carry-over effect. The ambient temperature 
was taken into account as a major confounder.1,3,15,16  
The calculated sample size was met. Participant compliance was good. Owing to the 
recruitment method used for participants in this study, it is possible to generalise the current 
findings for patients with idiopathic chronic chilblains as seen in primary care. 
Chronic chilblains meet the criteria for the definition of a common disease.17 The condition 
does not endanger health but is annoying to the patient and causes restrictions in everyday 
life.2 The relatively rare effect studies on patients suffering from chronic chilblains show no 
consensus concerning outcome measurement. Due to the disease characteristics the authors 
chose to address the complaints reported by the participants. Primary and secondary 
outcome were assessed with VAS scores on pain, itch, and disability using a diary. VAS scores 
are generally used and validated for these purposes.18–20 
The decision to test differences on VOC and VOD one-sided is based on a power issue. The 
aim of the study allows one-sided testing. The prevalence of chronic chilblains is low and 
inclusion is for obvious reasons limited to the winter months, necessitating the use of a 
design that requires a limited number of participants. 
The authors did not ask participants to change their habits during the study, leaving the 
possibility of a Hawthorne effect.21 It is not possible to exclude such an effect caused by 
efforts of participants to diminish their symptoms by changing habits during the study. 
Nevertheless such an effect is considered to be unlikely because patients with chronic 
chilblains already try almost everything to relieve their symptoms.2 
A remarkable reduction in complaints was found during placebo treatment. First, placebo 
effect may be responsible.22 Second, almost all studies on chilblains report that 60% to 70% 
of the patients show improvement on the different treatments.3 Third, the authors 
compared betamethasone cream with placebo cream and not to no treatment at all. It is 
possible that treatment with a cream not containing an active pharmaceutical agent, is 
responsible for the reduction of complaints. In the authors’ opinion, however, the reduction 
of complaints during placebo use reflects a placebo effect as well as the natural course of 
the disease.  
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Almost one in four of the participants reported Raynaud’s phenomenon as a comorbidity. 
This figure may suggest some sort of relationship between chronic chilblains and Raynaud’s 
phenomenon. Participants suffering from Raynaud’s phenomenon were not excluded. This is 
because the condition is easy to distinguish from chronic chilblains: Raynaud’s phenomenon 
is characterised by sudden onset and short episodes with (in typical cases) biphasic 
discoloration of fingers and toes after exposure to low ambient temperatures, whereas in 
chronic chilblains prolonged inflammatory symptoms are characteristic.23–25 
 
Comparison with existing literature 
The current findings oppose the findings of the original study.11 
 
Implications for practice 
The effectiveness of betamethasone valerate 0.1% cream in the treatment of chronic 
chilblains in primary care is to be called into question. Topical steroids should not be used in 
the treatment of chronic chilblains without new evidence. 
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Introduction  
In Chapter 1 we formulated the problems General Practitioners have when advising their 
patients with chronic chilblains and trying to understand their disease: We have minimal 
knowledge about patient experiences of the disease, the pathophysiological mechanism of 
chronic chilblains is undisclosed, and doctors issue different advice for the treatment of 
chronic chilblains. We formulated three research aims: i) How are patients affected by the 
disease and what do they expect from their doctors; ii) Is the familial clustering we observed 
caused by familial aggregation indicating a familial susceptibility to the disease; iii) What 
would be the best advice for the treatment of chronic chilblains? 
Research questions to be answered 
Based on the aims the following research questions were studied: 
1. On patient experiences: 
1.1. How do patients experience chronic chilblains, how do they cope with the disease 
and what are their needs? 
2. On familial susceptibility: 
2.1. Is phenotypic familial aggregation demonstrable in chronic chilblains? 
3. On treatment: 
3.1. What is known about the treatment of chilblains and how effective are these 
treatments? 
3.2. Is oral administration of 2000 IU vitamin D3 per day an effective treatment for 
chronic chilblains? 
3.3. Is oral administration of 60 mg nifedipine per day an effective treatment for chronic 
chilblains? 
3.4. Is topical administration of betamethasone valerate 0.1% cream twice a day an 
effective treatment of chronic chilblains? 
 
Findings 
Chapter 2 describes a qualitative study on the experiences of patients suffering from chronic 
chilblains in a primary care setting1. Most of the patients were troubled by red to purple 
discolouration, pain, and oedema. Increased sensitivity, itching, stiffness, numbness, fissures 
and wounds, a burning and glowing sensation, and tingling were mentioned as well. Patients 
experienced chronic chilblains as an annoying and disturbing condition leading to restrictions 
in everyday life. The seriousness of these restrictions and handicaps varied considerably, 
ranging from a necessity to use peeled and cut-up vegetables and fruits or not being able to 
write down the answers during an exam, to feeling ashamed and not being able to wear 
normal shoes. The majority of patients visited a general practitioner but complained of a 
shortage of information. We found a large number of measures that had been tried without 
positive effect. The patients were willing to try almost anything to get rid of their complaints, 
but they found the availability of effective measures to be lacking. Patients look upon 
chilblains as a disorder that is still commonly unknown and offers few therapeutic 
possibilities. Most patients stated that they could cope with this, but they hoped that a cure 
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would soon be found. Patients were not able to give a clear reason for the development of 
their complaints. However, all patients reported that chronic chilblains occurred at 
temperatures below 10-15 oC. The presence of chilblains in the first-degree relatives of 10 
patients suggested an hereditary component in the aetiology of chronic chilblains. Taken 
together, our findings support the observation that chilblains is an annoying and disturbing 
disorder, causing major restrictions in daily life. Patients reported lack of proper information 
about the disease and lack of an effective therapy.  
Chapter 3 describes our case-control family study on familial aggregation of chronic 
chilblains2. 31 case probands were traced and included. 287 cases were identified (9.3 per 
case proband) of which 223 were alive and 64 deceased. We approached 209 cases of which 
128 responded. 31 sex-matched and age-matched index controls were selected and 
included. 260 controls were identified (8.4 per index control), 193 alive and 67 deceased. 
174 controls could be approached of which 111 responded. Analyses of hearsay, self-
reported and confirmed episodes together gave an RR of 3.6 (95% CI 1.9-7.3). Analysis of 
only self-reported and confirmed episodes (Self-reported) gave an RR of 2.7 (95% CI 1.3-5.8). 
The differences are statistically significant. We confirmed five episodes among cases and 
none among controls. This difference is not statistically significant. Sensitivity analysis shows 
similar figures (Total: RR 2.2 (95% CI 1.1-4.4 and Self-reported: RR 2.6 (95% CI 1.3-5.7)). This 
figures implicates the existence of phenotypic familial aggregation in chronic chilblains.  
Chapter 4 describes an updated systematic literature review. We found one case series and 
three placebo-controlled randomised clinical trials concerning treatment of chilblains that 
met our minimal requirements of methodological quality3. We concluded that vitamin D3 
administered orally is not effective for the treatment of chronic chilblains. We cannot draw 
any further conclusions concerning effective treatment options for chronic chilblains. 
Nifedipine administered orally, fluocinolone cream applied locally and pentoxyfyline 
administered orally might appear to be effective but due to the moderate quality of the 
research no unequivocal statement could be made about this.  
Chapter 5 describes an RCT using time series analysis on the effect of oral administration of 
2000 IU vitamin D3 on the complaints of patients suffering from chronic chilblains4. We 
included 37 patients in our study. Data of 33 patients were available for analysis. We 
corrected for patients with an upward temperature trend during the intervention period or a 
downward ‘Complaint’ or ‘Disability’ trend in the baseline dataset, or both. In other words 
we corrected for a possible recovery for any reason other than vitamin D3 administration. 
After these corrections, the results revealed that 19% report fewer ‘Complaint’ and 6% less 
‘Disability’ after 3 weeks of placebo, with equal figures after 7 weeks of vitamin D3. We 
conclude that vitamin D3 is not better than placebo for the treatment of patients' chronic 
chilblains in general practice. 
Chapter 6 describes our randomised controlled trial on the effectiveness of nifedipine for the 
treatment of chronic chilblains in general practice5. Data of 32 participants were available for 
analysis. We did not find clinically or statistically significant differences in favour of 
nifedipine compared to placebo treatment. Systolic blood pressure was significantly lower in 
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the nifedipine group compared to the placebo group and oedema was reported significantly 
more in the nifedipine group compared to the placebo group. We did not find a significant 
carry-over effect on the primary or the secondary outcome. The positive effect of nifedipine 
in the treatment of chronic chilblains found by Rustin was not confirmed by our RCT. Instead 
nifedipine might cause adverse effects. We conclude that nifedipine should not be used for 
the treatment of chronic chilblains in general practice without new evidence. 
Chapter 7 describes our placebo-controlled trial on the effectiveness of topical 
betamethasone for the treatment of chronic chilblains in general practice6. Data of 34 
participants were available for analysis. We found no clinically or statistically significant 
difference between topical betamethasone valerate cream and placebo cream treatment. 
We also found no significant carry-over effect on either the primary or the secondary 
outcome. Adverse effects were absent. We conclude that the effectiveness of 
betamethasone valerate 0.1% cream in the treatment of chronic chilblains in primary care is 
to be doubted.  
 
Reflection on findings 
Based on the above described above we identified three related themes that we will discuss 
in more detail below: i) the proposed disease mechanism of chronic chilblains, ii) therapeutic 
options and iii) research on a common disease with a low prevalence. 
 
Proposed disease mechanism of chronic chilblains 
Despite the efforts of a variety of authors the underlying mechanism of chronic chilblains 
remains uncertain. After summarising the available evidence on the disease we consider that 
evidence useful for hypothesis development is available concerning the following aspects of 
chronic chilblains: 
 
Chilblains as disease entity 
Chronic chilblains has to be considered as a separate disease to be distinguished from acute 
chilblains and chronic-chilblain-like symptoms 10, 12, 15, 29-35. In summary, we are of the opinion 
that chronic chilblains occur after prolonged or repeated exposure to mean ambient 
temperatures below 15 oC in a patient susceptible to the disease. 
 
Relation to cold exposure, humidity and living conditions 
Doctors have always suspected a relationship between chilblains and low ambient 
temperatures. Müller spoke in 1687 about “frostbeulen”7. Also the Dutch designations for 
the disease “winterhanden” and “wintertenen” point to this relationship8. Lewis was able to 
induce acute chilblains on the hand of a patient susceptible to the disease by immersing the 
hand in water at 7 0C for two hours9. Jacob et al. described a well-documented case of 
chronic chilblains associated with a mean ambient temperature of 14.6 0C10. Raza studied 
111 cases and reported a relation between the onset of chilblains and low ambient 
temperatures of less than 10 oC11. In our own qualitative study with 26 participants 
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described in Chapter 2, all patients reported that chronic chilblains occurred at ambient 
temperatures below 10-15 oC1. A registration of visitors to our research website also reveals 
a pattern compatible with a relationship between chronic chilblains and low ambient 
temperatures.  
Several authors presume a relation between chilblains and high humidity9,12. Raza studied 
111 cases and reported a relation between the onset of chilblains and humidity over 60% (at 
low temperatures)11. 
One interesting publication by a school doctor working in the 1950s in the small Dutch town 
of Harderwijk proposes a relation between a low protein diet and chronic chilblains in 
children13. However, we think that the low protein diet seems to be an indicator of poor 
living conditions. At that time bad housing may have caused more exposure to low ambient 
temperatures in winter. 
In our opinion no direct relation between humidity and chronic chilblains exits. High 
humidity is probably related to chronic chilblains because it causes an increase of heat 
conduction and therefore heat loss in cold conditions. 
 
Susceptibility 
The need of some sort of susceptibility to develop chronic chilblains is also generally 
presumed14,15. 
 
Sex and ethnic differences 
In the first place the condition is more common among women than among men. Prevalence 
in primary care reported by the Netherlands Institute for Health Services Research (NIVEL) 
varies depending on year to year variation and coding issues between 0.4 - 2.1 in woman 
and 0.2 - 1.0 in man per 1000 respectively (written information NIVEL). 
Secondly, ethnic differences in the probability of developing peripheral cold injury (chronic 
chilblains was not specified) have been reported16. Male pacific islanders were reported to 
have a relative risk of 2.5 and young male African Americans a relative risk of 30 compared 
to Caucasians of developing cold injury following similar climate exposure. 
 
Familial clustering and familial aggregation 
Our observations in chilblained families and the outcomes of an earlier study indicate that 
familial clustering (the clinical sense of multiple diseased members in a family) is involved in 
chronic chilblains1. A case-control study from Pakistan also suggests familial clustering17. 
Familial clustering may suggest phenotypic familial aggregation (an on average greater 
frequency of disease in close relatives of chilblained individuals compared to relatives of 
healthy individuals)18. Phenotypic familial aggregation suggests involvement of genetic 
determinants in a disease19. In our study on the topic we demonstrated a familial relative of 
3.6, which implies the existence of phenotypic familial aggregation in chronic chilblains. The 
results concur with the familial clustering found in our 2004-2005 qualitative study and with 
the observation of familial clustering by Raza et al1,17. The phenotypic familial aggregation 
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found is robust but is probably based on a complex of genetic and non-genetic factors19. 
Therefore conclusions concerning the underlying mechanism of chronic chilblains cannot be 
based solely on the phenotypic familial aggregation found.  
 
Outcomes on the effect studies on vitamin D3, nifedipine and topical betamethasone 
Based on de findings of the studies reported in Chapters 5, 6 and 7 we conclude that the 
effect of oral vitamin D3, oral nifedipine and topical betamethasone does not exceed the 
effect of placebo for treatment of patients chronic chilblains in general practice4,5,6. These 
conclusions have implications concerning the possible disease mechanism. 
The use of vitamin D3 for treatment of chronic chilblains has been practised on an historical 
and empirical basis without solid pathophysiological support20. Vitamin D3 deficiency in 
relation to chronic chilblains has not been studied and our study showed no effect exceeding 
placebo of vitamin D3 supplementation on the complaints of chronic chilblains4.  
The use of nifedipine for treatment of chronic chilblains is based on the hypothesis of a 
vascular basis of the disease21. Nifedipine is a calcium channel blocker with a relaxing effect 
on human peripheral arteries and veins in vitro and in vivo22,23. We found nifedipine to be no 
more effective than placebo for treating the symptoms of chronic chilblains, which leaves 
unanswered questions about the role of calcium channels in chronic chilblains5.  
The use of topical corticosteroids is also not based on a well-defined pathophysiological 
basis. The anti-inflammatory effect of corticosteroids is presumed to be helpful24. We found 
topical betamethasone to be no more effective than placebo for treating the symptoms of 
chronic chilblains, which leaves unanswered questions about the role of inflammation in the 
disorder6.  
 
Histopathological characteristics 
Conclusions on the histopathological characteristics of chilblains vary between different 
publications. A perivascular lymphocytic vasculitis has been described in the two patients on 
whom histopathological examination was performed out of seven described in one study12. 
One histological study demonstrated a lymphocytic vasculitis, characterised by lymphocytes 
infiltrating the walls of blood vessels in eight of nine cases25. In a series of 26 cases clinically 
representing typical chilblains different histological patterns were recognised15. The majority 
of biopsies showed ‘classical’ pernio with a superficial variant (intense oedema of the 
papillary dermis, a marked perivascular mononuclear cell infiltrate in the superficial dermis 
relatively sparing the oedematous papillary dermis and ‘fluffy’ oedema of the blood vessel 
walls), a deep variant (without a prominent oedema of the dermis but with an intense 
perivascular mononuclear cell infiltrate and ‘fluffy’ oedema of the blood vessel walls 
throughout the dermis and subcutaneous fat) and a combination of both. A minority of the 
cases showed erythematosus multiforme, discoid lupus erythematosus and erythema 
induratum of Bazin (due to a granulomatous infiltrate, a positive Mantoux reaction and 
recovery after anti-tuberculosis therapy) mimicking chilblains. The histopathological features 
of chilblains were characteristic enough for the diagnoses. A study with 36 cases of clinically 
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typical chilblains found T-cell papillary and deep infiltrate with peri-eccrine reinforcement, 
associated with dermal oedema and necrotic keratinocytes to be characteristic for 
chilblains26. A lymphocytic infiltrate with perivascular and peri-eccrine distribution, dermal 
oedema and necrotic keratinocytes were also reported in a more recent study27. 
Taking all of these reports into account then chronic chilblains seems to be associated with 
histopathological signs of vascular damage combined with inflammatory changes of the 
dermis. Biopsies of affected skin areas show characteristic histopathological changes that in 
most cases consist of oedema of the papillary dermis, a perivascular mononuclear infiltrate 
and oedema of the blood vessel walls. 
 
Relation to other diseases 
Historically chilblains are associated with connective tissue disease, erythema nodosum and 
erythema induratum of Bazin12,15,28. 
In clinical settings, the symptoms of chronic chilblains are associated with connective tissue 
disease, particularly systemic lupus erythematosus29. The evidence for this association is not 
substantial. One study reported that up to one third of severe chilblains cases were 
diagnosed as chilblain lupus erythematosus30. On the other hand, the proportion of patients 
with chilblains in a group with systemic lupus erythematosus does not seem to differ from 
patients in the control group31. Histopathological studies conclude in general that chronic 
chilblains can be differentiated from chilblain lupus erythematosus on the basis of 
histopathological characteristics15,27,33.  
Erythema nodosum can mimic chronic chilblains. The disease consists of painful and non-
ulcerating nodules on the legs and is generally considered to be reactive to an underlying 
condition. Chronic chilblains and erythema nodosum have different histopathological 
characteristics10.  
Erythema induratum of Bazin, is related to tuberculosis and may mimic chronic chilblains as 
well. The condition can be differentiated from chronic chilblains on histopathological 
findings15. 
We found one publication describing erythema multiforme mimicking chilblains15. 
Histopathological characteristics differed from those of chilblains.  
Case reports have linked the disorder to rare forms of vessel disease and rare conditions 
such as Sjögren syndrome and chronic myelomonocytic leukaemia12,27,33,33.  
The presence of cryoproteins, cold agglutinins, and hereditary protein C and S deficiencies 
are not associated with chronic chilblains12,34,35,36. 
 
Vasospasm in chilblains 
Vasospasm triggered by cold challenge is a consequent finding. In all 9 participants studied 
out of a group of 39 patients and in all participants of a study with 5 patients suffering from 
chilblains vasospasm-triggered-vasospasm induced by cold challenge was demonstrated37,38.  
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Reported effect of alpha-reflector blockage 
In 1954 The South-East Scotland Faculty of the College of General Practitioners reported that 
the alpha-receptor blocker phenoxybenzamine definitely had a beneficial effect in the 
treatment of chilblains. We discussed this study in Chapter 439.  
 
Proposed disease mechanism 
Chronic chilblains are likely to be caused by exposure to low ambient temperatures in 
patients susceptible to the disease and has to be distinguished from acute chilblains and 
chronic-chilblain-like symptoms.  
In our opinion one key to understanding the underlying causes of chronic chilblains is the 
proposed susceptibility of patients to be prone to the condition. The second key is the 
phenotypic familial aggregation we demonstrated in chronic chilblains. Although phenotypic 
familial aggregation is usually based on a complex of genetic and non-genetic factors it may 
implicate a genetic factor19. The third key is vasospasm triggered by cold challenge and the 
fourth key is the consequent histopathological finding of a perivascular infiltrate suggesting 
perivascular tissue damage of the skin. The fifth and final key is our finding that vitamin D, 
nifedipine and topical betamethasone do not influence the symptoms of the disease. 
This key findings support the hypothesis that chronic chilblains is an inflammatory reaction 
of the skin on perivascular tissue damage, caused by the effects of vasospasm related to cold 
and an individual susceptibility, in which a genetic factor may be involved. Parts of this 
possible disease mechanism have been suggested by several authors9,10,12,14,15 .  
Involvement of the cold-induced vasodilatation (CIVD or hunting response) in chilblains has 
also been suggested before40,41 . CIVD can be seen as a protective mechanism to prevent skin 
damage during exposure to cold and is part of and influenced by other cold-induced vascular 
mechanisms42,43. Temperature homeostasis in humans exposed to low temperatures is 
regulated by central thermoregulatory areas in the brain and depends on heat production 
(shivering mediated by the motor system and non-shivering thermogenesis controlled by the 
sympathetic nervous system) on one the hand and control of heat loss (mediated by the 
noradrenergic sympathetic system regulating skin perfusion) on the other hand44. 
Additionally, exposure of the skin to low temperatures induces local vasoconstriction 
mediated by a direct and persistent response of superficial skin vessels and a transient 
response mediated by the central nerve system43. The mechanism that limits heat loss in fact 
favours homeostasis of central body temperature by sacrifying the homeostasis of skin 
temperature. CIVD prevents the skin temperature from damage due to low skin 
temperatures by intermittent vasodilatation of the skin vessels inducing a rise of the skin 
temperature43. The mechanism regulating CIVD is largely undisclosed. Artery-venous 
anastomoses located in the skin seem to be involved but how CIVD is regulated is not 
known45,46. Involvement of central processes, of the axon reflex, of local release of a 
vasodilatory agent, of local paralysis of smooth muscle cells and of failure of skin vessels to 
respond to noradrenalin at low temperatures have all been suggested43,46. CIVD is influenced 
by sympathetic nerve stimulation due to lowering of the central body temperature but also 
General discussion| 109 
 
by local cooling43,46. A lower central body temperature delays the start of CIVD, lowers the 
magnitude and frequency of the hunting waves and leads to less rewarming of the 
skin43,46,47. Local cooling also leads to less rewarming of the skin by CIVD46. The quality of 
CIVD varies between individuals. Sex and ethnic differences in CIVD have been 
demonstrated45. The central body temperature homeostasis ultimately seems to overrule 
local temperature homeostasis of the skin and the equilibrium may be subject to individual 
variety.  
The familial phenotypic aggregation we demonstrated in chronic chilblains concurs with 
individual differences in CIVD quality. Our finding that vitamin D3, nifedipine and topical 
betamethasone do not influence symptoms of chronic chilblains does not contradict 
involvement of CIVD. Vitamin D3 has, for example, a role in processes concerning peripheral 
arteries and inflammation48. Low vitamin D plasma levels are associated with peripheral 
vessel disease and arterial stiffness and also with increased autonomic nerve system 
activity48,49,50. Via this pathway vitamin D might theoretically be able to influence 
temperature homeostasis and CIVD quality. However, an association between low vitamin D 
serum levels and temperature homeostasis or low vitamin D serum levels and chronic 
chilblains has not been investigated. Our findings on vitamin D suggest that this association 
does not exist.  
The central body temperature homeostasis in cold conditions depends on a pathway 
involving the noradrenergic sympathetic nerve system and ultimately the calcium channels 
of the peripheral vascular smooth muscle cells. Calcium channel blockage inhibits smooth 
muscle cell contraction causing a less pronounced constriction of skin vessels in cold 
conditions. Calcium channel blockers might therefore influence the equilibrium between 
central body temperature homeostasis and local skin temperature homeostasis in favour of 
the lather and preventing local tissue damage. We found that nifedipine does not influence 
symptoms of chronic chilblains. This may be caused by the competition between the effect 
of noradrenergic sympathetic nerve system activity and the effect of calcium channel 
blockage. Peripheral vasodilatation caused by calcium channel blockage may cause increased 
heat loss and therefore activate increased noradrenergic sympathetic nerve activity by the 
central body temperature homeostasis mechanism competing with the vasodilatory effect of 
the same calcium channel blockage. The presence of such a mechanism is suggested by an 
early publication on the effect of nifedipine on peripheral vessel resistance and concurs with 
recent findings22,46.  
The use of topical corticosteroids in the treatment of chronic chilblains is based on the 
possible anti-inflammatory effects of the treatment24. We demonstrated that topical 
betamethasone does not influence the symptoms of chronic chilblains. In our opinion the 
inflammatory reaction in chronic chilblains represents a last step following tissue damage 
due to vasoconstriction of the skin vessels. Topical steroids may be able to diminish the 
inflammatory symptoms but have to compete with the inflammatory effect of the tissue 
damage that appears to prevent a positive effect of topical corticosteroids. 
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In conclusion, we suggest the hypothesis that the familial aggregation involved in chronic 
chilblains, among possible other factors, may represent a genetic predisposition that 
influences the quality of CIVD and the equilibrium between central body temperature 
homeostasis and local skin temperature homeostasis. This leads to skin damage after 
exposure to cold that results in symptoms of chronic chilblains.  
 
Therapeutic options 
Chronic chilblains have been treated with vitamin D3 injections, oral nifedipine, topical 
corticosteroids and a variety of other therapies8. We conclude that Vitamin D3, Nifedipine 
and topical corticosteroids are not effective for treatment of chronic chilblains in a primary 
care setting4,5,6. 
We did not study phenoxybenzamine for the treatment of chronic chilblains. A double-
blinded, placebo-controlled, parallel type RCT with 128 participants in a primary care setting 
published in 1954 by The South-East Scotland Faculty of the College of General Practitioners 
was reported on in Chapter 439 . The study was not identified for unknown reasons in our 
original search in 2004 but found during the update of the search in 2016. The alpha-
receptor blocker phenoxybenzamine 10 mg a day in the first week, 20 mg a day in the 
second week and 30 mg a day in the third and fourth week was compared to lactose as 
placebo. The daily dose was not increased in case of undesirable effects. Outcome was the 
assessment of the effect as reported by the doctor on a 3-point scale.  
62 participants completed the full 4-week study period. In this most strictly comparable 
group the good/not good ratio was 24/4 participants in the phenoxybenzamine group 
compared to 17/17 in the placebo group. The difference was statistically significant. In the 
total group (less comparable due to different treatment and observation periods) the 
good/not good ratio was 35/9 in the phenoxybenzamine group compared to 31/28 in the 
placebo group. This difference is also statistically significant. Adverse effects (dizziness, 
paraesthesia, tachycardia, swollen eyelids, lethargy, nasal congestion and dryness of the 
nose) were seen in 22 out of 59 patients receiving phenoxybenzamine urging 9 participants 
to discontinue treatment. Adverse effects (dizziness, heartburn, and constipation) were also 
seen in 7 out of the 59 patients receiving lactose as placebo urging 1 to discontinue 
treatment. The higher incidence of side effects in the phenoxybenzamine arm is statistically 
significant. The authors concluded that phenoxybenzamine has a definite beneficial effect in 
treatment of chilblains but causes side effects. 
We have discussed weaknesses of the study in Chapter 4. The results may be biased by 
differences in cold exposure and a different mix of acute and chronic chilblains between the 
study arms. Therefore the generalisability of the studies to current patients suffering from 
chronic chilblains in primary care can be questioned. Phenoxybenzamine is not standardly 
available in Europe. Despite our criticisms of this study we are of the view that 
phenoxybenzamine might be a treatment option depending on its availability and subject to 
a study that confirms its effectiveness in a well-defined study population. 
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Based on available evidence we have to conclude that none of the commonly advised 
therapeutic options is effective for treatment of chronic chilblains in general practice. 
Vitamin D3, nifedipine and topical steroids should not be advised without new evidence 
about the effectiveness for the indication. Phenoxybenzamine might be a treatment option 
for chronic chilblains dependent on its availability and its effectiveness being confirmed.  
 
Research on a cold-induced common disease with low prevalence 
Although the use of the concepts common disease and minor ailment (we use the 
qualification common disease) varies between authors. Chronic chilblains fulfils the required 
minimum of eight criteria proposed by Mulder and may therefore be defined as a common 
disease51,52 : i) The diagnoses chronic chilblains is not difficult.  ii) The disease is not 
progressive and, iii) although annoying and disturbing, not serious and, iv) not health 
threatening. v) Chronic chilblains resolve spontaneously in spring. vi) There is no consensus 
on pathophysiology and evidence on therapeutic options is weak. vii)The disease leads not 
always to consultation of a doctor. viii) Disability to work is rare and ix) referral to secondary 
care is seldom necessary. Chronic chilblains is also generally considered to be a common 
disease.  
Chronic chilblains is also a relatively rare condition: Dutch General Practitioners reported 
about 4 new cases per year in 2004 according to figures of the Continue Morbidity 
Registration (Nijmegen, the Netherlands)8. Incidence in Dutch primary care reported by the 
NIVEL varies between 0.1 - 1.4 per 1000 and prevalence between 0.3 - 1.7 depending on 
year-to-year variation and coding issues (written information NIVEL).  
Finally, chronic chilblains have a generally accepted relation to ambient temperature. 
Symptoms of chronic chilblains seem to increase in colder conditions and resolve when 
temperatures rise.  
The disease characteristics of a common disease as defined by Muller, the known low 
incidence and prevalence of chronic chilblains, and the influence of ambient temperatures 
on the complaints place specific demands on the study designs that can be used to study 
chronic chilblains. Although the diagnosis of chronic chilblains is not difficult a Dutch GP will 
diagnose about 2 to 4 cases per winter (and none in the other months of the year). As 
referral to secondary care is not usual, recruitment of study participants is limited to primary 
care centres with small numbers of potential participants per centre. Therefore inclusion of 
large numbers of participants is difficult to realise. Limited resources available for studies on 
common diseases necessitate the choosing of efficient study designs, especially in the case 
of the relatively expensive effect studies. As complaints of chronic chilblains emerge in the 
winter months only and resolve in spring, patients suffering from chronic chilblains only 
exhibit symptoms within a limited timeframe. This limits the length of inclusion and study 
periods for effect studies and it also places special demands on the study designs in general. 
The lack of consensus or knowledge on disease mechanism and the, implications of the 
disease for patients require an open approach. The lack of knowledge about a possible 
mechanism for therapeutic interventions has implications for the design of effect studies on 
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the topic. A combination of the lack of knowledge on underlying causes of chronic chilblains 
and therapy, the plausible relation with ambient temperature, the possible influence of 
clothing habits and the difficulty to include large numbers of participants makes effects 
studies on the disease prone to different forms of bias, which are probably partly of 
unknown origin but include a Hawthorne effect. The last effect refers to bias caused by 
participants changing their habits due to their inclusion in a study53.  
We are of the view that study designs suitable for research on common diseases, and more 
specifically chronic chilblains, should in general: be sufficient to answer the proposed 
research question, be safe in regard to the participants, require only a small number of 
participants, and require minimal resources like special facilities or intensive skills training. 
Studies exploring backgrounds of the disease should additionally have an open approach and 
be in general usable to induct new hypothesis. Effect studies should additionally require a 
limited research period per participant (proximally 3 months maximum) be independent of 
disease or therapeutic mechanism be insensitive for bias also of undisclosed origin and 
including the Hawthorne effect.  
We have therefore chosen specific designs for our different studies as we will explain in the 
strengths and limitations section below. 
 
Strengths and limitations 
Study design 
Patient experiences, coping and needs were studied using a qualitative design with semi-
structured interviews54,55. Therapeutic options were inventoried using the principles of 
systematic review56,57.  
To approach the proposed phenotypic familial aggregation we used a case control family 
design18,19 with population-based controls. A case-control family design can be seen as a 
retrospective cohort study of relatives. In a case-control family design with population based 
controls the case cohort is recruited among relatives of patients and the control cohort is 
recruited among relatives of individuals selected by population-based sampling. We studied 
cohort cases (relatives of the case probands: chilblained patients) and cohort controls. The 
study design is well described and very suitable for addressing phenotypic familial 
aggregation in relatively rare diseases like chronic chilblains. 
Designing a proper effect study for chronic chilblains we encountered many of the 
limitations associated with research on common diseases: recruitment is limited to primary 
care centres with small numbers of potential participants per centre with a limited length of 
inclusion and study periods due to the disease characteristics. The lack of consensus or 
knowledge concerning the disease mechanism and the possible mechanism of therapeutic 
interventions, which implies questions about carry-over effects and the washout period that 
needed to be addressed. And lastly there is expected bias due to the plausible relation with 
ambient temperature and the possible influence of clothing habits and unknown causes. 
These limitations placed special demands on the choice of the respective study designs58,59. 
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The effectivity of vitamin D3 was studied using a design analysing time series60. This design 
can be seen as a number of N=1 studies. Each participant serves as his or her own control in 
a parallel design. The moment of introduction of the active medication is randomised and 
disclosed to both participant and research personnel. A single-case time-series analysis tool 
with a sample size of eight data points per phase was used to evaluate changes in reported 
VAS-scores and temperature changes recorded for each patient and each time period. The 
technique is based on the C-statistic60. Significance was defined by a p-value of 0.05 (Z-value 
1.64 and higher). The C-statistic is powerful enough to detect a trend using this sample size 
and the formulae regarding this technique have been published61,62.We think this design is 
suitable to deal with most but not all of the problems related to research on chronic 
chilblains. Strength of the design is the possibility to use a participant both as an active 
participant and as a control in a limited study period. Problems due to washout effect do not 
influence the results and the design is not very sensitive to unknown causes of bias. A main 
limitation is that without rigorous correction the design remains sensitive to causes of bias 
not equally distributed over time, like fluctuation of ambient temperature, while a rigorous 
correction has negative consequences on the power of the design to detect effect.  
The effectivity of nifedipine and betamethasone was assessed using a crossover randomised 
clinical trial according to the two-stage model originally proposed by Grizzle63,64. The main 
strength of this study design is the ability to detect and deal with the existence of a carry-
over effect. This is important because the therapeutic mechanism and therefore the 
duration and existence of this possible effect of nifedipine and betamethasone in chronic 
chilblains is not known. The two-stage model makes it possible to use a crossover design 
instead of a parallel design, which would otherwise be the safest option. A crossover design 
dealing with the problems of an unknown carry-over effect is to be preferred above a 
parallel design for our purposes. In the first place the power is higher and therefore requires 
a lower minimum of inclusions to be able to detect an effect. Also the design is less sensitive 
to unknown sources of bias, as participants act as both active and control. Lastly the design 
facilitates a limited length of the study period required. This is important because chronic 
chilblains resolve spontaneously in spring thereby limiting the period available for study. 
The decision to test differences on VOC and VOD in our effect studies on nifedipine and 
betamethasone one-sided is based on the power issue. The prevalence of chronic chilblains 
is low and inclusion is for obvious reasons limited to the winter months. This necessitates 
the use of a design that requires a limited number of participants. One-sided testing 
increases the power of a study if that is applicable. The aim of the study was to assess if the 
active medication performed better than placebo. This aim allows one-sided testing. 
In all studies we found a remarkable reduction of complaints during placebo treatment. 
Firstly placebo effect may be responsible65. Secondly almost all studies on chilblains report 
that 60% to 70% of patients improve3. In none of these studies was a thorough correction 
made for the influence of exposure to cold and other confounders. Thirdly we did not collect 
information about previous therapy in previous episodes. In our opinion this is unlikely to 
influence our results. Lastly we did not ask our participants to avoid a change in their habits 
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during the study leaving the possibility of a Hawthorne effect53. We are not able to exclude 
such an effect caused by the efforts of participants to diminish their complaints by changing 
their habits during the study. Nevertheless, we consider it to be unlikely because chilblained 
patients already try almost everything to relief their complaints1. In our opinion the 
reduction of complaints during placebo use reflects placebo effect and the natural course of 
the disease. 
 
Measurements 
In all effect studies, primary and secondary outcome was assessed with VAS scores on pain, 
itch, and disability using a diary. VAS are generally used and validated on this purposes66,67,68. 
Because we feel that the use of a visual analogue scale to monitor itch is less common than 
for monitoring pain and disability, we performed a pilot study to estimate correlation 
between scores on itch by patients at 0 and 1 hour and 0 and 48 hours on a 5-point 
categorical scale and a 100 mm visual analogue scale respectively. We included 20 primary 
care patients with a wide range of conditions causing itch. For the 5-point categorical scale 
we found a correlation of 0.76 (0-1 hour) and 0.71 (0-48 hours). For the 100 mm visual 
analogue scale we found a correlation of 0.98 (0-1 hour) and 0.89 (0-48 hours). These 
findings support our choice of using 100 mm visual analogue scales to assess itch, pain and 
disability in our effect studies. 
 
Generalization  
We recruited the participants with the help of almost all general practitioners in Waterland, 
a region in the northwest of the Netherlands with approximately 130,000 inhabitants. The 
region contains a large town with 80,000 inhabitants, two small towns with 10,000 and 
30,000 inhabitants and rural areas. We included participants with complaints of chronic 
chilblains only when they fulfilled the following criteria: Itching and/or painful red-blue to 
purple-blue discoloured lesions in any of several locations (fingers, toes, feet, or lateral 
thigh) emerging in the winter months and lasting 3 weeks or more. No history of persistence 
of complaints into the summer months, connective tissue disease or other rheumatologic 
disorder was allowed. Swelling of lesions, ulceration and a history of episodes in previous 
winters could be present but were not mandatory. Therefore is our opinion that our findings 
can be generalised to all patients chronic chilblains in a primary care setting. 
 
Implications for practice 
Chronic chilblains must be clearly differentiated from acute chilblains and chronic-chilblain-
like symptoms. We propose the following seven criteria for chronic chilblains. i) Itching 
and/or painful red-blue to purple-blue discoloured lesions in any of several locations 
(fingers, toes, feet, or lateral thigh) . ii) Symptoms emerge in the winter months and last 3 
weeks or more. iii) No history of persistence of complaints into the summer months. iv) No 
history of connective tissue disease or other rheumatologic disorder. v) Swelling of lesions 
can be present but is not mandatory. vi) Ulceration of lesions can be present but is not 
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mandatory. vii) A history of episodes in previous winters can be present but is not 
mandatory.  
Although self-limiting and not life-threatening, chronic chilblains is an annoying and 
disturbing condition leading to restrictions in daily life. Patients visit a general practitioner if 
they consult a doctor at all. They are in need of proper advice about the disease and the 
therapeutic options. 
Robust phenotypic familial aggregation of chronic chilblains has been demonstrated. Family 
members of a patient with at least one episode of chronic chilblains have a lifetime relative 
risk of 3.6 compared to family members of healthy controls. 
There is no evidence of effectiveness for any therapy for chronic chilblains. The best advice 
so far is to wear warm clothes and avoid cooling. There is no direct evidence for this advice. 
It is based on our thoughts about a possible disease mechanism, a malfunction of the body 
temperature regulating mechanisms and, more specifically, the cold-induced vascular 
response. 
 
Implications for research 
We think that further research on chronic chilblains should primarily focus on the disease 
mechanism and the proposed susceptibility needed to develop the disease in low ambient 
temperatures. Based on our findings, disclosing the cause of the demonstrated phenotypic 
familial aggregation may be worthwhile. More specific research on the existence of a genetic 
basis for the susceptibility of individuals to chronic chilblains would be worthwhile and this 
should include gene-typing the members of one affected family. 
We also think that research on the role of temperature-regulating mechanisms like the cold-
induced vascular response is interesting. Once concrete ideas about the disease mechanism 
have been formulated then new therapeutic options may be more promising than these 
have been up until now. In line with our hypothesis on the disease mechanism of chronic 
chilblains, alpha-receptor inhibiting may be more effective than calcium-channel blocking. 
Therefore an effect study on phenoxybenzamine would be an obvious next step.  
Although chronic chilblains is a well-described disorder there is no consensus regarding the 
criteria to be fulfilled for diagnosis1,2,3. We propose the seven diagnostic criteria mentioned 
in the implications for practice section as obligatory. 
The recruitment of study participants requires specific attention due to the characteristics of 
chronic chilblains as a common disease, the relatively low incidence, and the specific relation 
between symptoms and low ambient temperatures. As referral to secondary care is seldom 
indicated, participants should generally be found in primary care centres. Each centre or 
surgery will be able to identify only a limited number of potential participants and in a limed 
time window (the winter months). This matters this thesis. We are of the opinion that a 
primary care network would be extremely useful in research on chronic chilblains and 
relatively rare common diseases in general. 
Research on a common disease has to compete for funds with a broad spectrum of other 
diseases, in most cases with a higher overall impact on health. This also matters this thesis. 
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Therefore we are convinced that a specific funding program as a ZonMw/NHG-program 
Common Diseases is indispensable for further research on chronic chilblains and common 
diseases in general. 
General conclusion 
Our study discusses several aspects of chronic chilblains. We launch the hypothesis that the 
familial aggregation involved in chronic chilblains, among possible factors, may represent a 
genetic predisposition that influences the quality of CIVD and the equilibrium between 
central body temperature homeostasis and local skin temperature homeostasis, which leads 
to skin damage after exposure to cold resulting in symptoms of chronic chilblains.  
We also suggest that research on low-prevalence common diseases and more specifically 
chronic chilblains places specific demands on the study designs to be used. In general, the 
design should be sufficient to answer the proposed research question, be safe in regard to 
the participants, require only a small number of participants, and require minimal resources 
like special facilities or intensive skills training. 
Based on formulated recommendations for clinical practice we conclude that chronic 
chilblains must be clearly differentiated from acute chilblains and chronic-chilblain-like 
symptom. We propose seven criteria obligatory for diagnosis of chronic chilblains. 
Although chronic chilblains is not life threatening and self-limiting, it is an annoying and 
disturbing condition that leads to restrictions in daily life. Unfortunately to date there is no 
evidence for any therapy for chronic chilblains. Our best advice at present is to wear warm 
clothing and avoid cooling and is based on the proposed disease mechanism.  
Research should primary aim on the disease mechanism, including the involvement of a 
genetic factor related to phenotypic familial aggregation and the role of the cold induced 
vascular response.  
New research on therapeutic options will be more promising after concrete ideas about the 
disease mechanism have been formulated. 
Finally, we suggest to establish the mentioned specific source of funding for research on 
common diseases. 
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The Introduction describes the problems general practitioners have when advising their 
patients with chronic chilblains and trying to understand their disease: We have minimal 
knowledge about patient experiences of the disease, the pathophysiological mechanism of 
chronic chilblains is undisclosed, and doctors issue different advice for the treatment of 
chronic chilblains. We formulated three research aims: i) How are patients affected by the 
disease and what do they expect from their doctors; ii) Is the familial clustering we observed 
caused by familial aggregation indicating a familial susceptibility to the disease; iii) What 
would be the best advice for the treatment of chronic chilblains? Based on the aims the 
following research questions were studied: 
1. On patient experiences: 
1.1. How do patients experience chronic chilblains, how do they cope with the disease 
and what are their needs? 
2. On familial susceptibility: 
2.1. Is phenotypic familial aggregation demonstrable in chronic chilblains? 
3. On treatment: 
3.1. What is known about the treatment of chilblains and how effective are these 
treatments? 
3.2. Is oral administration of 2000 IU vitamin D3 per day an effective treatment for 
chronic chilblains? 
3.3. Is oral administration of 60 mg nifedipine per day an effective treatment for chronic 
chilblains? 
3.4. Is topical administration of betamethasone valerate 0.1% cream twice a day an 
effective treatment of chronic chilblains? 
 
Chapter 2 describes a qualitative study on the experiences of patients suffering from chronic 
chilblains in a primary care setting. Most of the patients were troubled by red to purple 
discoloration, pain, and oedema. Increased sensitivity, itching, stiffness, numbness, fissures 
and wounds, a burning and glowing sensation, and tingling were mentioned as well. Patients 
experienced chronic chilblains as an annoying and disturbing condition leading to restrictions 
in everyday life. The seriousness of these restrictions and handicaps varied considerably, 
ranging from having to use peeled and cut-up vegetables and fruits or not being able to 
write down the answers during an exam, to feeling ashamed and not being able to wear 
normal shoes. The majority of patients visited a general practitioner but complained of a 
shortage of information. We found a large number of measures that had been tried without 
positive effect. The patients were willing to try almost anything to get rid of their complaints, 
but they found the availability of effective measures to be lacking. Patients look upon 
chilblains as a disorder that is still commonly unknown and offers few therapeutic 
possibilities. Most patients stated that they could cope with this, but they hoped that a cure 
would soon be found. Patients were not able to give a clear reason for the development of 
their complaints. However, all patients reported that chronic chilblains occurred at 
temperatures below 10-15 oC. The presence of chilblains in the first-degree relatives of 10 
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patients suggested an hereditary component in the aetiology of chronic chilblains. Taken 
together, our findings support the observation that chilblains is an annoying and disturbing 
disorder, causing major restrictions in daily life. Patients reported lack of proper information 
about the disease and lack of an effective therapy.  
 
Chapter 3 describes our case-control family study on familial aggregation of chronic 
chilblains. 31 case probands were traced and included. 287 cases were identified (9.3 per 
case proband) of which 223 were alive and 64 deceased. We approached 209 cases of which 
128 responded. 31 sex-matched and age-matched index controls were selected and 
included. 260 controls were identified (8.4 per index control), 193 alive and 67 deceased. 
174 controls could be approached of which 111 responded. Analyses of hearsay, self-
reported and confirmed episodes together gave an RR of 3.6 (95% CI 1.9-7.3). Analysis of 
only self-reported and confirmed episodes gave an RR of 2.7 (95% CI 1.3-5.8). The 
differences are statistically significant. We confirmed five episodes among cases and none 
among controls. This difference is not statistically significant. Sensitivity analysis shows 
similar figures (Total: RR 2.2 (95% CI 1.1-4.4) and Self-reported: RR 2.6 (95% CI 1.3-5.7)). 
These figures imply the existence of phenotypic familial aggregation in chronic chilblains.  
 
Chapter 4 describes an updated systematic literature review. We found one case series and 
three placebo-controlled randomised clinical trials concerning treatment of chilblains that 
met our minimal requirements of methodological quality. We concluded that vitamin D3 
administered orally is not effective for the treatment of chronic chilblains. We cannot draw 
any further conclusions concerning effective treatment options for chronic chilblains. 
Nifedipine administered orally, fluocinolone cream applied locally and pentoxyfyline 
administered orally might appear to be effective but due to the moderate quality of the 
research no unequivocal statement could be made about this.  
 
Chapter 5 describes an RCT using time series analysis on the effect of oral administration of 
vitamin D3 on the complaints of patients suffering from chronic chilblains. We included 37 
patients in our study. Data of 33 patients were available for analysis. We corrected for 
patients with an upward temperature trend during the intervention period or a downward 
‘Complaint’ or ‘Disability’ trend in the baseline dataset, or both. In other words we corrected 
for a possible recovery for any reason other than vitamin D3 administration. After these 
corrections, the results revealed that 19% report fewer ‘Complaint’ and 6% less ‘Disability’ 
after 3 weeks of placebo, with equal figures after 7 weeks of vitamin D3. We conclude that 
vitamin D3 is not better than placebo for the treatment of patients' chronic chilblains in 
general practice. 
 
Chapter 6 describes our randomised controlled trial on the effectiveness of nifedipine for the 
treatment of chronic chilblains in general practice. Data of 32 participants were available for 
analysis. We did not find clinically or statistically significant differences in favour of 
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nifedipine compared to placebo treatment. Systolic blood pressure was significantly lower in 
the nifedipine group compared to the placebo group and oedema was reported significantly 
more in the nifedipine group compared to the placebo group. We did not find a significant 
carry-over effect on the primary or the secondary outcome. The positive effect of nifedipine 
in the treatment of chronic chilblains found earlier by Rustin et al. was not confirmed by our 
RCT. Instead nifedipine might cause adverse effects. We conclude that nifedipine should not 
be used for the treatment of chronic chilblains in general practice without new evidence. 
 
Chapter 7 describes our placebo-controlled trial on the effectiveness of topical 
betamethasone for the treatment of chronic chilblains in general practice. Data of 34 
participants were available for analysis. We found no clinically or statistically significant 
difference between topical betamethasone valerate cream and placebo cream treatment. 
We also found no significant carry-over effect on either the primary or the secondary 
outcome. Adverse effects were absent. We conclude that the effectiveness of 
betamethasone valerate 0.1% cream in the treatment of chronic chilblains in primary care is 
to be doubted.  
 
Chapter 8 discusses several aspects of chronic chilblains in relation to our findings. We 
identified three related themes that we will discuss in more detail: i) the proposed disease 
mechanism of chronic chilblains, ii) therapeutic options and iii) research on a common 
disease with a low prevalence. Strengths and limitations, implications for practise and 
implications for research are also discussed. 
The disease mechanism of chronic chilblains remains uncertain. We consider that evidence 
useful for hypothesis development is available concerning the following aspects of chronic 
chilblains:  
Chronic chilblains has to be considered as a separate disease to be distinguished from acute 
chilblains and chronic-chilblain-like symptoms.  
Chronic chilblains occur after prolonged or repeated exposure to mean ambient 
temperatures below 10 - 15 oC in a patient susceptible to the disease.  
The disease is more common among women than among men and ethnic differences in the 
probability of developing peripheral cold injury have been reported.  
Familial clustering (the clinical sense of multiple diseased members in a family) has been 
observed in chronic chilblains. Additionally we demonstrated the existence of phenotypic 
familial aggregation. 
Our findings that the effect of oral vitamin D3, oral nifedipine and topical betamethasone 
does not exceed the effect of placebo for treatment of patients chronic chilblains in general 
practice have implications concerning the possible disease mechanism. The use of vitamin 
D3 for treatment of chronic chilblains has been practised on an historical and empirical basis 
but vitamin D3 deficiency in relation to chronic chilblains has not been studied and our study 
showed no effect that exceeded placebo of vitamin D3 supplementation on the complaints 
of chronic chilblains. The use of nifedipine for the treatment of chronic chilblains is based on 
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the hypothesis of a vascular basis of the disease. Nifedipine is a calcium channel blocker with 
a relaxing effect on human peripheral arteries and veins in vitro and in vivo. We found 
nifedipine to be no more effective than placebo for treating the symptoms of chronic 
chilblains, which leaves unanswered questions about the role of calcium channels in chronic 
chilblains. The use of topical corticosteroids is also not based on a well-defined 
pathophysiological basis. The anti-inflammatory effect of corticosteroids is presumed to be 
helpful. We found topical betamethasone to be no more effective than placebo for treating 
the symptoms of chronic chilblains, which leaves unanswered questions about the role of 
inflammation in the disorder. The alpha-receptor blocker phenoxybenzamine possibly has a 
beneficial effect in the treatment of chilblains.  
Taking the reports on histopathological findings into account then chronic chilblains seems 
to be associated with histopathological signs of vascular damage combined with 
inflammatory changes of the dermis. Biopsies of affected skin areas show characteristic 
histopathological changes that in most cases consist of oedema of the papillary dermis, a 
perivascular mononuclear infiltrate and oedema of the blood vessel walls.  
Historically chilblains are associated with connective tissue disease, erythema nodosum and 
erythema induratum of Bazin and in clinical settings with connective tissue disease, 
particularly systemic lupus erythematosus although the evidence for this association is not 
substantial. Histopathological studies conclude in general that chronic chilblains can be 
differentiated from chilblain lupus erythematosus on the basis of histopathological 
characteristics. Erythema nodosum, Erythema induratum of Bazin and erythema multiforme 
can mimic chronic chilblains but can be differentiated from chronic chilblains on 
histopathological findings. Case reports have linked the disorder to rare forms of vessel 
disease and rare conditions such as Sjögren syndrome and chronic myelomonocytic 
leukaemia. The presence of cryoproteins, cold agglutinins, and hereditary protein C and S 
deficiencies are not associated with chronic chilblains.  
Vasospasm triggered by cold challenge is a consequent finding. In all 9 participants studied 
out of a group of 39 patients and in all participants of a study with 5 patients suffering from 
chilblains, vasospasm-triggered-vasospasm induced by cold challenge was demonstrated.  
Based on this evidence, chronic chilblains are likely to be caused by exposure to low ambient 
temperatures in patients susceptible to the disease and has to be distinguished from acute 
chilblains and chronic-chilblain-like symptoms. The findings support the hypothesis that 
chronic chilblains is an inflammatory reaction of the skin on perivascular tissue damage, 
caused by the effects of vasospasm related to cold and an individual susceptibility, in which a 
genetic factor may be involved. Parts of this possible disease mechanism have been 
suggested by several authors. Involvement of the cold-induced vasodilatation (CIVD or 
hunting response) in chilblains has also been suggested before. CIVD can be seen as a 
protective mechanism to prevent skin damage during exposure to cold and is part of and 
influenced by other cold-induced vascular mechanisms. The familial phenotypic aggregation 
we demonstrated in chronic chilblains concurs with individual differences in CIVD quality. 
Our finding that vitamin D3, nifedipine and topical betamethasone do not influence 
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symptoms of chronic chilblains does not contradict involvement of CIVD. In conclusion, we 
suggest the hypothesis that the familial aggregation involved in chronic chilblains, among 
possible other factors, may represent a genetic predisposition that influences the quality of 
CIVD and the equilibrium between central body temperature homeostasis and local skin 
temperature homeostasis. This leads to skin damage after exposure to cold that results in 
symptoms of chronic chilblains.  
Chronic chilblains have been treated with vitamin D3 injections, oral nifedipine, topical 
corticosteroids and a variety of other therapies. We conclude that Vitamin D3, Nifedipine 
and topical corticosteroids are not effective for treatment of chronic chilblains in a primary 
care setting. 
We did not study phenoxybenzamine for the treatment of chronic chilblains. A placebo-
controlled, parallel type RCT with 128 participants published in 1954 was reported on in 
Chapter 4. The authors concluded that phenoxybenzamine has a definite beneficial effect in 
treatment of chilblains but causes side effects. The generalisability of the study to current 
patients suffering from chronic chilblains in primary care can be questioned because the 
results may be biased by differences in cold exposure and a different mix of acute and 
chronic chilblains between the study arms. Despite these criticisms we are of the view that 
phenoxybenzamine might be a treatment option depending on its availability and subject to 
a study that confirms its effectiveness in a well-defined study population. 
Based on available evidence we have to conclude that none of the commonly advised 
therapeutic options are effective for treatment of chronic chilblains in general practice. 
Vitamin D3, nifedipine and topical steroids should not be advised without new evidence 
about the effectiveness for the indication. Phenoxybenzamine might be a treatment option 
for chronic chilblains dependent on its availability and its effectiveness being confirmed.  
The disease characteristics of a common disease, the known low incidence and prevalence of 
chronic chilblains, and the influence of ambient temperatures on the complaints place 
specific demands on the study designs that can be used to study chronic chilblains. We are of 
the view that study designs suitable for research on common diseases, and more specifically 
chronic chilblains, should in general: be sufficient to answer the proposed research question, 
be safe in regard to the participants, require only a small number of participants, and require 
minimal resources like special facilities or intensive skills training. 
Studies exploring backgrounds of the disease should additionally have an open approach and 
be in general usable to induct new hypothesis. Effect studies should additionally require a 
limited research period per participant (approximately 3 months maximum) be independent 
of disease mechanism or therapeutic mechanism and be insensitive for bias also of 
undisclosed origin and including the Hawthorne effect. We therefore chose specific designs 
for our different studies. 
Patient experiences, coping and needs were studied using a qualitative design with semi-
structured interviews. Therapeutic options were inventoried using the principles of 
systematic review. 
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To approach the proposed phenotypic familial aggregation we used a case-control family 
design with population-based controls. A case-control family design can be seen as a 
retrospective cohort study of relatives. In a case-control family design with population-based 
controls the case cohort is recruited among relatives of patients and the control cohort is 
recruited among relatives of individuals selected by population-based sampling. We studied 
a cohort cases (relatives of the case probands: chilblained patients) and cohort controls. The 
study design is well described and highly suitable for addressing phenotypic familial 
aggregation in relatively rare diseases like chronic chilblains.  
Designing the effect studies for chronic chilblains we encountered many of the limitations 
associated with research on common diseases:  
Recruitment is limited to primary care centres with small numbers of potential participants 
per centre and with a limited length of inclusion and study periods due to the disease 
characteristics.  
The lack of consensus or knowledge concerning the disease mechanism and the possible 
mechanism of therapeutic interventions, implies questions about carry-over effects and the 
washout period that needed to be addressed. There is expected bias due to the plausible 
relation with ambient temperature and the possible influence of clothing habits and 
unknown causes.  
These limitations placed special demands on the choice of the respective study designs. The 
effectivity of vitamin D3 was studied using a design analysing time series. Each participant 
serves as his or her own control in a parallel design while the moment of introduction of the 
active medication is randomised and disclosed. A strength of the design is the possibility to 
use a participant both as an active participant and as a control in a limited study period. 
Problems due to washout effect do not influence the results and the design is not very 
sensitive to unknown causes of bias. A main limitation is that without rigorous correction the 
design remains sensitive to causes of bias not equally distributed over time, like fluctuation 
of ambient temperature, while a rigorous correction has negative consequences on the 
power of the design to detect effect. The effectivity of nifedipine and betamethasone was 
assessed using a crossover randomised clinical trial according to the two-stage model 
originally proposed by Grizzle. The main strength of this study design is the ability to detect 
and deal with the existence of a carry-over effect. A crossover design dealing with the 
problems of an unknown carry-over effect is to be preferred above a parallel design for our 
purposes. In the first place the power is higher and therefore requires a lower minimum of 
inclusions to be able to detect an effect. Also the design is less sensitive to unknown sources 
of bias, as participants act as both active and control. Lastly the design facilitates a limited 
length of the study period required. This is important because chronic chilblains resolve 
spontaneously in spring thereby limiting the period available for study.  
The decision to test differences on primary and secondary outcomes in our effect studies on 
nifedipine and betamethasone one-sided is based on the power issue. The prevalence of 
chronic chilblains is low and inclusion is for obvious reasons limited to the winter months. 
This necessitates the use of an analysis that requires a limited number of participants.  
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In all studies we found a remarkable reduction of complaints during placebo treatment. In 
our opinion the reduction of complaints during placebo use reflects placebo effect and the 
natural course of the disease. In all effect studies, primary and secondary outcome was 
assessed with visual analogue scale (VAS) scores on pain, itch, and disability using a diary. 
VAS are generally used and validated for these purposes.  
We recruited the participants with the help of almost all general practitioners in Waterland, 
a region in the northwest of the Netherlands with approximately 130,000 inhabitants. The 
region contains a large town, two small towns and rural areas. We included participants with 
complaints of chronic chilblains only when they fulfilled the following criteria: Itching and/or 
painful red-blue to purple-blue discoloured lesions in any of several locations (fingers, toes, 
feet, or lateral thigh) emerging in the winter months and lasting 3 weeks or more. No history 
of persistence of complaints into the summer months, connective tissue disease or other 
rheumatologic disorder was allowed. Swelling of lesions, ulceration and a history of episodes 
in previous winters could be present but were not mandatory. We therefore believe that our 
findings can be generalised to all patients with chronic chilblains in a primary care setting. 
We formulated recommendations for clinical practice and concluded that chronic chilblains 
must be clearly differentiated from acute chilblains and chronic-chilblain-like symptoms. We 
propose seven obligatory criteria for the diagnosis of chronic chilblains: i) Itching and/or 
painful red-blue to purple-blue discoloured lesions in any of several locations (fingers, toes, 
feet, or lateral thigh), ii) Symptoms emerge in the winter months and last 3 weeks or more, 
iii) No history of persistence of complaints into the summer months, iv) No history of 
connective tissue disease or other rheumatologic disorder, v) Swelling of lesions can be 
present but is not mandatory, vi) Ulceration of lesions can be present but is not mandatory, 
vii) A history of episodes in previous winters can be present but is not mandatory. 
Although chronic chilblains is not life-threatening and is self-limiting, it is nevertheless an 
annoying and disturbing condition that leads to restrictions in daily life. Unfortunately, no 
evidence for any therapy for chronic chilblains has been found to date. Our best advice at 
present is to wear warm clothing and avoid cooling. This is based on the proposed disease 
mechanism. We postulate that a possible disease mechanism is an imbalance of the body 
temperature regulating mechanisms and more specifically a dysfunction of the cold-induced 
vascular response.  
Research should primarily focus on the disease mechanism, including the involvement of a 
genetic factor related to phenotypic familial aggregation and the role of the cold induced 
vascular response.  
New research on therapeutic options will be more promising once concrete ideas about the 
disease mechanism have been formulated. Finally, we suggest establishing a specific source 
of funding for research on common diseases, as described earlier in this thesis. 
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De introductie (introduction) beschrijft de problemen die huisartsen ondervinden bij het 
adviseren van hun patiënten met chronische perniones (winterhanden en wintertenen) en 
het begrijpen van hun ziektebeeld: We hebben slechts beperkte kennis over hoe patiënten 
de ziekte ervaren, het pathofysiologische mechanisme van chronische perniones is 
onbekend en dokters geven geen eensluidend advies over de behandeling van de 
aandoening. We waren geïnteresseerd in drie onderwerpen: i) Hoe ervaren patiënten de 
aandoening en wat verwachten zij van hun huisarts; ii) wordt de waargenomen familiare 
clustering bevestigd door het aantonen van familiaire aggregatie wijzend op een familiaire 
vatbaarheid voor de aandoening; iii) Wat is het beste behandeladvies bij chronische 
perniones. Op basis hiervan werden de volgende onderzoeksvragen geformuleerd: 
1. Over de ervaringen van patiënten: 
1.1. Hoe ervaren patiënten chronische perniones, hoe gaan zij er mee om en waar 
zouden zij baat bij hebben?  
2. Over familiare vatbaarheid voor de aandoening: 
2.1. Is familiare aggregatie van chronische perniones aantoonbaar? 
3. Over de behandeling: 
3.1. Welke behandelingen voor chronische perniones zijn al bekend en hoe effectief zijn 
ze?  
3.2. Is het slikken van 2000 IE vitamine D3 per dag een zinvolle behandeling voor 
chronische perniones? 
3.3. Is het slikken van 60 mg nifedipine per dag een zinvolle behandeling voor chronische 
perniones? 
3.4. Is het 2 maal per dag aanbrengen van bètamethasonvaleraat 0,1 % crème een 
zinvolle behandeling van chronische perniones? 
 
Hoofdstuk (chapter) 2  beschrijft een kwalitatief onderzoek naar de ervaringen van 26 
patiënten met chronische perniones zoals de huisarts die ziet. De meeste patiënten 
noemden hinder door een rode tot paarse verkleuring, pijn en oedeem van de aangedane 
huid. Een verhoogde gevoeligheid, jeuk, stijfheid, gevoelloosheid en een branderige en 
gloeiende sensatie van de aangedane huid en verder kloven en wondjes werden ook 
genoemd. De patiënten bleken chronische perniones als een hinderlijke aandoening de 
ervaren welke leidt tot beperkingen in het dagelijks functioneren. De ernst van deze 
beperkingen varieerde van de noodzaak geschild en gesneden fruit en groente te gebruiken 
en het ondervinden van hinder bij het noteren van de antwoorden bij een examen tot 
schaamte en het niet kunnen dragen van normaal schoeisel. De meerderheid van de 
patiënten bezochten een huisarts maar klaagden over een gebrek aan informatie over de 
aandoening. De deelnemers hadden een groot aantal remedies uitgeprobeerd zonder daar 
baat bij te hebben. Patiënten beschouwen chronische perniones als een aandoening 
waarover maar weinig bekend is en waarvoor geen goede behandeling bestaat. De meeste 
patiënten blijken daar goed mee om te kunnen gaan maar hopen dat er snel een goede 
behandeling gevonden wordt. De patiënten hebben geen goede verklaring voor het ontstaan 
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van hun klachten maar rapporteerden wel dat die ontstonden bij een 
omgevingstemperatuur beneden de 10 tot 12O C. Het voorkomen van chronische perniones 
bij 1e graads verwanten van 10 deelnemers suggereert de betrokkenheid van een erfelijke 
component bij de aandoening. Samengevat bevestigen onze bevindingen de observatie dat 
chronische perniones een hinderlijke aandoening is die forse beperkingen bij het dagelijks 
functioneren met zich mee brengt. Patiënten rapporteren een gebrek aan goede informatie 
over de ziekte en het ontbreken van een effectieve behandeling. Chronische perniones 
ontstaat bij een lage omgevingstemperatuur en er wordt familiaire clustering waargenomen. 
 
Hoofdstuk 3  beschrijft ons patiënt-controle familie onderzoek naar familiare aggregatie van 
chronische perniones. We includeerden 31 indexpatiënten en identificeerden 287 
familieleden (9.3 per index patiënt). Daarvan waren 223 personen in leven en 64 niet meer. 
We konden 209 familieleden benaderen waarvan er 128 de ingevulde vragenlijst 
retourneerden. We includeerden daarnaast 31 naar sekse en leeftijd met de index patiënten 
gepaarde indexcontroles en identificeerden 260 familieleden (8.4 per index controle). 
Daarvan waren 193 personen in leven en 67 niet meer. 174 familieleden konden worden 
benaderd waarvan er 111 de ingevulde vragenlijst terugzonden. Analyse van informatie over 
door de indexpatiënten en indexcontroles gerapporteerde episoden bij hun overleden 
familieleden, zelf-rapportage en door ons bevestigde episoden van chronische perniones te 
samen lieten een familiair relatief risico (RR) zien van 3.6 (95% CI 1.9-7.3). Analyse van zelf-
rapportage en door ons bevestigde episoden gaven een RR van 2.7 (95% CI 1.3-5.8). Deze 
verschillen zijn statistisch significant. We konden vijf episoden bevestigen bij familieleden 
van indexpatiënten tegen geen enkele episode bij familieleden van indexcontroles, Dit 
verschil is statistisch niet significant. Sensitiviteit analyse gaf vergelijkbare uitkomsten (Alle 
episoden: RR 2.2 (95% CI 1.1-4.4). Alleen zelf-rapportage en bevestigde episoden: RR 2.6 
(95% CI 1.3-5.7)). Deze uitkomsten impliceren het bestaan van familiaire aggregatie van 
chronische perniones.  
 
Hoofdstuk 4  beschrijft een tot recent bijgewerkt systematisch literatuuronderzoek. We 
vonden een patiënten serie en drie placebo gecontroleerde gerandomiseerde onderzoeken 
met controlegroep (RCT) die voldeden aan onze, beperkte, eisen van methodologische 
kwaliteit. We trekken de conclusie dat vitamine D3 oraal (via de mond toegediend) niet 
effectief is bij de behandeling van chronische perniones. Het bleek niet mogelijk conclusies 
over andere behandel opties voor chronische perniones te trekken. Nifedipine oraal, 
bètamethason crème en pentoxyfyline oraal bleken mogelijk wel effectief, maar door de 
matige kwaliteit van het onderzoek was hierover geen eenduidige uitspraak mogelijk.  
 
Hoofdstuk 5  beschrijft een RCT met gebruik van tijdserie analyse naar het effect van 2000 IE 
vitamine D3 oraal op de klachten van patiënten met chronische perniones. Er werden 37 
patiënten in de studie opgenomen. De gegevens van 33 patiënten waren beschikbaar voor 
analyse. Er werd gecorrigeerd voor patiënten waarbij sprake was van een stijgende 
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temperatuur trend tijdens de onderzoeksperiode en voor patiënten waarbij tijdens de 
nulmeting een dalende trend waargenomen werd voor gerapporteerde “klachten” (een 
gecombineerde uitkomstmaat bepaald door de hoogste VAS-score voor ondervonden jeuk of 
pijn) of “beperkingen” (de VAS-score voor ondervonden beperkingen). Met andere woorden: 
er werd gecorrigeerd voor een mogelijke verbetering door andere oorzaken dan de 
toediening van vitamine D3. Na correctie bleek dat 19% van de deelnemers minder 
“klachten” en 6% van de deelnemers minder “beperkingen” had na 3 weken placebo 
gebruik. De uitkomsten na 7 weken gebruik van vitamine D3 waren daaraan gelijk. We 
concluderen daarom dat voor de behandeling van patiënten met chronische perniones in de 
huisartspraktijk vitamine D3 niet beter is dan placebo.  
 
Hoofdstuk 6  beschrijft een RCT naar de effectiviteit van nifedipine bij de behandeling van 
chronische perniones in de huisartspraktijk. De gegevens van 32 deelnemers waren 
beschikbaar voor analyse. We vonden geen klinisch relevante of statisch significante 
verschillen ten gunste van nifedipine in vergelijking met placebo behandeling. De systolische 
bloeddruk was wel lager in de nifedipine groep in vergelijking met de placebogroep en 
oedeem werd ook meer gerapporteerd in de nifedipine groep dan in de placebogroep. Deze 
verschillen waren bovendien statisch significant. We vonden geen nawerkingseffect (carry-
over effect). Het positieve effect van nifedipine op perniones dat eerder gevonden werd 
door Rustin et al. konden wij dus niet bevestigen terwijl nifedipine wel bijwerkingen kan 
veroorzaken.  
We concluderen dat nifedipine niet gebruikt moet worden bij de behandeling van chronische 
perniones in de huisartspraktijk zonder nieuw bewijs voor de effectiviteit ervan.  
 
Hoofdstuk 7  beschrijft een RCT naar de effectiviteit van bètamethasoncrème bij de 
behandeling van chronische perniones in de huisartspraktijk. De gegevens van 34 
deelnemers waren beschikbaar voor analyse. We vonden geen klinisch relevante of statisch 
significante verschillen ten gunste van behandeling met bètamethason crème in vergelijking 
met placebocrème. We vonden ook geen nawerkingseffect. Bijwerkingen waren afwezig.  
Wij concluderen dat de effectiviteit van bètamethasonvaleraat 0,1% crème voor de 
behandeling van chronische perniones in de huisartspraktijk betwijfeld moet worden.  
 
Hoofdstuk 8  bespreekt, in relatie tot onze bevindingen, verschillende aspecten van 
chronische perniones. We bespreken drie met dit onderwerp verbonden thema’s  i) 
overwegingen over de mogelijke pathofysiologie van chronische perniones, ii) de 
therapeutische opties en iii) het onderzoek aan alledaagse ziekten met een lage prevalentie. 
We bespreken verder de sterke en zwakke punten van de studies en de betekenis van het 
besprokene voor de dagelijkse praktijk en voor verder onderzoek.  
Over de pathofysiologie van chronische perniones bestaat geen zekerheid. De volgende 
feiten met betrekking tot chronische perniones moeten bij het formuleren van een 
hypothese overwogen worden:  
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Chronische perniones moet onderscheiden worden van acute perniones en van op 
chronische perniones lijkende klachten veroorzaakt door andere ziekten. 
Chronische perniones ontstaat na langdurige of herhaalde blootstelling aan een gemiddelde 
omgevingstemperatuur beneden 10 – 15oC bij patiënten die gevoelig zijn voor de 
aandoening. 
De ziekte komt vaker voor bij vrouwen dan bij mannen en er zijn etnische verschillen wat 
betreft de kans om perifeer koude letsel te ontwikkelen. 
Familiare clustering (de klinische observatie van meerdere ziektegevallen in één familie) 
komt voor bij chronische perniones. In aanvulling hierop toonden wij het bestaan van 
familiare aggregatie (een gemiddeld hogere frequentie van ziektegevallen bij naaste 
familieleden van patiënten met de aandoening in vergelijking met familieleden van gezonde 
controle personen) van chronische perniones aan. 
Ook van belang is dat het effect van vitamine D3 oraal, nifedipine oraal en 
bètamethasoncrème het effect van placebo bij de behandeling van patiënten met 
chronische perniones niet overtreft. Het gebruik van vitamine D3 bij de behandeling van 
chronische perniones is gebaseerd op overlevering en ervaring maar niet op een 
verondersteld ziekte mechanisme. Vitamine D3 gebrek in relatie tot chronische perniones is 
niet onderzocht terwijl onze studie liet zien dat suppletie niet beter werkte dan placebo bij 
klachten van deze aandoening. Het gebruik van nifedipine is gebaseerd op een mogelijke 
vasculaire basis voor de ziekte. Nifedipine is een calciumkanaal blokkerende stof met zowel 
in laboratoriumproeven als in het levende lichaam een vaatverwijdend effect op perifere 
slagaders en aders. Ons onderzoek toont aan dat nifedipine niet effectiever is dan placebo 
bij de behandeling van chronische perniones waardoor er vragen rijzen met betrekking tot 
de rol van het calciumkanaal bij deze aandoening. Ook het gebruik van corticosteroïd 
houdende crèmes bij chronische perniones is niet gebaseerd op een helder 
pathofysiologische basis. Verondersteld wordt wel dat het ontstekingsremmende effect van 
corticosteroïden nuttig zou zijn. Wij toonden aan dat bètamethasoncrème niet beter werkt 
dan placebocrème zodat de precieze rol van ontsteking in het ziekte mechanisme van 
chronische perniones onduidelijk blijft. Mogelijk heeft het alfareceptor blokkerende middel 
phenoxybenzamine wel een positief effect bij behandeling van chronische perniones. 
De publicaties over de histopathologische kenmerken van chronische perniones wijzen op 
een associatie met tekenen van vasculaire schade in combinatie met tekenen van ontsteking 
van de huid. Biopsie van de aangedane huid laat, volgens veel auteurs kenmerkende, 
weefselveranderingen zien die in de meeste gevallen bestaan uit oedeem van de bovenste 
laag van de lederhuid, een mononucleair ontstekingsinfiltraat rond de bloedvaten van de 
lederhuid en oedeem van de bloedvaatwanden. 
Van oudsher wordt perniones in verband gebracht met bindweefsel aandoeningen 
(connective tissue disease), erythema nodosum en het erythema induratum van Bazin. Ook 
nu wordt vooral in de 2e lijn perniones in verband gebracht met bindweefselziekten, in het 
bijzonder systemische lupus erythematosus. Het bewijs voor dit verband is echter niet sterk. 
Histopathologisch onderzoek laat in het algemeen zien dat chronische perniones goed 
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onderscheiden kan worden van lupus pernio. Erythema nodosum, erythema induratum van 
Bazin en erythema multiforme kunnen lijken op chronische perniones maar kunnen op basis 
van histopathologische kenmerken eveneens goed onderscheiden worden. 
Gevalsbeschrijvingen hebben chronische perniones ook wel in verband gebracht met 
zeldzame vaataandoeningen zeldzame aandoeningen als het syndroom van Sjögren en een 
vorm van chronische leukemie. De aanwezigheid van cryoglobulinen, koude agglutininen en 
erfelijke proteïne c en s deficiënties hebben geen verband met chronische perniones. 
Door blootstelling aan lage temperaturen veroorzaakte vasoconstrictie wordt stelselmatig 
waargenomen bij perniones.  
De genoemde feiten overziend lijkt chronische perniones veroorzaakt te worden door 
blootstelling aan een lage omgevingstemperatuur van patiënten die gevoelig zijn voor deze 
aandoening. Het ziektebeeld moet onderscheiden worden van acute perniones en op 
chronische perniones lijkende klachten veroorzaakt door andere ziekten. De bevindingen 
steunen de hypothese dat chronische perniones een ontstekingsreactie van de huid op 
weefselschade rond de bloedvaten van de huid is, welke veroorzaakt wordt door 
vaatvernauwing als gevolg van afkoeling en een individueel bepaalde gevoeligheid waarbij 
een genetische factor betrokken zou kunnen zijn. Delen van dit mogelijke ziekte mechanisme 
zijn eerder door verschillende auteurs gesuggereerd. De betrokkenheid van de door een lage 
huidtemperatuur geïnduceerde vasodilatatie (cold-induced vasodilatation, CIVD of hunting 
respons) bij perniones is ook eerder gesuggereerd. CIVD kan gezien worden als een 
beschermend mechanisme dat huidschade bij blootstelling aan lage temperaturen tegengaat 
en deel uit maakt van, maar ook beïnvloed wordt door, andere met lage temperaturen in 
verband staande vaatreacties. De familiare aggregatie van chronische perniones die wij 
hebben aantoond past bij individuele verschillen in kwaliteit van de CIVD. Onze bevinding 
dat vitamine D3, nifedipine en bètamethasoncrème de symptomen van chronische 
perniones niet beïnvloeden is ook niet in tegenspraak met betrokkenheid van de CIVD.  
Concluderend suggereren wij de hypothese dat de familiaire aggregatie van chronische 
perniones, samen met andere factoren, een genetische factor representeert die de kwaliteit 
van de CIVD en het evenwicht tussen de homeostase van de centrale lichaamstemperatuur 
en de plaatselijke huidtemperatuur beïnvloed met als gevolg weefselschade van de huid bij 
blootstelling aan lage temperaturen en resulterend in de symptomen van chronische 
perniones. 
Chronische perniones is in het verleden behandeld met vitamine D3 injecties, nifedipine 
oraal , corticosteroïd houdende crèmes en een variëteit aan anderen behandelingen. We 
concluderen dat vitamine D3 injecties, nifedipine oraal en corticosteroïd houdende crèmes 
niet effectief zijn bij de behandeling van chronische perniones in de huisartspraktijk. Het 
gebruik van phenoxybenzamine voor de behandeling van chronische perniones is door ons 
niet onderzocht. In hoofdstuk 4 van dit proefschrift wordt een in 1954 gepubliceerde 
placebo gecontroleerde RCT van het parallelle type met 128 deelnemers besproken. De 
auteurs concludeerden dat phenoxybenzamine een duidelijk voordelig effect had bij de 
behandeling van perniones maar dat het gebruik ervan ook bijwerkingen met zich mee 
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bracht. De generaliseerbaarheid van deze studie naar de huidige patiënten met chronische 
perniones in de huisartspraktijk is niet vanzelfsprekend omdat de resultaten beïnvloed 
kunnen zijn door verschillen in de blootstelling aan lage temperaturen en verschillen in de 
verhouding van acute perniones en chronische perniones in de twee armen van de studie. In 
weerwil van deze overwegingen denken wij dat phenoxybenzamine, afhankelijk van de 
beschikbaarheid van het middel en een nadere evaluatie van de werkzaamheid in een studie 
met een goed omschreven studiepopulatie, een goede behandeling zou kunnen zijn. 
Het beschikbare bewijs overziend moeten wij concluderen dat geen van de gebruikelijke 
behandeladviezen effectief is bij de behandeling van chronische perniones in de 
huisartspraktijk. Vitamine D3, nifedipine en corticosteroïd houdende crèmes moeten niet 
meer geadviseerd worden zonder nieuw bewijs voor ze zin ervan. Phenoxybenzamine is 
mogelijk, en afhankelijk van de beschikbaarheid ervan en aanvullend bewijs, een 
behandeloptie. 
De ziekte kenmerken van een alledaagse ziekte, de lage incidentie en prevalentie van 
chronische perniones en de invloed van wisselingen in de omgevingstemperatuur op de 
klachten stellen specifieke eisen aan de methodiek die gebruikt wordt bij onderzoek aan 
chronische perniones. Wij zijn van mening dat een voor dit doel te gebruiken 
onderzoeksmethode in het algemeen geschikt moet zijn voor het beantwoorden van de 
onderzoeksvraag, veilig moet zijn voor de deelnemers, geschikt moet zijn voor toepassing bij 
een beperkt aantal deelnemers en geschikt moet zijn voor toepassing zonder bijzondere 
voorwaarden zoals ingewikkelde apparatuur of een intensieve vaardigheidstraining. Studies 
naar de achtergrond van de aandoening moeten daarbij een open benadering mogelijk 
maken en, meer in het algemeen, geschikt zijn voor het genereren van nieuwe hypothesen. 
Effectstudies moeten aanvullend geschikt zijn voor gebruik met een beperkte 
onderzoeksperiode per deelnemer (arbitrair maximaal 3 maanden), mogen niet beïnvloed 
worden door het grotendeels onbekende ziektemechanisme of het daarom vooralsnog 
eveneens onzekere therapeutische mechanisme van de medicatie en niet gevoelig zijn voor 
verstoringen van onbekende origine en het Hawthorne effect. 
We hebben daarom specifieke methoden gekozen voor onze verschillende studies. 
De ervaringen van patiënten, de wijze waarop zij met de aandoening omgaan en hun 
wensen werden onderzocht door middel van een kwalitatieve onderzoeksmethode met 
semigestructureerde interviews. De behandelmogelijkheden zijn geïnventariseerd op basis 
van de principes van systematisch literatuuronderzoek. 
De waargenomen familiare clustering van chronische perniones is verder onderzocht met 
een patiënt-controle familie onderzoek met controlefamilies afkomstig uit de algemene 
populatie. Dit type onderzoek kan het beste gezien worden als retrospectief (terugkijkend in 
de tijd) cohort (groepen) onderzoek waarbij een cohort bestaande uit familieleden van 
patiënten vergeleken wordt met een cohort bestaande uit familieleden van gezonde 
deelnemers. Wij bestudeerden een cohort patiënten (familieleden van patiënten met 
chronische perniones) en een cohort controles (familieleden van gezonde personen). De 
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methode is eerder gebruikt, goed beschreven en bijzonder geschikt om familiaire aggregatie 
bij relatief zeldzame aandoeningen als chronische perniones te bestuderen. 
Bij het ontwerp van de effectstudies bleken veel van de beperkingen die samenhangen met 
onderzoek naar alledaagse ziekten ook voor ons van belang: werving van deelnemers is 
beperkt tot huisartsenpraktijken met een beperkt aantal potentiele deelnemers per praktijk 
met, omdat chronische perniones alleen in de wintermaanden voorkomt, een beperkte 
periode waarin werving mogelijk is en een beperkte studieperiode per deelnemer. Het 
gebrek aan kennis en consensus over de pathofysiologie en het mogelijke 
werkingsmechanisme van de behandelmogelijkheden veroorzaakt onzekerheid met 
betrekking tot nawerkingseffecten en de benodigde uitspoelperiode (wash-out periode) bij 
de wisseling tussen de actieve medicatie en het placebo. In de laatste plaats is het zeer 
waarschijnlijk dat de resultaten ook beïnvloed worden door de vrijwel zeker bestaande 
relatie tussen klachten en omgevingstemperatuur, de mogelijke invloed van kleding 
gewoonten en de invloed van nog onbekende factoren samenhangend met het nog 
onbekende ziektemechanisme. De werkzaamheid van vitamine D3 is bestudeerd met een 
RCT methode die gebruik maakt van de analyse van tijdreeksen van onderzoeksgegevens. 
Iedere deelnemer dient bij deze methode als zijn of haar eigen controle in een parallel 
ontwerp waarbij één van twee mogelijke tijdstippen van de introductie van de actieve 
medicatie door toeval, en zonder dat de patiënt of de onderzoekers dat tijdens de 
onderzoeksperiode kunnen achterhalen, wordt toegewezen aan de deelnemers. De kracht 
van deze methode is de mogelijkheid om iedere deelnemer in een beperkte 
onderzoeksperiode én als actieve deelnemer én als controle deelnemer te gebruiken. Een 
eventueel nawerkingseffect van de actieve medicatie heeft geen invloed op de uitkomsten 
en de methode is ook beperkt gevoelig voor verstoring van het resultaat door onbekende 
oorzaken. Een belangrijke beperking is dat zonder rigoureuze correctie de methode gevoelig 
blijft voor oorzaken van verstoring die niet gelijk verdeeld zijn in de tijd, zoals fluctuaties van 
de omgevingstemperatuur, terwijl rigoureuze correctie negatieve gevolgen heeft voor het 
vermogen van de methode om een behandeleffect aan te tonen. De werkzaamheid van 
nifedipine en bètamethasoncrème zijn onderzocht met een RCT van het cross-over type met 
gebruik van de twee stap methode geïntroduceerd door Grizzle. De kracht van deze 
methode is het vermogen om het bestaan van een nawerkingseffect aan te tonen en daar 
consequenties aan te verbinden. Een cross-over studieontwerp dat rekening houdt met de 
problemen van een onbekend nawerkingseffect is voor ons doel te verkiezen boven een 
parallel studieontwerp. In de eerste plaats is het onderscheidend vermogen (de “power” ) 
groter waardoor het minimum aantal deelnemers dat noodzakelijk is voor het aantonen van 
een effect (de “sample size”) kleiner is. Verder is de methode minder gevoelig voor 
onbekende bronnen van verstoring van de uitkomsten omdat elke deelnemer als actieve 
deelnemer en als controle fungeert. In de laatste plaats staat de methode een beperkte 
lengte van de onderzoeksperiode toe. Dit is belangrijk omdat chronische perniones spontaan 
geneest in de lente zodat de tijd die per patiënt beschikbaar is voor onderzoek wordt 
beperkt. De beslissing om de verschillen voor zowel de primaire als de secondaire uitkomst 
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in deze effectstudies te analyseren met behulp van een eenzijdige toets is ook gebaseerd op 
overwegingen met betrekking tot het onderscheidend vermogen en het minimaal aantal 
benodigde deelnemers. De prevalentie van chronische perniones is laag en de inclusie van 
deelnemers is vanwege eerder genoemde redenen beperkt tot de wintermaanden. Dit 
dwingt tot gebruik van een statistisch test die een beperkt aantal deelnemers toestaat. 
Bij alle effectstudies hebben we de primaire uitkomst (pijn en jeuk) en de secondaire 
uitkomst (beperkingen) gemeten met behulp van Visueel Analoge Schaal (VAS) scores. VAS 
scores worden algemeen gebruikt en zijn gevalideerd voor deze metingen.  
Tenslotte is opmerkelijk dat wij in alle effectstudies een forse afname van klachten 
gedurende placebo behandeling waarnamen. Naar onze mening berust deze afname van 
klachten op het placebo effect en het natuurlijk beloop van chronische perniones.  
Wij hebben de deelnemers aan onze studies kunnen werven met de hulp van bijna alle 
huisartsen in Waterland, een gebied in de provincie Noord-Holland met ongeveer 130.000 
inwoners. De regio bevat een middelgrote stad, twee kleinere stedelijke gebieden en verder 
plattelandsgebied. We hebben deelnemers met klachten van chronische perniones 
uitsluitend geïncludeerd wanneer zij aan de volgende criteria voldeden: Jeukende en/of 
pijnlijke roodblauw tot paarsblauw verkleurde huidlaesies op een of meer kenmerkende 
plaatsen (vingers, tenen, voeten of de buitenzijde van het dijbeen), die ontstaan in de 
wintermaanden en 3 weken of langer blijven bestaan. Er mochten geen aanwijzingen zijn 
voor het voortduren van de klachten in de zomermaanden, een bindweefselziekte of een 
andere reumatologische aandoening. Zwelling van de aangedane huid, ulceratie en klachten 
in voorgaande winters waren toegestaan maar niet vereist.  
Door de wijze van werven van de deelnemers zijn wij van mening dat onze bevindingen van 
toepassing zijn voor alle patiënten met chronische perniones in de huisartspraktijk.  
We hebben aanbevelingen gedaan voor de dagelijkse praktijk en concluderen dat chronische 
perniones goed onderscheiden moet worden van acute perniones en van op chronische 
perniones lijkende klachten veroorzaakt door andere ziekten. We stellen voor zeven criteria 
te hanteren voor de diagnose chronische perniones: i) Jeukende en/of pijnlijke roodblauw 
tot paarsblauw verkleurde huidlaesies op een of meer kenmerkende plaatsen (vingers, 
tenen, voeten of de buitenzijde van het dijbeen). ii) de klachten ontstaan in de 
wintermaanden en houden ten minste 3 weken aan. iii) Geen aanwijzingen voor het 
voortduren van de klachten in de zomermaanden. iv) Geen aanwijzingen voor een 
bindweefsel ziekte of andere reumatologische aandoening. v) zwelling van de aangedane 
huid kan voorkomen maar is niet vereist. vi) Ulceratie kan voorkomen maar is niet vereist. 
vii) klachten in voorgaande winters kunnen voorkomen maar zijn niet vereist. 
Hoewel chronische perniones niet bedreigend is voor de gezondheid en vanzelf overgaat 
gaat het om een hinderlijke aandoening welke tot beperkingen bij dagelijkse bezigheden 
aanleiding geeft. Jammer genoeg is er tot op heden geen bewijs voor enige behandeling van 
chronische perniones. Ons beste advies op dit moment is het dragen van warme kleding en 
het vermijden van afkoeling. Dit advies is gebaseerd op het door ons veronderstelde ziekte 
mechanisme.  
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Verder onderzoek moet zich in de 1e plaats richten op de pathofysiologie van chronische 
perniones, de betrokkenheid van een genetische factor gerelateerd aan de familiare 
aggregatie van de aandoening en de rol van de door een lage huidtemperatuur 
geïnduceerde vasodilatatie (CIVD). Het formuleren van een zeker ziektemechanisme 
bevorderd de kans op zinvol onderzoek naar behandelmogelijkheden voor chronische 
perniones. In de laatste plaats suggereren we het herstel van een fonds dat zich richt op het 
bekostigen van onderzoek aan alledaagse ziekten. 
 
 
 
  
Samenvatting| 141 
 
 
142 | Chapter 11 
 
  
Dankwoord| 143 
 
Chapter 11 
 
Dankwoord 
  
144 | Chapter 11 
 
Bij het voltooien van dit proefschrift wil ik graag aandacht besteden aan diegenen die 
hebben bijgedragen aan mijn proefschrift en zullen bijdragen aan de verdediging daarvan, 
aan diegenen die een bijzonder rol hebben gehad bij mijn opleiding en het feit dat ik nu al 
bijna 25 jaar huisarts ben en tenslotte aan mijn naasten. 
 
Ik had dit proefschrift niet kunnen voltooien zonder de begeleiding, steun en samenwerking 
van en met een aantal door mij bijzonder gewaardeerde mensen. 
 
Ik dank in de eerste plaats mijn promotores prof.dr. Toine Lagro-Janssen en prof.dr. Paul 
Smits. Toine, ik heb het handgeschreven briefje nog waarmee je mij in 2001, nadat wij elkaar 
uitgebreid gesproken hadden tijdens de Wonca in Durban, uitnodigde om een afspraak met 
je te maken om te spreken over het doen van onderzoek. Je hebt mij de kans gegeven om, 
aanvankelijk onverplicht en vooral voor het genoegen, de eerste stappen te zetten in 
onderzoek dat uiteindelijk heeft geleid tot dit proefschrift. Je bent door een heel goede en 
geduldige begeleiding in staat geweest mij het ambacht van het doen van huisarts-
geneeskundig onderzoek in een heel brede zin bij te brengen. Belangrijk was daarbij dat je 
mij steeds op de juiste momenten hebt aangezet tot weer een volgende stap. Je had goed 
door wat ik moeilijk vond en waar ik tegen op zag en hebt mij dat met zachte en soms iets 
hardere hand toch laten doen. Daarbij ben je altijd geïnteresseerd geweest in wat er verder 
in mijn leven gebeurde. Toine, dank je voor je steun en bemoedigende woorden al die jaren. 
Paul, dank je voor de vriendelijke en bemoedigende wijze waarop je mij hebt laten 
profiteren van je kennis. En ook voor je humorvolle en relativerende opmerkingen op zijn 
tijd. Ik heb veel genoegen beleeft aan de contacten met jou.  
 
De leden van de manuscriptcommissie, prof.dr. Ronald Laan, prof.dr. David Burger en 
prof.dr. Henriëtte van der Horst dank ik hartelijk voor hun aandacht en tijd. 
 
Hans Bor dank ik voor de ondersteuning die hij mij als statisticus heeft gegeven. Hans, ik heb 
onze contacten als buitengewoon plezierig ervaren. Prof.dr. Nine Knoers dank ik voor de 
adviezen en hulp bij het ontwerp van de studie naar familiare clustering en de rapportage 
ervan. Ik heb het contact als bijzonder plezierig ervaren. 
 
Ik dank ook mijn onderzoeksassistentes. Betty Lurvink en Rina Siemons zijn onmisbaar 
geweest bij het uitvoeren van het onderzoek dat tot dit proefschrift heeft geleid. Als 
dorpsdokter was het een ongekend voorrecht om met onderzoeksassistentes te mogen 
werken. Betty en Rina bleken onmisbaar te zijn bij het opzetten en uitvoeren van mijn 
onderzoek. Beiden hebben veel werk gehad aan het opzetten en onderhouden van het 
netwerk van huisartsen in Waterland dat nodig was om de deelnemers aan de verschillende 
studies te kunnen werven. Ze bleken vervolgens voor de deelnemers gewaardeerde 
vertrouwenspersonen en hebben heel veel werk verzet bij het onderhouden van de 
contacten met hen. Het verzamelen en ordenen van alle gegevens en waarnemingen is ook 
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veel werk geweest. Betty en Rina hebben ook nog eens geweldig samengewerkt met mijn 
praktijkpersoneel. Praktijkpersoneel, overigens, dat ook een onmisbare rol heeft gehad bij 
de organisatie van het onderzoek waarbij de deelnemers grotendeels in mijn praktijk 
ontvangen werden (en soms ook bij het opmonteren van hun baas). Mary-Ann, Sylvia, 
Margot, Aat, Angela en Jelly: dank jullie wel. 
 
Wim ter Heide, huisarts dank ik voor zijn bereidwilligheid om zich beschikbaar te stellen voor 
de rol van onafhankelijk arts ten behoeve van de deelnemers aan de verschillende 
onderzoeken. 
 
Arnoul van Mierlo en Carolien Veerman-Smit, beiden apotheker in Volendam en de 
ziekenhuisapotheek van het Radboudumc dank ik voor het samenstellen van de 
onderzoeksmedicatie voor de effectstudies over respectievelijk vitamine D3, 
bètamethasoncrème en nifedipine. 
 
Lynn Robins en Deborah Smaal hebben tijdens hun respectievelijke wetenschappelijke 
stages geassisteerd bij twee studies die in dit proefschrift zijn opgenomen. Ik dank jullie voor 
jullie enthousiaste bijdrage. 
 
De huisartsen verbonden aan mijn huisartsengroep, de huisartsen in Waterland die bereid 
waren deelnemers voor mijn onderzoek te werven en de patiënten die bereid waren aan 
mijn onderzoek mee te doen ben ik buitengewoon erkentelijk voor hun medewerking. 
 
Dr. Joost Zaat dank ik voor zijn belangstelling voor en vertrouwen in mijn project, zijn 
waardevolle hulp op de achtergrond, en zijn beslissing als toenmalig hoofdredacteur om de 
eerste twee bijdragen die ik over het onderwerp chronische perniones schreef in Huisarts en 
Wetenschap te plaatsen. Dat was voor mij een belangrijk moment. Fijn dat je ook de tijd 
neemt om oppositie te voeren bij mijn promotie. 
 
Het Nederlands instituut voor onderzoek van de gezondheidszorg, en vooral Sara Dorsman 
en Irina Stirbu-Wagner, dank ik voor het beschikbaar stellen van incidentie- en 
prevalentiecijfers over chronische perniones. 
 
Twanny Jeijsman-Rouwhorst heeft mij enorm geholpen met het klaarmaken van het 
manuscript voor de manuscriptcommissie en daarna met het klaarmaken ervan voor de 
drukker. Heel hartelijk bedankt voor je werk. 
 
J.R. Wikler, dermatoloog, dank ik voor zijn hulp bij het verifiëren van mijn diagnosen bij de 
vitamine D studie. 
 
146 | Chapter 11 
 
Dr. Gavin ten Tusscher dank ik voor zijn hulp om mijn eerste Engelstalige artikel in goed 
Engels te herschrijven. Ik weet zeker dat dat doorslaggevend is geweest bij deze voor mij 
heel bemoedigende publicatie. Dave Thomas dank ik voor zijn professionele hulp bij de 
correctie van de overige publicaties en dit proefschrift. Dave, we hadden een wat bijzondere 
relatie, uitsluitend via e-mail eigenlijk, maar ik heb ons contact als heel plezierig ervaren. 
 
Het ZonMW/NHG programma Alledaagse Ziekten dank ik voor beide projectsubsidies die ik 
van hen kreeg. Vooral de projectleiders Maarten Slijper en Dunja Dreesens dank ik voor de 
vriendelijke wijze waarop ik steeds te woord ben gestaan. 
 
Prof.dr. Henk van Weert, prof.dr. Peter van de Kerkhof en dr. Gé Donker dank ik voor hun 
bereidheid tijd voor het voeren van oppositie bij mijn promotie vrij te maken. 
 
Wim Derks, mijn vriend door dik en dun, dank ik voor zijn bereidheid mij tijdens de 
promotieplechtigheid ter zijde te staan. Jouw aanwezigheid en die van Mark waardeer ik 
enorm. 
 
Dit is ook een goed moment om stil te staan bij de mensen die belangrijk zijn geweest bij 
mijn vorming tot arts en huisarts. 
In de eerste plaats is dat mijn vader, hij kan dit niet meer meemaken. Dokter zijn leek hem 
erg ingewikkeld maar toch is hij er in hoge mate de aanstichter van dat ik het toch geworden 
ben. Tijdens wandelingen door het duin en bos rond Bergen heeft hij mij wegwijs gemaakt in 
allerlei aspecten van de biologie. Hij heeft mij geleerd hoe leuk het is om dingen te begrijpen 
en dat bleek een goede basis voor later. Grootvader Koppen is ook belangrijk voor mij 
geweest. Hij heeft mij tijdens mijn coassistentschappen en ook later op weg geholpen met 
de levensvragen waar een jonge dokter mee geconfronteerd wordt. Van de hoogleraren die 
aan mijn opleiding hebben bijgedragen hebben vooral prof.dr. W.H. Brummelkamp, prof.dr. 
N.A.M. Urbanus en prof.dr. A. Becker grote indruk op mij gemaakt omdat ze meer deden dan 
doceren over hun eigen specialisme. Ze besteedden ook aandacht aan hun mening over het 
dokter zijn. Ik neem indertijd door hen gegeven regels en adviezen over wat van een arts 
verwacht mag worden nog altijd ter harte. Dr. W.W. Oosterhuis, huisarts en indertijd 
verbonden aan de afdeling huisartsgeneeskunde AMC-UvA heeft mij voor het eerst kennis 
laten maken met het doen van huisartsgeneeskundig wetenschappelijk onderzoek. Ik 
bewaar daar fijne herinneringen aan. Bij Dick Haan en Jan Voorburg, beiden cardioloog in 
Harderwijk heb ik mijn eerste ervaring als arts op kunnen doen. Van mijn assistentschap bij 
hen heb ik heel veel geleerd over urgentie denken en over betrokken zijn bij de patiënt. Ik 
dank beiden voor hun inzichten en wijze waarop zij mij begeleid hebben. Voor mijn opleiding 
tot huisarts is Frits Gard, indertijd als agoog verbonden aan de Huisartsopleiding AMC-UvA, 
buitengewoon belangrijk geweest. Ook zijn adviezen gebruik ik nog heel vaak, als huisarts, 
maar ook als opleider en docent. Frits, ik heb je enorm gewaardeerd, heel hartelijk dank. 
Ook Bernadien Wanrooij, indertijd als huisarts verbonden aan de zelfde opleiding, G.M.J. 
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Matser en P.H. Breedveld, indertijd huisartsopleiders in respectievelijk Sprang-Capelle en 
Amsterdam Zuidoost dank ik voor hun rol bij mijn opleiding. Tenslotte dank ik Frans Rutten, 
anesthesioloog verbonden aan de Scola Medica, voor wat ik van hem mocht leren over 
spoedzorg in de huisartspraktijk. Zeker voor een dorpsdokter is dat, naast chronische 
perniones, ook een onderwerp dat er toe doet. 
 
Tenslotte wil ik mijn naasten bedanken. Maaike, bedankt voor nu bijna 40 jaar samen, je 
bent al die tijd heel belangrijk voor mij geweest. We hebben samen veel beleefd, lief en ook 
leed. Toen wij elkaar nog maar kort kenden heb ik kunnen bijdragen aan je weerzin tegen 
havermoutpap tijdens onze tochten in Scandinavië. We hebben drie prachtige kinderen 
gekregen en opgevoed. Maaike, ik dank je voor dit alles, en ook voor je geduld in de lange 
periode waarin ik veel tijd heb gestoken in het onderzoek dat uiteindelijk geleid heeft tot dit 
proefschrift. Ik hoop op nog een lange tijd samen. Lotte, Lars en Kari-Anne, jullie zijn 
inmiddels volwassen en ik ben enorm trots op wie jullie zijn geworden en wat jullie allemaal 
doen. Dit boekje is dan eindelijk het resultaat van de “sommetjes van papa”. Mijn moeder 
dank ik voor het vertrouwen en de steun die zij mij van kinds af aan heeft gegeven, ook in 
perioden waarin ik het haar niet gemakkelijk heb gemaakt, en voor de belangstelling die ze 
nog steeds voor mij laat blijken. Mijn broer Mark gaat mij tijdens de verdediging van dit 
proefschrift bijstaan. Van hem kan ik onder alle omstandigheden op aan. Hoewel we te 
weinig samen zeilen zijn juist dat de momenten dat ik merk hoe goed wij elkaar vertrouwen. 
Mark, ik dank je daarvoor. Ten slotte wil ik hier mijn zus Hilde memoreren, 
röntgenlaborante, en veel te jong gestorven. Het spijt mij enorm haar te moeten missen.
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Ibo Harold Souwer was born on 9 May 1960 in Bergen (NH) the Netherlands. After 
completing secondary school RSG Noord Kennemerland in Alkmaar, he studied biology for 
one year and then medicine at the University of Amsterdam where he graduated in 1989 
cum laude. After a residency in cardiology at the St. Jansdal Hospital in Harderwijk he 
specialised in general practice at the Department of General Practice AMC/University of 
Amsterdam where he graduated in 1992. Since 1993 he has worked as a general practitioner 
in the village of Middelie in the northwest of the Netherlands. He has been attached to the 
Department of General Practice AMC/University of Amsterdam as a GP trainer since 2001, to 
Scola Medica in Utrecht as an instructor on emergency medicine in general practice since 
2014 and to the Department of General Practice AMC/University of Amsterdam as a lecturer 
since 2016.  
He has researched chronic chilblains since 2001 with the support of the Department of 
Primary and Community Care, Gender and Women’s Health of Radboud university medical 
center in Nijmegen. 
Ibo is married to Maaike Bouman and they have three adult children Lotte, Lars and Kari-
Anne.
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